Pyridine derivatives as TMEM16A modulators for use in the treatment of respiratory conditions
Novel pyridine derivatives directly modulate TMEM16A channels to enhance anion secretion and mucociliary clearance, addressing the limitations of indirect TMEM16A regulation in respiratory diseases by improving mucus hydration and clearance mechanisms.
Patent Information
- Application Number
- JP2022504089
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-04-20
- Filing Date
- 2020-07-24
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2040-07-24
AI Technical Summary
Current treatments for respiratory diseases such as cystic fibrosis and chronic bronchitis, which involve indirect regulation of TMEM16A channels, do not provide sustainable anion secretion and mucociliary clearance due to transient effects and receptor desensitization, leading to inadequate hydration and mucus clearance.
Development of novel pyridine derivatives that act as direct positive modulators of TMEM16A channels, enhancing anion secretion and mucociliary clearance by increasing fluid accumulation in the airway mucosa, thereby improving mucus hydration and clearance mechanisms.
The pyridine derivatives sustainably enhance anion secretion and mucociliary clearance, providing clinical benefits for respiratory diseases by improving innate defenses and mucus hydration, applicable to all CF patients and non-CF respiratory conditions.
Smart Images

Figure 0007583022000310 
Figure 0007583022000001 
Figure 0007583022000002
Abstract
Description
[Technical Field]
[0001] The present invention relates to novel compounds that have activity as positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The invention also relates to methods for preparing the compounds and pharmaceutical compositions containing them, and to the use of these compounds in treating diseases and conditions modulated by TMEM16A, particularly respiratory diseases and conditions. [Background technology]
[0002] Humans can inhale up to 12,000 L of air each day, potentially allowing airborne pathogens (such as bacteria, viruses, and fungal spores) to enter the respiratory tract. To protect against these airborne pathogens, the lungs have evolved natural defense mechanisms to minimize the likelihood of infection and colonization of the respiratory tract. One such mechanism is the mucus clearance system, whereby secreted mucus is propelled in and out of the airways by the coordinated beating of cilia along with cough expulsion. This ongoing "cleansing" of the lungs constantly removes inhaled particles and microorganisms, thereby reducing the risk of infection.
[0003] In recent years, it has become clear that the hydration of the mucus gel is important to enable mucus clearance (Boucher 2007; Matsui et al. 1998). In normal, healthy airways, the mucus gel is typically 97% water and 3% w / v solids, under which conditions mucus is cleared by mucociliary action. Airway mucosal hydration is regulated by the coordinated activity of several ion channels and transporters. Anion transport (Cl) is mediated via the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride conductance (CaCC; TMEM16A). - / HCO3 - ) secretion and epithelial Na + Na via the ENaC channel +The balance with absorption determines the hydration state of the airway mucosa: as ions are transported across the epithelium, water is forced to follow osmotically, and thus fluid is secreted or absorbed.
[0004] In respiratory diseases such as chronic bronchitis and cystic fibrosis, the % solids of the mucus gel increases as hydration decreases and mucus clearance decreases (Boucher, 2007). In cystic fibrosis, where loss-of-function mutations in CFTR attenuate the airway's ability to secrete fluid, the % solids can increase to 15%, which is thought to contribute to small airway obstruction and impaired mucus clearance. Strategies to increase airway mucus hydration include stimulating anions, thereby increasing fluid secretion or Na + To this end, stimulating TMEM16A channel activity increases anion secretion and thus increases fluid accumulation in the airway mucosa, hydrating the mucus and enhancing mucus clearance mechanisms.
[0005] TMEM16A, also known as anoctamin-1 (Ano1), is a molecule identical to the calcium-activated chloride channel (Caputo et al., 2008; Yang et al., 2008). TMEM16A channels open in response to elevated intracellular calcium levels, allowing bidirectional flow of chloride, bicarbonate, and other anions across the cell membrane. Functional TMEM16A channels have been proposed to regulate transepithelial ion transport, gastrointestinal peristalsis, nociception, and cell migration / proliferation (Pedemonte & Galietta, 2014).
[0006] TMEM16A channels are expressed by epithelial cells in different organs, including the lung, liver, kidney, pancreas, and salivary glands. In the airway epithelium, TMEM16A is expressed at high levels in mucus-producing goblet cells, ciliated cells, and submucosal glands. Physiologically, TMEM16A is activated by intracellular calcium, a stimuli that mobilizes purinergic agonists (ATP, UTP), released by the respiratory epithelium in response to cyclic shear stress caused by breathing and other mechanical stimuli, such as coughing. In addition to increasing anion secretion, which leads to enhanced airway hydration, TMEM16A activation plays an important role in bicarbonate secretion. Bicarbonate secretion is a key regulator of mucus properties and has been reported to be important in controlling airway luminal pH and, therefore, the activity of natural antibacterial agents such as defensins (Pezzulo et al., 2012).
[0007] Indirect modulation of TMEM16A via elevated intracellular calcium has been clinically investigated, for example, with denufosol (Kunzelmann & Mall, 2003). Although promising initial results were observed in small patient cohorts, this approach failed to provide clinical benefit in larger patient cohorts (Accurso et al., 2011; Kellerman et al., 2008). This lack of clinical efficacy was attributed to only transient increases in anion secretion, the short half-life of denufosol at the epithelial surface, and the resulting receptor / pathway desensitization, as well as undesirable effects of elevated intracellular calcium, such as increased mucus release from goblet cells (Moss, 2013). Compounds that act directly on TMEM16A and enhance channel opening at low levels of elevated calcium are expected to sustainably enhance anion secretion and mucociliary clearance in patients, improving innate defenses. Because TMEM16A activity is independent of CFTR function, positive modulators of TMEM16A have the potential to provide clinical benefit to all CF patients and non-CF respiratory diseases characterized by mucus congestion, including chronic bronchitis and severe asthma.
[0008] TMEM16A modulation has been implicated as a treatment for dry mouth (xerostomia), dry eye, cholestasis, and gastrointestinal motility disorders resulting from salivary gland dysfunction in Sjogren's syndrome and from radiation therapy.
[0009] Our application, WO 2019 / 145726, relates to compounds that are positive modulators of TMEM16A and therefore have use in the treatment of diseases and conditions, particularly respiratory diseases and conditions, in which regulation of TMEM16A plays a role.
[0010] The present inventors have developed additional compounds that are positive modulators of TMEM16A. Many of the compounds of the present invention have advantages over the related compounds exemplified in WO 2019 / 145726. These advantages include reduced lipophilicity (as represented by a lower logD value) and reduced metabolic clearance, properties that result in improved pharmacokinetics (PK) when the compounds are administered systemically, e.g., orally. In particular, reduced lipophilicity results in increased aqueous solubility. Some of the compounds of the present invention have improved solubility and / or reduced metabolic clearance compared to the compounds exemplified in WO 2019 / 145726. This results in advantages such as lower effective doses, longer half-lives after administration, or, when administered orally, higher bioavailability. Summary of the Invention
[0011] In a first aspect of the present invention, there is provided a compound of general formula (I) including all tautomers, all enantiomeric and isotopic variants thereof: TIFF0007583022000001.tif43170In formula, R 1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; or R 2 and R 3 together with the carbon atoms to which they are attached, form R 1In addition to the group, R forms a 4- to 6-membered carbocyclic ring substituted with OH, halo, methyl, or CHOH. 1 may also be H, or R 2 and R 3 together with the carbon atoms to which they are attached, form R 1 When forming a 4- to 6-membered carbocyclic ring that is unsubstituted except for the R 1 may be CHOH, R 2 is selected from methyl and CHOH; R 3 is selected from H and methyl; or R 2 and R 3 together with the carbon atoms to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, any of which may be selected from R 1 In addition to the groups OH, halo, C 1-4 Alkyl, C substituted with one or more OH substituents 1-4 Alkyl, and C 1-4 haloalkyl; R 1 , R 2 and R 3 together with the carbon atoms to which they are attached, form OH, halo, and C 1-4 Alkyl and C 1-4 forming a 5- to 8-membered bridged carbocyclic or heterocyclic ring system optionally substituted with one or more substituents selected from haloalkyl; R 4 is H or halo, R 5 and R 7 each independently represents H, halo, C 1-3 Alkyl and C 1-3 haloalkyl; R 6 is optionally substituted with one or more substituents selected from H, halo, CN, and halo and OH; 1-4 alkyl, R 8is methyl or ethyl, either of which may be substituted with one or more halogen substituents; R 9 is OH, CHOH, or methyl or ethyl, any of which may be substituted with one or more halogen substituents; or R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 In addition to the group, either a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted with one or more substituents selected from OH, F and CHOH, or an ethenyl group optionally substituted with one or two halogen substituents; R 10 is H, CN, OH, cycloalkyl optionally substituted with OH, and C optionally substituted with one or more substituents selected from halo, OH, and 3- to 6-membered cycloalkyl or heterocyclic groups; 1-4 alkyl, any of which may be substituted with OH; or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from OH, F and CHOH; however, iR 5 and R 7 is H and R 6 is H or F, then R 1 , R 2 , R 3 , R 8 , R 9 and R 10 is not all methyl, and ii.R 2 , R 3 , R 8 , R 9 and R 10 are all methyl, R 5 , R 6 and R 7is not all H, and iii.R 1 is CN and R 2 and R 3 together with the carbon atoms to which they are attached form a 3- to 10-membered oxygen-containing heterocyclic ring, R 8 , R 9 and R 10 is not all methyl, and iv.R 9 and R 10 However, none of them are OH. and salts and solvates thereof.
[0012] Suitably, compounds of general formula (I) are provided. Salts of compounds of formula (I), such as pharmaceutically acceptable salts, are also provided. Solvates (e.g., hydrates) or compounds of formula (I) are also provided.
[0013] The compounds of general formula (I) are positive modulators of TMEM16A and are therefore useful in the treatment of diseases and conditions in which the regulation of TMEM16A plays a role, particularly respiratory diseases and conditions. DETAILED DESCRIPTION OF THE INVENTION
[0014] In this specification, unless the context requires otherwise by explicit language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" are used in the inclusive sense, i.e., to specify the presence of stated features but do not exclude the presence or addition of further features in various embodiments of the invention.
[0015] All publications and patent documents mentioned herein are incorporated by reference to the fullest extent possible.
[0016] As used herein, reference to "medical use" refers to use for administration to humans or animals, particularly humans or mammals, such as domestic animals or domestic mammals, for the treatment or prevention of a disease or condition. The term "pharmaceutical composition" refers to a composition suitable for pharmaceutical use, and "pharmaceutically acceptable" refers to an agent suitable for use in a pharmaceutical composition. Other similar terms should be construed accordingly.
[0017] Salts and solvates (such as hydrates) of compounds of general formula (I) are suitably pharmaceutically acceptable. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and are described, for example, by Gupta et al. (2018). Some particularly suitable salts of compounds of general formula (I) include base addition salts such as sodium, potassium, calcium, aluminum, zinc, magnesium, and other metal salts, as well as choline, diethanolamine, ethanolamine, ethyldiamine, and meglumine salts. Alternatively, acid addition salts, such as hydrochloride, mesylate, hydrobromide, sulfate, and fumarate, may be formed. Salts of synthetic intermediates do not necessarily have to be pharmaceutically acceptable.
[0018] As used herein, "C 1-4 The term "alkyl" refers to a straight or branched chain, fully saturated hydrocarbon group having from 1 to 4 carbon atoms. This term encompasses methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, and t-butyl. Other alkyl groups, such as C 1-6 Alkyl and C 1-3 Alkyl is as defined above but containing the stated number of carbon atoms.
[0019] The term "3- to 10-membered carbocyclic" refers to a non-aromatic hydrocarbon ring system containing 3 to 10 ring carbon atoms. A carbocyclic ring system may contain one or more carbon-carbon double bonds, but is preferably a cycloalkyl group. A carbocyclic ring system may be a single ring, or may contain two rings that may be fused or spiro-arranged or bridged, with the carbon atoms in the bridge being included in the number of ring carbon atoms. A carbocyclic ring system may contain other numbers of ring atoms as described, such as 5 to 8 ring atoms or 3 to 6 ring atoms.
[0020] In the context of this specification, the term "cycloalkyl" refers to a fully saturated carbocyclic ring system as defined above. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, as well as bridged cycloalkyl systems such as bicyclo[1.1.1]pentyl.
[0021] In the context of this specification, the terms "3- to 10-membered heterocyclic" and "3- to 10-membered heterocyclyl" refer to a non-aromatic ring system containing 3 to 10 ring atoms, including at least one heteroatom selected from N, O, and S. The heterocyclic ring system may contain one or more carbon-carbon double bonds, but is preferably fully saturated. The heterocyclic ring system may be monocyclic or may contain two or three rings, which may be fused or spiro-arranged or bridged, the bridge atoms being included in the number of ring atoms. An oxygen-containing heterocyclic ring contains at least one oxygen ring atom and, optionally, one or two additional heteroatoms selected from O, N, and S. Examples of 3- to 6-membered heterocyclic ring systems include oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and 2-oxaspiro[3.3]heptan-6-yl. Heterocyclic ring systems may contain other numbers of ring atoms as stated, for example, 5 to 8 ring atoms or 3 to 6 ring atoms.
[0022] The term "halogen" refers to fluorine, chlorine, bromine, or iodine, and the term "halo" refers to a fluoro, chloro, bromo, or iodo group. Similarly, "halide" refers to fluoride, chloride, bromide, or iodide.
[0023] As used herein, "C 1-4 The term "haloalkyl" refers to a C alkyl group as defined above in which one or more hydrogen atoms are replaced by a halo group. 1-4 It refers to an alkyl group. Any number of hydrogen atoms may be substituted, up to perhalo substitution. Examples include trifluoromethyl, chloroethyl, and 1,1-difluoroethyl. A fluoroalkyl group is a haloalkyl group where the halo is fluoro. Other haloalkyl groups, such as C 1-3 Haloalkyl is as defined above but containing the stated number of carbon atoms.
[0024] The term "isotopic variant" refers to an isotopically labeled compound identical to those listed in Formula (I), except for the fact that one or more atoms have been replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature, or the proportion of atoms having an atomic mass or mass number less commonly found in nature has been increased (the latter concept is called "isotopic enrichment"). Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, iodine, and chlorine, such as 2H (deuterium), 3H, 11C, 13C, 14C, 18F, 123I, or 125I (e.g., 3H, 11C, 14C, 18F, 123I, or 125I), which may be naturally occurring or non-naturally occurring isotopes.
[0025] Particularly suitable isotopic variants of compounds of general formula (I) include those in which some or all of the methyl groups are replaced by CD. For example, R 8 , R 9 and R 10 One, two or all of these may be CD3.
[0026] In some suitable compounds of general formula (I), R 1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl, and CN; R 2 is selected from methyl and CHOH; R 3 is selected from H and methyl; or R 2 and R 3 together with the carbon atoms to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, any of which may be selected from R 1 In addition to the groups OH, halo, C 1-4 Alkyl and C 1-4 haloalkyl; R 1 , R 2 and R 3 together with the carbon atoms to which they are attached, form OH, halo, and C 1-4 Alkyl and C 1-4 forming a 5- to 8-membered bridged carbocyclic or heterocyclic ring system optionally substituted with one or more substituents selected from haloalkyl; R 4 is H or halo, R 5 and R 7 each independently represents H, halo, C 1-3 Alkyl and C 1-3 haloalkyl; R 6 is optionally substituted with one or more substituents selected from H, halo, CN, and halo and OH; 1-4 alkyl, R 8 is methyl or ethyl, either of which may be substituted with one or more halogen substituents; R 9 is OH, CHOH, or methyl or ethyl, any of which may be substituted with one or more halogen substituents; or R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 In addition to the group, either a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted with one or more substituents selected from OH, F and CHOH, or an ethenyl group optionally substituted with one or two halogen substituents; R 10 is H, CN, OH, cycloalkyl optionally substituted with OH, and C optionally substituted with one or more substituents selected from halo, OH, and 3- to 6-membered cycloalkyl or heterocyclic groups; 1-4 alkyl, any of which may be substituted with OH; or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from OH, F and CHOH; however, iR 5 and R 7 is H and R 6 is H or F, then R 1 , R 2 , R 3 , R 8 , R 9 and R 10 is not all methyl, and ii.R 2 , R 3 , R 8 , R 9 and R 10 are all methyl, R 5 , R 6 and R 7 is not all H, and iii.R 1 is CN and R 2 and R 3 together with the carbon atoms to which they are attached form a 3- to 10-membered oxygen-containing heterocyclic ring, R 8 , R9 and R 10 is not all methyl, and iv.R 9 and R 10 However, neither of them is OH.
[0027] In other suitable compounds of general formula (I): R 1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; or R 2 and R 3 When taken together with the carbon atoms to which they are attached form a 4- to 6-membered carbocyclic ring substituted with OH, halo, methyl, or CHOH, R 1 may also be H, R 2 is selected from methyl and CHOH; R 3 is selected from H and methyl; or R 2 and R 3 together with the carbon atoms to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, either of which is R 1 In addition to the groups OH, halo, C 1-4 Alkyl, C substituted with one or more OH substituents 1-4 Alkyl, and C 1-4 haloalkyl; R 1 , R 2 and R 3 together with the carbon atoms to which they are attached, form OH, halo, and C 1-4 Alkyl and C 1-4 forming a 5- to 8-membered bridged carbocyclic or heterocyclic ring system optionally substituted with one or more substituents selected from haloalkyl; R 4 is H or halo, R 5 and R 7 each independently represents H, halo, C1-3 Alkyl and C 1-3 haloalkyl; R 6 is optionally substituted with one or more substituents selected from H, halo, CN, and halo and OH; 1-4 alkyl, R 8 is methyl or ethyl, either of which may be substituted with one or more halogen substituents; R 9 is OH, CHOH, or methyl or ethyl, any of which may be substituted with one or more halogen substituents; or R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 In addition to the group, either a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted with one or more substituents selected from OH, F and CHOH, or an ethenyl group optionally substituted with one or two halogen substituents; R 10 is H, CN, OH, cycloalkyl optionally substituted with OH, and C optionally substituted with one or more substituents selected from halo, OH, and 3- to 6-membered cycloalkyl or heterocyclic groups; 1-4 alkyl, any of which may be substituted with OH; or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from OH, F and CHOH; however, iR 5 and R 7 is H and R 6 is H or F, then R 1 , R 2 , R 3 , R 8 , R 9 and R 10is not all methyl, and ii.R 2 , R 3 , R 8 , R 9 and R 10 are all methyl, R 5 , R 6 and R 7 is not all H, and iii.R 1 is CN and R 2 and R 3 together with the carbon atoms to which they are attached form a 3- to 10-membered oxygen-containing heterocyclic ring, R 8 , R 9 and R 10 is not all methyl, and iv.R 9 and R 10 However, neither of them is OH.
[0028] In some compounds of general formula (I), R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 In addition to the group, it forms a 3-6 membered cycloalkyl or oxygen-containing heterocyclic ring which is substituted with one or more CHOH substituents and optionally with one or more further substituents selected from OH and F, or R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 In addition to the group, a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted with one or more substituents selected from OH and F, and R 10 is CN or C substituted with one or more substituents selected from OH, a 3- to 6-membered cycloalkyl group optionally substituted with OH, and a 3- to 6-membered heterocyclic group optionally substituted with OH. 1-4 alkyl, or R 8 and R 9together with the carbon atoms to which they are attached form an ethenyl group which may be substituted by one or two halogen substituents, or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form a 5-8 membered fused or bridged carbocyclic ring system which is substituted with one or more CHOH substituents and optionally with one or more further substituents selected from OH and F; Either:
[0029] In these compounds, more particularly R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring system that is unsubstituted except for the group R 10 is selected from CN and CH2OH, or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system substituted with CH2OH; Either:
[0030] In some compounds of general formula (I), R 8 is methyl or ethyl, either of which may be substituted with one or more halogen substituents; and R 9 is OH, CHOH, or methyl or ethyl, any of which may be substituted with one or more halogen substituents; or R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 In addition to the group, R forms a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted with one or more substituents selected from OH and F, 10is optionally substituted with H, OH, or one or more halo substituents; 1-4 alkyl, or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form a 5-8 membered fused or bridged carbocyclic ring system which may be substituted with one or more substituents selected from OH and F.
[0031] In some of the more suitable compounds of this type: R 8 is methyl or ethyl, and R 9 is OH or CHOH, and R 10 is methyl or ethyl. More suitably, R 8 is methyl, R 9 is OH or CHOH, and R 10 is methyl or ethyl. Even more suitably, R 8 is methyl and R 9 is OH and R 10 is methyl or ethyl, or R 8 is methyl and R 9 is CH2OH and R 10 is methyl.
[0032] Alternatively, R 8 is methyl or ethyl, and R 9 is methyl or ethyl, and R 10 , is OH or C substituted with OH 1-4 More suitably, R 8 is methyl and R 9 is methyl or ethyl, and R 10 is OH or CH2CH2OH. Even more suitably, R 8 is methyl and R 9 is methyl or ethyl, R 10 is OH or R 8 is methyl and R 9 is methyl and R 10 is CH2OH.
[0033] In other more suitable compounds of this type, R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 A 3- to 6-membered cycloalkyl ring is formed which is unsubstituted except for the substituents, and R 10 is OH or CHOH. Even more suitably, R 8 and R 9 together with the carbon atoms to which they are attached, form R 10 R forms a cyclopropyl or cyclobutyl ring that is unsubstituted except for the substituents. 10 is CH2OH.
[0034] In other more suitable compounds of this type, R 8 , R 9 and R 10 are all methyl.
[0035] In some compounds of general formula (I), R 1 , R 2 and R 3 is not all methyl.
[0036] In some compounds of general formula (I), R 8 , R 9 and R 10 is not all methyl.
[0037] In some compounds of general formula (I), R 1 , R 2 , R 3 , R 8 , R 9 and R 10 is not all methyl
[0038] Suitably, in compounds of general formula (I), R 1 is methyl, difluoromethyl, trifluoromethyl, ethynyl or CN.
[0039] In some compounds of general formula (I), R 1is methyl.
[0040] In some compounds of general formula (I), R 1 is ethynyl.
[0041] In some more suitable compounds of general formula (I), R 1 is difluoromethyl or trifluoromethyl, especially trifluoromethyl.
[0042] In other more suitable compounds of general formula (I), R 1 is CN.
[0043] In some compounds of general formula (I), R 2 is methyl.
[0044] In other compounds of general formula (I), R 2 is CH2OH.
[0045] R 2 In compounds of general formula (I) where R is methyl or CHOH, 3 is H or methyl.
[0046] In some such compounds, R 3 is H, but more appropriately, R 3 is methyl.
[0047] In some suitable compounds of general formula (I), R 2 is methyl and R 3 is H. In some suitable compounds of general formula (I), R 2 is methyl and R 3 is methyl.
[0048] Alternatively, as mentioned above, R 2 and R 3together with the carbon atoms to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, which may be substituted as described above. In some suitable compounds of general formula (I), the ring system is a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring. In this case, the ring may be a cycloalkyl ring, such as cyclopropyl, cyclobutyl, or cyclopentyl, especially cyclopropyl. Alternatively, the ring may be a fully saturated 3- to 6-membered oxygen-containing heterocyclic ring, such as a tetrahydropyran, tetrahydrofuran, or oxetane ring. The 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring may be a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring, such as R 1 In addition to OH, halo, C 1-4 Alkyl and C 1-4 It may be substituted by one or more substituents selected from haloalkyl, more suitably OH, halo, methyl, difluoromethyl or trifluoromethyl, even more suitably OH and halo, such as OH and fluoro.
[0049] Appropriately, R 2 and R 3 When forms this type of ring system, R 1 is H, methyl, trifluoromethyl, difluoromethyl or CN, more suitably methyl, difluoromethyl, trifluoromethyl or CN, even more suitably trifluoromethyl or CN, especially trifluoromethyl. 2 and R 3 However, the ring system they form together with the carbon atoms to which they are attached is a group R 1 Apart from that it is properly unsubstituted.
[0050] R 1 is H and R 2 and R 3 together with the carbon atom to which they are attached form a 4-6 membered carbocyclic ring substituted with OH, halo, methyl or CHOH, a preferred substituent on the 4-6 membered carbocyclic ring is OH. Suitably the ring is a cyclopentyl ring.
[0051] In some suitable compounds, R 2 and R3 together with the carbon atoms to which they are attached, form R 1 Separately from the group, it forms an unsubstituted 4- to 6-membered carbocyclic ring.
[0052] In some suitable compounds of this type, R 1 is CH2OH. In this case, R 2 and R 3 together with the carbon atoms to which they are attached suitably form a cyclobutyl or cyclopentyl ring, most suitably R 1 The group forms an unsubstituted cyclobutyl ring.
[0053] In some particularly suitable compounds, R 1 is trifluoromethyl and R 2 and R 3 together with the carbon atoms to which they are attached, form R 1 forms a cyclopropyl ring which is unsubstituted except for
[0054] In some suitable compounds of general formula (I), R 1 , R 2 and R 3 together with the carbon atoms to which they are attached, form OH, halo, and C 1-4 Alkyl and C 1-4 It forms a 5-8 membered bridged carbocyclic or heterocyclic ring system which may be substituted with one or more substituents selected from haloalkyl.
[0055] In some suitable compounds, R 4 is halo, such as H or F. In particularly suitable compounds, R 4 is H.
[0056] In some suitable compounds, R 5 and R 7 Each of is H.
[0057] In suitable compounds of general formula (I), R 6is selected from H, halo, CN, and methyl optionally substituted with one or more substituents selected from halo and OH. More suitably, R 6 is H, halo, CN, CH3, CF3, CHF2, CH2F or CH2OH, even more suitably halo or methyl, especially halo such as fluoro or chloro.
[0058] In suitable compounds of general formula (I), R 4 is H and / or R 5 and R 7 each of is H, and / or R 6 is H, halo, CN, CH3, CF3, CHF2, CH2F or CH2OH. Suitably, R 4 is H and R 5 and R 7 Each of R is H. Suitably, 4 is H and R 6 is H, halo, CN, CH3, CF3, CHF2, CH2F or CH2OH. Suitably, R 5 and R 7 is H and R 6 is H, halo, CN, CH3, CF3, CHF2, CH2F or CH2OH. Suitably, R 4 is H and R 5 and R 7 Each of is H and R 6 is H, halo, CN, CH3, CF3, CHF2, CH2F or CH2OH.
[0059] In some suitable compounds of general formula (I), R 8 is methyl or ethyl, especially methyl.
[0060] In some suitable compounds of the invention, R 8 is methyl or ethyl, especially methyl, and R 9 is methyl, CHOH or OH. In particular, R 8 is methyl and R 9 is OH.
[0061] In other suitable compounds of the invention, R 8 and R 9 are each independently methyl or ethyl. More suitably, R 8 and R 9 one of which is methyl and R 8 and R 9 The other is methyl or ethyl.
[0062] Alternatively, R 8 and R 9 taken together with the carbon atoms to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring, the ring is 10 It is properly unsubstituted except for the R moiety. 8 and R 9 The rings formed by together with the carbon atoms to which they are attached are suitably selected from cycloalkyl rings and heterocyclic rings having a single ring oxygen atom, such as cyclopropyl, cyclobutyl, tetrahydropyranyl, tetrahydrofuranyl and oxetanyl.
[0063] R 10 is suitably selected from H, CN, cyclopropyl, cyclobutyl and methyl or ethyl, which methyl or ethyl is unsubstituted or substituted with one or more substituents selected from fluoro, OH and 3- to 6-membered cycloalkyl or heterocyclyl groups.
[0064] More appropriately, R 10 is CN, cyclopropyl, cyclobutyl, unsubstituted methyl, or methyl substituted with one or more substituents selected from fluoro, OH, and 3- to 6-membered cycloalkyl or heterocyclyl groups.
[0065] R 10is methyl or ethyl substituted with a heterocyclic group, it is suitably a 5- or 6-membered nitrogen-containing heterocycle optionally containing one or more additional heteroatoms and bonded to a carbon atom in the methyl or ethyl group via a ring nitrogen atom. Examples of such heterocyclic groups include morpholinyl, pyrrolidinyl, piperidinyl and piperazinyl.
[0066] In particularly suitable compounds of general formula (I), R 10 is CN, methyl, CF3, CH2OH, cyclopropylmethyl or morpholinylmethyl, such as morpholin-4-ylmethyl, especially CH2OH.
[0067] R 8 is methyl or ethyl, and R 9 When R is OH or CHOH, 10 is suitably methyl or ethyl.
[0068] R 8 is methyl or ethyl, R 9 is methyl or ethyl, and R 10 is suitably OH or C substituted with OH 1-4 It is alkyl, more suitably OH or CH2OH.
[0069] R 8 and R 9 together with the carbon atoms to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring, R 10 is more suitably methyl, ethyl, CH2OH, CH2CH2OH, trifluoromethyl or CN.
[0070] In some particularly suitable compounds, R 10 is CH2OH.
[0071] In some compounds of general formula (I), R 8 and R 9together with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl or oxetanyl ring, in particular a cyclopropyl, cyclobutyl or oxetanyl ring, which are R 10 may be unsubstituted except for the R 10 In addition to the R 10 is methyl, CH2OH, trifluoromethyl or cyano.
[0072] In some such compounds, R 10 is CH2OH or cyano.
[0073] In some such compounds, the ring is R 10 is unsubstituted except for the R 10 is CH2OH or cyano, especially CH2OH.
[0074] In other such compounds, the ring is R 10 is unsubstituted except for the R 10 is methyl or trifluoromethyl.
[0075] R 8 , R 9 and R 10 taken together with the carbon atoms to which they are attached form an unsubstituted 5- to 8-membered fused or bridged carbocyclic ring system, which is suitably a bridged ring system such as bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane or bicyclo[2.2.1]heptane. Suitably the ring is unsubstituted or substituted with a single CHOH substituent.
[0076] Specific examples of compounds of general formula (I) include the following: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (compound 1), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (compound 1.1), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclopentyl)pyridine-2-carboxamide (compound 1.2), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanoethyl)pyridine-2-carboxamide (compound 1.3), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyanoethyl]pyridine-2-carboxamide (compounds 1.3a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyanoethyl]pyridine-2-carboxamide (compounds 1.3a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (compound 1.4), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (compound 1.5), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide (compound 1.6), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (compound 1.6a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (compound 1.6a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 1.7), 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.1), N-tert-butyl-4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.2), 4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.3), N-tert-butyl-4-[[2-[4-(1-cyanocyclopropyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.4), N-(1-cyano-1-methyl-ethyl)-4-[[2-[4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.5), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.6), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.7), 4-[[2-[4-(1-cyclopropyl-1-hydroxy-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.8), 4-[[2-[4-(4-cyanotetrahydropyran-4-yl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.9), 4-[[2-[2-fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.10), 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.11), 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.11a / b), 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.11a / b), 4-[[2-[5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.12), 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclobutyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.13), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.14), 4-[[2-[2-fluoro-5-hydroxy-4-[4-(hydroxymethyl)tetrahydropyran-4-yl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.15), 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclopropyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.16), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)-5-fluoro-pyridine-2-carboxamide (compound 3), N-(1-cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (compound 4), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclobutyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 5), N-tert-butyl-4-[[2-(4-tert-butyl-5-hydroxy-2-isopropyl-phenyl)acetyl]amino]pyridine-2-carboxamide (compound 6), N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 7), 4-[[2-(2-fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 7.1), N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclopropyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 8), N-(1-cyanocyclopropyl)-4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxamide (compound 9), 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (compound 10), 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 10.1), 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (compound 10.2), 4-[[2-[2-fluoro-5-hydroxy-4-(3-hydroxy-1,1-dimethyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 11), N-(4-cyanotetrahydropyran-4-yl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 12), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[3-(trifluoromethyl)oxetan-3-yl]pyridine-2-carboxamide (compound 12.1), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (compound 12.2), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide (compound 12.3), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (compound 12.4), 4-[[2-[2-fluoro-5-hydroxy-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 13), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 14), 4-[[2-[5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 14.1), N-(3,3-difluoro-1-methyl-cyclobutyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 15), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (compound 15.1), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide (compound 15.2), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(difluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 15.3), N-[1-(difluoromethyl)cyclopropyl]-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 15.4), N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 16), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (compound 16.1), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 16.2), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (compound 16.3), 4-[[2-[2,6-difluoro-3-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 16.4), 4-[[2-[2-fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 17), 4-[[2-[2-chloro-6-fluoro-3-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 18), 4-[[2-[2-chloro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 19), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 20), 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 20a / b), 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 20a / b), and salts and solvates of the above.
[0077] The compound of general formula (I) may be a compound of general formula (II): TIFF0007583022000002.tif43170 (in the formula, R 4 , R5 , R 6 , R 7 , R 8 , R 9 and R 10 is as defined for general formula (I), General formula (III): TIFF0007583022000003.tif19170 (in the formula, R 1 , R 2 and R 3 can be prepared by reacting a compound of general formula (I) with a compound of general formula (I)
[0078] Suitably, the reaction is carried out in the presence of a coupling reagent and under basic conditions, for example in the presence of an amine such as diisopropylethylamine (DIPEA) and in an organic solvent such as DMF.
[0079] Suitable coupling reagents include known peptide coupling agents, such as O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (TB ... tetramethyluronium tetrafluoroborate (TATU), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), carbodiimides such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), and triazoles such as 1-hydroxy-7-azabenzotriazole (HOAt) or hydroxybenzotriazole (HOBt).
[0080] Suitably, when these coupling agents are used, the reaction is carried out under basic conditions, for example in the presence of an amine such as diisopropylethylamine (DIPEA) and in an organic solvent such as DMF.
[0081] Alternatively, the coupling reagent may be propylphosphonic anhydride (T3P (registered trademark)). When T3P is used as the coupling reagent, the reaction may be carried out under basic conditions, for example, in the presence of an amine such as diisopropylethylamine (DIPEA) or triethylamine (TEA), in an organic solvent such as dioxane.
[0082] Coupling agents such as HATU, HBTU, TBTU and TATU are particularly suitable for this reaction.
[0083] Compounds of general formula (III) are readily available or can be synthesized by known methods.
[0084] The compound of general formula (II) may be represented by general formula (IV): TIFF0007583022000004.tif41170 (in the formula, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is as defined for general formula (I), and R 15 and R 16 Each of the is independently C 1-6 The compound can be prepared by deprotecting a compound of formula (I) where I is an alkyl group.
[0085] Suitably, deprotection is carried out by reaction with boron tribromide, which gives R 15 and R 16 It is particularly useful when both are methyl.
[0086] Deprotection of boron tribromide can be carried out in a polar organic solvent such as dichloromethane. Initial cooling, for example to about -5 to 5°C, may be required, after which the reaction can be allowed to warm to a temperature of about 15 to 25°C, typically room temperature.
[0087] The compound of general formula (IV) may be represented by general formula (V): TIFF0007583022000005.tif41170 (in the formula, R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is as defined for general formula (I), and R 16 is as defined for general formula (IV), General formula (VI): TIFF0007583022000006.tif32170 (in the formula, R 4 is as defined for general formula (I), and R 15 can be prepared by reacting a compound of formula (IV) with a compound of formula (IV)
[0088] Suitably the reaction is carried out in the presence of a coupling agent as described above, with T3P® being particularly suitable.
[0089] Compounds of general formula (VI) are known and readily available or can be synthesized by known methods.
[0090] The synthesis of compounds of general formula (V) is discussed in more detail below.
[0091] An alternative method for synthesizing compounds of general formula (IV) is to prepare a compound of general formula (VII): TIFF0007583022000007.tif40170 (in the formula, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10is as defined for general formula (I), and R 16 is as defined for general formula (IV), and R 17 is halo, e.g., bromo) by carbonylation of the compound.
[0092] Carbonylation can be carried out by reaction with carbon monoxide in the presence of a palladium catalyst such as Pd(dppf)Cl2 ([1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)) and a base such as trimethylamine in an alcoholic solvent such as methanol. Carbon monoxide can be generated in situ by reaction of formic acid and methanesulfonyl chloride with triethylamine.
[0093] The compound of general formula (VII) can be prepared by reacting the compound of general formula (V) defined above with a compound of general formula (VIII): TIFF0007583022000008.tif23170 (in the formula, R 4 is as defined for general formula (I), and R 17 can be prepared by reacting a compound of general formula (VII) with a compound of general formula (VII)
[0094] Suitably the reaction is carried out in the presence of a coupling reagent as defined above, with T3P® being particularly suitable.
[0095] Compounds of general formula (VIII) are known and readily available or can be prepared by known methods.
[0096] R 8 and R 9 together with the carbon atom to which they are attached form a cycloalkyl group, and R 10 The compound of general formula (IV) in which is methyl can be represented by general formula (XXXI): TIFF0007583022000009.tif42170 (in the formula, R 4 , R 5 , R 6 and R 7is as defined for general formula (I), and R 15 and R 16 is as defined for general formula (IV), General formula (XXXII): TIFF0007583022000010.tif28170 (wherein n is 0 to 3).
[0097] Suitably the reaction is carried out in the presence of concentrated sulfuric acid.
[0098] Compounds of general formula (XXXII) are known and readily available or can be synthesized by one skilled in the art.
[0099] The compound of general formula (XXXI) is a compound of general formula (IX): TIFF0007583022000011.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 16 is as defined for general formula (IV), It can be prepared by reacting with a compound of general formula (VI) as defined above.
[0100] Suitably the reaction is carried out in the presence of a coupling agent as described above, with T3P® being particularly suitable.
[0101] Compounds of general formula (VI) and (IX) are known and readily available or can be synthesized by known methods.
[0102] Depending on the nature of the substituents, there are several methods for preparing compounds of general formula (V).
[0103] For example, R 8 and R 9 is methyl and R 10Compounds of general formula (V) in which is methyl or halomethyl can be prepared by alkylation of compounds of general formula (IX) as defined above.
[0104] Suitable alkylation reactions include those of the general formula (X): TIFF0007583022000012.tif20170 (in the formula, R 10 is methyl optionally substituted with halo, and R 18 The method includes Friedel-Crafts alkylation using a compound of R (where R is halo, e.g., chloro or bromo) in the presence of a Lewis acid catalyst, e.g., FeCl. 6 is particularly suitable for compounds where is F.
[0105] Alternatively, R 6 For compounds of general formula (IX) where is halo, alkylation can be carried out by reacting a compound of general formula (XI): TIFF0007583022000013.tif20170 (in the formula, R 10 is methyl optionally substituted with halo).
[0106] Suitably the reaction is carried out in the presence of concentrated sulfuric acid.
[0107] Alternatively, the alkylation can be carried out by a method according to the general formula (XIII): TIFF0007583022000014.tif21170 (in the formula, R 10 is methyl optionally substituted with halo) in the presence of concentrated sulfuric acid.
[0108] Compounds of general formulae (X), (XI) and (XIII) are known and readily available or can be prepared by known methods.
[0109] Compounds of general formula (IX) are known and readily available or can be prepared by known methods. For example, R 6The compound of general formula (IX) in which is Cl or Br can be represented by general formula (XII): TIFF0007583022000015.tif34170 (in the formula, R 5 and R 7 is as defined for general formula (I), and R 16 is as defined for general formula (IV)) can be prepared by chlorination or bromination.
[0110] Suitable halogenating agents include N-chlorosuccinimide and N-bromosuccinimide.
[0111] Compounds of general formula (XII) are known and readily available or can be prepared by known methods.
[0112] An alternative method for preparing compounds of general formula (I) is to prepare a compound of general formula (XXI): TIFF0007583022000016.tif42170 (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is as defined for general formula (I), and R 20 is benzyl optionally substituted with one or more methoxy groups).
[0113] Deprotection can be suitably achieved by catalytic hydrogenation using, for example, a palladium catalyst, typically palladium on carbon. The reaction can be carried out in an alcoholic solvent, such as methanol or ethanol. 20When is benzyl substituted with one or more methoxy groups, deprotection can also be achieved by treatment with a strong acid such as hydrochloric acid or trifluoroacetic acid. Further deprotection methods include treatment with sodium borohydride in the presence of a nickel(II) salt, for example under the conditions described in Example 19 below.
[0114] This method is particularly useful when the heterocyclic ring is attached to CH2 through a nitrogen atom, R 10 is particularly suitable for compounds of general formula (I) where R is OH, CN, halomethyl (e.g., CF), or methyl substituted with OH or a heterocyclic ring. 8 and R 9 together with the carbon atoms to which they are attached to form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring (alone or in combination with the above-mentioned R 10 Suitable for use in combination with any of the groups.
[0115] The compound of general formula (XXI) can be represented by general formula (XXII): TIFF0007583022000017.tif34170 (in the formula, R 1 , R 2 , R 3 and R 4 is as defined for general formula (I), General formula (XXV): TIFF0007583022000018.tif42170 (in the formula, R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is as defined for general formula (I), and R 20 can be prepared by reacting a compound of general formula (XXI) with a compound of formula (XXI).
[0116] Suitably, the reaction is carried out in the presence of a coupling reagent as described above. Typically, T3P® can be used as the coupling reagent.
[0117] The compound of general formula (XXII) can be prepared by reacting the compound of general formula (III) defined above with a compound of general formula (XXIII): TIFF0007583022000019.tif33170 (in the formula, R 4 can be prepared by reacting a compound of formula (I) with a compound of formula (I)
[0118] Suitably the reaction is carried out in the presence of a coupling reagent such as those described above, for example HATU.
[0119] Compounds of general formula (XXIII) are known and readily available or can be prepared by known methods.
[0120] Some compounds of general formula (XXV) are known, others can be synthesized by one skilled in the art.
[0121] For example, R 8 and R 9 each independently is methyl or ethyl; 10 The compound of general formula (XXV) in which is OH can be represented by general formula (XXVI): TIFF0007583022000020.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 8 and R 9 is independently methyl or ethyl; 20is prepared from a compound of general formula (XXI) (as defined for general formula (XXI)) by reaction with an alkali metal salt of a malonic acid monoester (such as potassium methyl malonate) or an alkali metal salt of cyanoacetic acid (such as potassium 2-cyanoacetate) in the presence of a Pd catalyst (such as [Pd(allyl)Cl]), a phosphine ligand (such as BINAP), and an organic base (such as DMAP). The resulting ester or nitrile can then be hydrolyzed with aqueous base.
[0122] The compound of general formula (XXVI) is represented by general formula (XXVII): TIFF0007583022000021.tif43170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 8 is methyl or ethyl, R 20 can be prepared from a compound of general formula (XXI)
[0123] Under appropriate conditions, R 9 -MgBr(wherein, R 9 It is prepared by reaction with an alkyl Grignard reagent, such as (wherein is methyl or ethyl).
[0124] The compound of general formula (XXVII) can be represented by general formula (XXVIII): TIFF0007583022000022.tif43170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 8 is methyl or ethyl, and R 17 is as defined for general formula (VII), 20 -Br(wherein, R 20can be prepared by protection by reaction with (as defined for general formula (XXI)), suitably in the presence of a weak base such as potassium carbonate.
[0125] The compound of general formula XXVIII) can be prepared by the reaction of a compound of general formula (XXIX): TIFF0007583022000023.tif56170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 8 is methyl or ethyl, and R 17 can be prepared from a compound of formula (VII) (as defined for general formula (VII)) by reaction with aluminum chloride in a solvent-free reaction at elevated temperatures, typically about 150-200°C.
[0126] The compound of general formula (XXIX) is represented by general formula (XXX): TIFF0007583022000024.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII) 8 For compounds of general formula (XXIX) where R is methyl, ethanoyl chloride, or 8 Compounds of general formula (XXIX) in which is ethyl can be prepared by reaction with propanoyl chloride.
[0127] Compounds of general formula (XXX) are known and readily available or can be prepared by known methods.
[0128] R 9 is methyl or halomethyl, and R 10 The compound of general formula (XXV) where is CN can be represented by general formula (XXXV): TIFF0007583022000025.tif43170 (in the formula, R 5 , R6 , R 7 and R 8 is as defined for general formula (I), and R 9 is methyl and R 17 is as defined for general formula (VII), and R 20 is as defined for general formula (XXI)) by reacting with an alkali metal salt of a malonic acid monoester (such as potassium methyl malonate) in the presence of a Pd catalyst (such as [Pd(allyl)Cl]), a phosphine ligand (such as BINAP), and an organic base (such as DMAP). The resulting ester can then be hydrolyzed with aqueous base.
[0129] R 8 and R 9 is independently methyl or ethyl, the compound of general formula (XXXV) can be converted to a compound of general formula (XXXVI): TIFF0007583022000026.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 20 can be prepared from a compound of general formula (XXI)
[0130] R 8 and R 9 For compounds in which the general formula (XXXVI) is the same, the compound of the general formula: R 8 -I (In the formula, R 8 is methyl or ethyl) and The reaction can be carried out in the presence of a strong base such as sodium hydride.
[0131] R 8 and R 9 are not the same, the general formula: R 8 and R 9 -I (In the formula, R 8 and R 9 one of which is methyl and the other is ethyl) Again, the sequential reactions can be carried out in the presence of a strong base such as sodium hydride.
[0132] The compound of general formula (XXXVI) has the general formula (XXXVII): TIFF0007583022000027.tif43170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII)) with a compound R 20 -Br(wherein, R 20 can be prepared by reacting a compound represented by general formula (XXI) with a compound represented by general formula (XXI).
[0133] Compound R 20 --Br is known and readily available or can be prepared by known methods.
[0134] The compound of general formula (XXXVII) can be represented by the general formula (XXXVIII): TIFF0007583022000028.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 25 is an OH protecting group, e.g., tri(C 1-6 alkyl)silyl or benzyl, and R 26 is halo, for example chloro or bromo) with sodium cyanide, followed by aqueous workup to remove the silyl protecting group.
[0135] The compound of general formula (XXXVI) is R 25It can also be prepared directly from a compound of general formula (XXXVIII) in which is benzyl by reaction with sodium cyanide.
[0136] The compound of general formula (XXXVIII) can be represented by general formula (XXXIX): TIFF0007583022000029.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 25 can be prepared from a compound of general formula (XXXVIII) by reaction with a suitable halogenating agent. For example, R 26 When is chloro, thionyl chloride may be used.
[0137] The compound of general formula (XXXIX) can be represented by general formula (XL): TIFF0007583022000030.tif43170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 27 is C 1-6 from a compound of general formula (XXXVIII) (wherein the OH group is alkyl or benzyl), by converting the OH group into a group R as defined above for general formula (XXXVIII) 25 and subsequent reaction with a reducing agent, typically a hydride such as sodium borohydride or lithium borohydride.
[0138] Compounds of general formula (XL) are readily available or can be synthesized by known methods.
[0139] R 8 and R 9 together with the atoms to which they are attached form a carbocyclic ring, and R 10The compound of general formula (XXV) in which is CN can be represented by general formula (XXXVa): TIFF0007583022000031.tif40170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 20 can be prepared from a compound of general formula (XXI) (where n is 0, 1, 2 or 3) by reaction with an alkali metal salt of a malonic acid monoester (such as potassium methyl malonate) in the presence of a Pd catalyst (such as [Pd(allyl)Cl]), a phosphine ligand (such as BINAP) and an organic base (such as DMAP), followed by aqueous basic hydrolysis as described above for the conversion of a compound of general formula (XXXV) to a compound of general formula (XXV).
[0140] Compounds of general formula (XXXVa) can be prepared from compounds of general formula (XXXVI) as defined above by the addition of compounds of general formula (XLIa): R 28 -CH2-(CH2) n -CH2-R 29 (XLIa) (wherein n is as defined above for general formula (XXXVa), and R 28 and R 29 Each of which is independently a halo such as chloro, bromo, or iodo) can be prepared by reaction with a compound of
[0141] R 8 and R 9 together with the atoms to which they are attached form a 3- to 6-membered oxygen-containing heterocyclic ring, and R 10 Compounds of general formula (XXV) where is CN can be prepared from compounds of general formula (XXXVc): TIFF0007583022000032.tif43170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R17 is as defined for general formula (VII), and R 20 is as defined for general formula (XXI), and each p and q is 0, 1, 2, 3, or 4, with the proviso that the sum of p and q is 1 to 4).
[0142] This method is similar to that described above for the reaction of compounds of general formula (XXV) and (XXXVa).
[0143] Compounds of general formula (XXXVa) can be prepared from compounds of general formula (XXXVI) as defined above by the addition of compounds of general formula (XLIc): R 28 -(CH2) p -O-(CH2) q -R 29 (XLIc) (wherein p and q are as defined above for general formula (XXXVc), and R 28 and R 29 Each of which can be prepared independently by reaction with a compound of general formula (XLIa) as defined above.
[0144] Compounds of general formula (XLIa) and (XLIc) are known and readily available or can be prepared by known methods.
[0145] R 8 and R 9 is methyl and R 10 is a heterocyclic group, in particular a methyl substituted with a nitrogen-containing heterocyclic group attached to the methyl carbon via a ring nitrogen atom, can be represented by the general formula (XXXVb): TIFF0007583022000033.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 20 is as defined for general formula (XXI), and R 30can be prepared from compounds of the formula (III) (a heterocyclic group, particularly a nitrogen-containing heterocyclic group attached to the methyl carbon through a ring nitrogen atom) by reaction with an alkali metal salt of a malonic acid monoester (such as potassium methyl malonate) in the presence of a Pd catalyst (such as [Pd(allyl)Cl]), a phosphine ligand (such as BINAP), and an organic base (such as DMAP), followed by aqueous base hydrolysis as described above.
[0146] Compounds of general formula (XXXVb) can be prepared from compounds of general formula (XXXV) defined above in two steps. First, the compound of general formula (XXXV) is reduced using a hydride reducing agent such as diisobutylaluminum hydride (DIBAL) to convert the cyano group to an aldehyde. The aldehyde moiety is then converted to a compound of formula R under acidic conditions (e.g., acetic acid) and in the presence of a reducing agent such as sodium triacetoxyborohydride (STAB). 30 -H(wherein, R 30 is reacted with a compound of general formula (XXXVb) as defined above.
[0147] R 8 and R 9 together with the carbon atoms to which they are attached to form an oxetane ring, and R 10 The compound of general formula (XXV) in which is methyl optionally substituted with halo can be represented by general formula (L): TIFF0007583022000034.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 10 is methyl optionally substituted with halo, and R 17 is as defined for general formula (VII), and R 20can be prepared from a compound of general formula (XXI)) by reaction with halo-(2-alkoxy-2-oxo-ethyl)zinc (such as bromo-(2-tert-butoxy-2-oxo-ethyl)zinc) in the presence of a palladium catalyst (such as [Pd(allyl)Cl]), a phosphine ligand (such as QPhos) and an organic base such as DMAP, followed by hydrolysis of the resulting ester using aqueous base.
[0148] The compound of general formula (L) has the general formula (LI): TIFF0007583022000035.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 10 is methyl optionally substituted with halo, and R 17 is as defined for general formula (VII), and R 20 can be prepared from compounds of general formula (XXI) by reaction with a sulfur ylide such as trimethylsulfoxonium iodide in a Corey Chaykovsky type reaction.
[0149] The compound of general formula (LI) has the general formula (LII): TIFF0007583022000036.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 10 is methyl optionally substituted with halo, and R 17 is as defined for general formula (VII), and R 20 is as defined for general formula (XXI)
[0150] The oxidation can be carried out under acidic conditions, for example using Dess-Martin periodinane in the presence of trifluoroacetic acid.
[0151] R10 The compounds of general formula (LII) in which is CF3 or CHF2 can be represented by general formula (LIII): TIFF0007583022000037.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 20 is as defined for general formula (XXI)) from a compound of general formula (LIV): (CH3)3-Si-R 10 (LIV) (In the formula, R 10 can be prepared by reaction of a compound of the formula (III) with a compound of the formula (III) (wherein R is methyl, optionally substituted with halo, or alternatively a trialkylsilane).
[0152] The reaction can be carried out in an organic solvent such as dichloromethane at about 15-25°C, typically at room temperature.
[0153] Compounds of general formula (LIV) are readily available or can be synthesized by known methods.
[0154] The compound of general formula (LIII) can be represented by the general formula (LIX): TIFF0007583022000038.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 16 is as defined for general formula (IV)), for example with boron tribromide, after reaction with dichloro(methoxy)methane in the presence of a Lewis acid such as titanium tetrachloride, to give the group R 16 Remove compound R 20 -Br to form the group R 20 can be prepared by reprotecting with the group R 20is as defined for general formula (XXI), suitably in the presence of a weak base such as potassium carbonate.
[0155] Compounds of general formula (LIX) are known and readily available or can be synthesized by known methods.
[0156] Compounds of general formula (LIII) can be modified by treating the aldehyde with an olefination reaction, for example a Wittig type reaction, and the product can be further modified to give compounds similar in structure to compounds of general formula (XXXV), (XXXVa), (XXXVb), (XXXVc), (XXXVI), (XXXVII) and (L), but containing R 7 Compounds with alternative substituents at positions between the substituent and the OH substituent can be generated (see preparation of intermediate R below). The synthesis of additional similar compounds with alternative substituents is also shown below (see preparation of intermediates B, BA, BB, BC, BD, BE, C, CA, CB, D, E, M, N, and W).
[0157] R 10 C 1-4 To obtain a compound of general formula (LII) that is alkyl, an appropriate Grignard reagent can be reacted with a compound of general formula (LIII).
[0158] The compound of general formula (LIII) can be represented by the general formula (LV): TIFF0007583022000039.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 20 is as defined for general formula (XXI).
[0159] A suitable oxidizing agent for this reaction is manganese dioxide, and the reaction may be carried out in an organic solvent such as toluene at the reflux temperature of the solvent.
[0160] The compound of general formula (LV) has the general formula (LVI): TIFF0007583022000040.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 17 is as defined for general formula (VII), and R 20 is as defined for general formula (XXI), and R 21 is halo, for example chloro or bromo, by reaction with a hydroxide, suitably an alkali metal hydroxide, such as sodium hydroxide or potassium hydroxide, in an organic solvent such as dioxane. Suitably, the reaction is carried out at the reflux temperature of the solvent.
[0161] Compounds of general formula (LV) can also be prepared directly from compounds of general formula (XL) via protection of the phenol followed by reduction of the ester using a reducing agent such as NaBH4.
[0162] Compounds of general formula (LVI) may contain a group R as defined above for general formula (XXI). 20 may be prepared from compounds of general formula (XL) as defined above by protecting the OH group with, followed by reduction of the ester and then conversion of the resulting alcohol to an alkyl halide (for example using thionyl chloride).
[0163] A further method for preparing compounds of general formula (XXV) is to prepare a compound of general formula (LVII): TIFF0007583022000041.tif40170 (in the formula, R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is as defined for general formula (I), and R 20(wherein XXI is as defined for XXI) with a hydroxide, for example an aqueous base, for example an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, in a solvent such as THF. The reaction can be carried out in an organic solvent such as tetrahydrofuran at elevated temperature, for example the reflux temperature of the solvent.
[0164] This method is 8 , R 9 and R 10 are particularly suitable for compounds which, taken together with the carbon atoms to which they are attached, form a fused or bridged ring system.
[0165] R 8 , R 9 and R 10 taken together with the carbon atoms to which they are attached to form a fused or bridged ring system, the compound of general formula (LVII) may be a compound of formula (LVIII): TIFF0007583022000042.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 20 is as defined for general formula (XXI), and R 22 can be prepared from a compound in which the aryl group is halo, for example chloro or bromo.
[0166] Compounds of general formula (LVIII) can be reacted with suitable bridged or fused ring halides and the substituents on the rings can be manipulated as required.
[0167] Compounds of general formula (LVIII) are readily available or can be synthesized by known methods.
[0168] R 9 is OH and R 10 Compounds of general formula (I) where R is methyl optionally substituted with halo can be prepared from compounds of general formula (LX), which can be prepared from compounds of general formula (LX) 8 and R 9are bonded to form an ethenyl group, and R 10 can be reacted with an aqueous acid such as methanesulfonic acid in a mixture of 1,4-dioxane and water to give the halo: TIFF0007583022000043.tif43170 (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is as defined in general formula (I), and R 10 is methyl optionally substituted with halo).
[0169] The compound of general formula (LX) can be represented by general formula (LXI): TIFF0007583022000044.tif43170 (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is as defined for general formula (I), and R 12 can be prepared from the compound halo, e.g., chloro or bromo, by reaction with 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in the presence of tripotassium phosphate, tricyclohexylphosphine, and palladium acetate (Pd(OAc)).
[0170] Using a similar method, R 8 and R 9 are linked to form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring, and R 10 Compounds of general formula (I) where is OH can be prepared by reacting a compound of general formula (LXI) with an appropriate cyclic 1,3,2-dioxaborolane to form a compound similar to that of general formula (LX) but with the moiety -C(=CH)-R at the position where the cyclic group is attached to the rest of the molecule. 10is replaced with a cyclic group containing a C=C double bond, which can be hydrated under reducing conditions, for example as described in Example 13 below, to give the required product.
[0171] The compound of general formula (LXI) is represented by general formula (LXII): TIFF0007583022000045.tif42170 (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 16a is C 1-6 alkyl or benzyl, and R 12 can be prepared by protecting a compound of general formula (LXI)).
[0172] Deprotection is suitably achieved by treatment with boron tribromide as described above for the deprotection of compounds of general formula (IV).
[0173] The compound of general formula (LXII) can be prepared by reacting the compound of general formula (XXII) defined above with a compound of general formula (LXIII): TIFF0007583022000046.tif43170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 16a is as defined for general formula (LXII), and R 12 can be prepared by reacting a compound of general formula (LXI) with a compound of general formula (LXI).
[0174] Suitably the reaction is carried out under similar conditions as described above for the reaction of a compound of general formula (V) with a compound of general formula (VI).
[0175] Compounds of general formula (LXIII) are known and readily available or can be prepared by known methods.
[0176] The compound of general formula (LXIII) can be represented by general formula (LXIV): TIFF0007583022000047.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 16b is H or C 1-6 The compound may be prepared by brominating or chlorinating a compound of formula (I) (wherein the compound is an alkyl group).
[0177] Bromination or chlorination may be carried out using any suitable agent, such as N-bromosuccinimide, N-chlorosuccinimide, or bromine. 16b When R is H, reaction with a suitable protecting reagent can be carried out to give compounds of general formula (LXIII). For example, reaction with benzyl bromide gives R 16a is benzyl to obtain a compound of formula (LXIII).
[0178] R 8 and R 9 combine with the carbon atoms to which they are attached to form a cyclopropyl ring, and R 10 The method for preparing a compound of general formula (XXI) wherein is methyl optionally substituted with halo can be prepared by reacting a compound of general formula (LXV): TIFF0007583022000048.tif41170 (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 16 is as defined for general formula (IV), and R 10is methyl optionally substituted with halo) with 8-(iodomethyl)-8,8'-spirobi[7,9-dioxa-8-silanuidabicyclo[4.3.0]nona-1,3,5triene], triethylammonium in the presence of (4,4'-di-t-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-kN)phenyl-kC]iridium(III) hexafluorophosphate under irradiation with blue light.
[0179] Suitably the process is as described in Example 8 below and is carried out in an anhydrous organic solvent such as dimethylsulfoxide under an inert atmosphere such as nitrogen.
[0180] R 10 Compounds of general formula (LXV) wherein is methyl may be prepared from compounds of general formula (LXII) defined above by reaction with 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and tripotassium phosphate, followed by tricyclohexylphosphine and palladium acetate.
[0181] In some cases, the introduction of the cyclopropyl group can be carried out at an earlier stage in the process. TIFF0007583022000049.tif43170 (in the formula, R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 15 and R 16 is as defined for general formula (IV), and R 12 A compound of formula (LXXI) (wherein R is halo, e.g., chloro or bromo) can be treated with bis(pinacolato)diboron in the presence of a palladium catalyst such as Pd(dppf)Cl. The boronic ester product of this reaction can then be converted to a compound of formula (LXXI): TIFF0007583022000050.tif20170 (in the formula, R 10 is methyl optionally substituted with halo, and R13 is halo, for example chloro or bromo, and has the general formula (LXXII): TIFF0007583022000051.tif42170 (in the formula, R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 15 and R 16 is as defined for general formula (IV), and R 10 is methyl optionally substituted with halo), the compound of general formula (LXXII) can be treated with a compound of formula (LXXII) to give a product of formula (LXXII) 8 and R 9 together with the carbon atom to which they are attached to form a cyclopropyl group, and R 10 is methyl optionally substituted with halo by reaction with 8-(iodomethyl)-8,8'-spirobi[7,9-dioxa-8-silanuidabicyclo[4.3.0]nona-1,3,5triene], triethylammonium and (4,4'-di-t-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-kN)phenyl-kC]iridium(III) hexafluorophosphate under irradiation with blue light as described for the reaction of compounds of general formula (LXV) above.
[0182] Compounds of general formula (LXI) can be prepared by reacting intermediates similar to compounds of general formulas (V) and (XXV) with -C(R 8 )(R 9 )(R 10 ) group R instead of the substituent 12 These compounds can be prepared by methods similar to those described above for compounds of general formula (I), except that:
[0183] R 8 and R 8 is methyl or ethyl, and R 10 The compound of general formula (I) in which is CHOH or CHCHOH can be represented by general formula (LXXV): TIFF0007583022000052.tif53170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 8 and R 9 each is independently methyl or ethyl, and X is a bond or —CH—, by reduction, for example, by using a hydride reducing agent such as lithium borohydride.
[0184] Suitably the reaction is carried out in an organic solvent such as tetrahydrofuran and the reducing agent is added with cooling, for example at -78°C.
[0185] Compounds of general formula (LXXV) can be prepared by reacting compounds of general formula (XXII) defined above with compounds of general formula (LXXX): TIFF0007583022000053.tif56170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 8 and R 9 Each of these can be prepared by reacting a compound of formula (LXXV) with a compound of formula (LXXV) where each of the following is independently methyl or ethyl and X is as defined for general formula (LXXV).
[0186] Suitably, the reaction is carried out in the presence of a coupling reagent as described above, with T3P® being particularly preferred.
[0187] In some cases, the compound of general formula (LXXV) is isolated and purified prior to reduction to give the compound of general formula (I). In other cases, however, compounds of general formulas (LXXX) and (XXII) are reacted to give a compound of general formula (LXXX), which is then reduced without further purification to give the compound of general formula (I). This is more commonly the case for the five-membered lactone intermediate (LXXX), i.e., when X is a bond.
[0188] In a variant of this method, the compound of general formula (LXXV) can be prepared by reacting a compound of general formula (III) as defined above with a compound of general formula (LXXVI): TIFF0007583022000054.tif56170 (in the formula, R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 8 and R 9 Each of these can be prepared by reacting a compound of formula (LXXV) with a compound of formula (LXXV) where each of the following is independently methyl or ethyl and X is as defined for general formula (LXXV).
[0189] Suitably the reaction is carried out in the presence of a coupling reagent as described above, HATU being an example of a suitable coupling reagent.
[0190] The compound of general formula (LXXV) can be reduced to the compound of general formula (I) without further purification.
[0191] The compound of general formula (LXXVI) can be prepared by the reaction of a compound of general formula (LXXVII): TIFF0007583022000055.tif55170 (in the formula, R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 15 is as defined for general formula (IV), and R 8 and R 9 each of which is independently methyl or ethyl, and X is as defined for general formula (LXXV).
[0192] Suitably the hydrolysis is a base hydrolysis, for example carried out using lithium hydroxide in a solvent such as tetrahydrofuran.
[0193] Compounds of general formula (LXXVII) may be prepared by reacting a compound of general formula (VI) as defined above with a compound of general formula (LXXX) as defined above.
[0194] Suitably, the reaction is carried out in the presence of a coupling reagent as described above, with T3P® being particularly preferred.
[0195] Compounds of general formula (LXXX) where X is -CH2- can be represented by the general formula (LXXXI): TIFF0007583022000056.tif41170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I)) from a compound of general formula (LXXXII): TIFF0007583022000057.tif21170 (in the formula, R 8 and R 9 is as defined for general formula (I), and R 35 is C 1-6 The compound may be prepared by reaction with a compound of formula (I) in which the aryl group is an alkyl group.
[0196] Suitably the reaction is carried out in the presence of a strong acid such as methanesulfonic acid.
[0197] Compounds of general formula (LXXXI) and (LXXXII) are known and readily available or can be prepared by methods known to those skilled in the art.
[0198] The compound of general formula (LXXX) has the general formula (LXXXIII): TIFF0007583022000058.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 16 is as defined for general formula (IV), and R 36 is C 1-6 alkyl or benzyl, and R 37 is C 1-6alkyl, and R 8 and R 9 wherein each is independently methyl or ethyl) by reaction with boron tribromide. The reaction is typically carried out in a solvent such as dichloromethane at a temperature of about -5 to 5°C.
[0199] The compound of general formula (LXXXIII) can be represented by general formula (LXXXIV): TIFF0007583022000059.tif42170 (in the formula, R 5 , R 6 and R 7 is as defined for general formula (I), and R 16 is as defined for general formula (IV), and R 36 is as defined for general formula (LXXXIII), and R 38 is a halogen, in particular bromine or chlorine, more in particular bromine), by reacting a compound of the general formula (LXXXV): TIFF0007583022000060.tif32170 (in the formula, R 37 is as defined for general formula (LXXXIII), and R 8 and R 9 Each of which is independently methyl or ethyl) can be prepared by reacting the compound
[0200] The reaction is carried out using zinc fluoride and Pd(P t It may be carried out in the presence of a palladium / platinum catalyst such as Bu3)2. Suitably the reaction is carried out under an inert atmosphere, for example under nitrogen.
[0201] Compounds of general formula (LXXXV) are known and readily available or can be prepared by methods known to those skilled in the art.
[0202] The compound of general formula (LXXXIV) can be represented by the general formula (LXXXVI): TIFF0007583022000061.tif42170 (in the formula, R 5 , R 6 and R7 is as defined for general formula (I), and R 16 is as defined for general formula (IV), and R 38 is halogen, in particular bromine or chlorine, more in particular bromine, for example to give compounds R 36 -Hal.
[0203] The reaction may be carried out under mildly basic conditions, for example in the presence of potassium carbonate, in a solvent such as N,N-dimethylformamide.
[0204] Compounds of general formula (LXXXVI) can be prepared by halogenating compounds of general formula (IX) as defined above. Suitable halogenating agents include bromine in a solvent such as acetonitrile. Alternatively, N-chlorosuccinimide or N-bromosuccinimide may be used.
[0205] An alternative method for preparing compounds of general formula (LXXV) where X is a bond is a compound of general formula (XC): TIFF0007583022000062.tif43170 (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 16 is as defined for general formula (IV), and R 37 is as defined for general formula (LXXXIII), and R 8 and R 9 each of which is independently methyl or ethyl) with boron tribromide.
[0206] Typically, the reaction is carried out in a solvent such as dichloromethane.
[0207] R 8 is methyl or ethyl, and R9 is CH2OH and R 10 An alternative procedure for the synthesis of compounds of general formula (XXI) where is H is a compound of general formula (XCV): TIFF0007583022000063.tif42170 (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is as defined for general formula (I), and R 37 is as defined for general formula (LXXXIII), and R 8 is methyl or ethyl), typically using a hydride reducing agent such as lithium aluminum hydride.
[0208] Suitably the reaction is carried out in a solvent such as tetrahydrofuran at low temperature, typically -78°C.
[0209] Compounds of general formula (XCV) can be prepared by reacting a compound of general formula (LXII) as defined above with a compound of general formula (XCVI): TIFF0007583022000064.tif24170 (in the formula, R 8 is methyl or ethyl, and R 37 can be prepared by reacting a compound of general formula (LXXXIII) with a compound of general formula (LXXXIII).
[0210] The reaction is carried out using zinc fluoride and Pd(P t It may be carried out in the presence of a palladium / platinum catalyst such as Bu3)2. Suitably the reaction is carried out under an inert atmosphere, for example under nitrogen.
[0211] Compounds of general formula (I) can also be converted to other compounds of general formula (I). For example, R 6Compounds of general formula (I) where R is halo, in particular bromo or chloro, can be reacted with an appropriate alkyl- or alkenyl-boronic ester, for example alkyl- or alkenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, in the presence of tricyclohexylphosphine and palladium acetate and a base (such as K2CO3) to give 6 can be converted to a compound of general formula (I) wherein is alkyl.
[0212] R 5 Compounds of general formula (I) where R is H can be converted to R by reaction with a suitable halogenating agent such as N-chlorosuccinimide or N-bromosuccinimide, suitably at a temperature of about 15-25°C, for example at room temperature, and in a solvent such as N,N-dimethylformamide. 5 can be converted to a compound of general formula (I) wherein is halo, for example chloro or bromo.
[0213] Since the compounds of general formula (I) are positive modulators of TMEM16A, in a further aspect of the present invention there is provided a compound of general formula (I) as defined above for use in medicine, in particular in the treatment or prevention of diseases and conditions affected by modulation of TMEM16A.
[0214] There is also provided the use of a compound of general formula (I) as defined above in the manufacture of a medicament for the treatment or prevention of diseases and conditions affected by modulation of TMEM16A.
[0215] There is also provided a method for the treatment or prevention of diseases and conditions affected by the modulation of TMEM16A, which method comprises administering to a patient in need of such treatment an effective amount of a compound of general formula (I) as defined above.
[0216] Diseases and conditions affected by modulation of TMEM16A include respiratory diseases and conditions, dry mouth (xerostomia), intestinal hypermotility, cholestasis, and ophthalmic conditions. Also provided are:
[0217] A compound of general formula (I) as defined above for use in the treatment or prevention of respiratory diseases and conditions.
[0218] A compound of general formula (I) as defined above for use in the treatment or prevention of dry mouth (xerostomia).
[0219] A compound of general formula (I) as defined above for use in the treatment or prevention of intestinal hypermotility.
[0220] A compound of general formula (I) as defined above for use in the treatment or prevention of cholestasis.
[0221] A compound of general formula (I) as defined above for use in the treatment or prevention of an ophthalmic condition. The present invention also provides:
[0222] Use of a compound of general formula (I) as defined above in the manufacture of a medicament for the treatment or prevention of respiratory diseases and conditions.
[0223] Use of a compound of general formula (I) as defined above in the manufacture of a medicament for treating or preventing dry mouth (xerostomia).
[0224] Use of a compound of general formula (I) as defined above in the manufacture of a medicament for treating or preventing intestinal hypermotility.
[0225] Use of a compound of general formula (I) as defined above in the manufacture of a medicament for treating or preventing cholestasis.
[0226] Use of a compound of general formula (I) as defined above in the manufacture of a medicament for the treatment or prevention of an ophthalmic condition. Additionally, the following is provided:
[0227] A method for the treatment or prevention of respiratory diseases and conditions, which method comprises administering to a patient in need of such treatment an effective amount of a compound of general formula (I) as defined above.
[0228] A method for treating or preventing dry mouth (xerostomia), which comprises administering to a patient in need of such treatment an effective amount of a compound of general formula (I) as defined above.
[0229] A method for treating or preventing intestinal hypermotility, comprising administering to a patient in need of such treatment an effective amount of a compound of general formula (I) as defined above.
[0230] A method for treating or preventing cholestasis, comprising administering to a patient in need of such treatment an effective amount of a compound of general formula (I) as defined above.
[0231] A method for the treatment or prevention of ocular conditions, comprising administering to a patient in need of such treatment an effective amount of a compound of general formula (I) as defined above.
[0232] Respiratory diseases and conditions that may be treated or prevented by the compounds of general formula (I) include cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis (including non-cystic fibrosis bronchiectasis), asthma and primary ciliary dyskinesia.
[0233] Dry mouth (xerostomia) which may be treated or prevented by the compounds of general formula (I) may result from Sjogren's syndrome, radiation therapy and xerogenic drugs.
[0234] Intestinal hypermotility which may be treated or prevented by the compounds of general formula (I) may be associated with gastric dyspepsia, gastroparesis, chronic constipation and irritable bowel syndrome.
[0235] Ophthalmic conditions that may be treated or prevented by the compounds of general formula (I) include dry eye disease.
[0236] The compounds of the invention will generally be administered as part of a pharmaceutical composition and therefore the invention further provides a pharmaceutical composition comprising a compound of general formula (I) together with a pharmaceutically acceptable excipient.
[0237] The pharmaceutical compositions may be formulated for oral, rectal, nasal, topical (including dermal, transdermal, ophthalmic, buccal and sublingual topical administration), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration and may be prepared by any of the methods well known in the art of pharmacy.
[0238] The compounds of the present invention are particularly well suited for oral administration.
[0239] The composition can be prepared by associating the active agent defined above with an excipient.Generally, the formulation is prepared by uniformly and intimately associating the active agent with a liquid carrier or a finely divided solid carrier, or both, and then, if necessary, shaping the product.The present invention also encompasses a method for preparing a pharmaceutical composition, which comprises combining or associating the compound of general formula (I) with a pharmaceutically acceptable carrier or vehicle.
[0240] Formulations for oral administration herein may be presented as discrete units such as capsules, sachets or tablets, each containing a predetermined amount of the active agent; as a powder or granules; as a solution or suspension of the active agent in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as a bolus, etc.
[0241] For compositions for oral administration (e.g., tablets and capsules), the term "acceptable carrier" includes common excipients, such as binders, vehicles such as syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone (povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose, and starch; fillers and carriers, such as corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid; and lubricants, such as magnesium stearate, sodium stearate, and other metallic stearates, glycerol stearate, stearic acid, silicone fluid, talc wax, oils, and colloidal silica. Flavoring agents, such as peppermint, jasmine oil, cherry flavoring, and the like, can also be used. It may be desirable to add a coloring agent to make the dosage form easily identifiable. Tablets can also be coated by methods well known in the art.
[0242] Tablets can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing the active agent in a free-flowing form as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surfactant, or dispersing agent, in a suitable machine. Molded tablets can be made by molding a mixture of a moistened powdered compound and an inert liquid diluent in a suitable machine. Tablets can optionally be coated or grooved, and can be formulated to provide a slow or controlled release of the active agent.
[0243] Other formulations suitable for oral administration include lozenges which contain the active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles which contain the active agent in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes which contain the active agent in a suitable liquid carrier.
[0244] For topical application to the skin, the compounds of general formula (I) may be made up into creams, ointments, jellies, solutions or suspensions, etc. Cream or ointment formulations that may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
[0245] Topical administration to the lung can be achieved by use of aerosol formulations. Aerosol formulations typically contain the active ingredient suspended or dissolved in a suitable aerosol propellant, such as a chlorofluorocarbon (CFC) or hydrofluorocarbon (HFC). Suitable CFC propellants include trichloromonofluoromethane (Propellant 11), dichlorotetrafluoromethane (Propellant 114), and dichlorodifluoromethane (Propellant 12). Suitable HFC propellants include tetrafluoroethane (HFC-134a) and heptafluoropropane (HFC-227). The propellant typically constitutes 40% to 99.5% by weight, e.g., 40% to 90% by weight, of the total inhalation composition. The formulation may contain excipients, including cosolvents (e.g., ethanol) and surfactants (e.g., lecithin, sorbitan trioleate, etc.). Other possible excipients include polyethylene glycol, polyvinylpyrrolidone, glycerin, etc. The aerosol formulation is packaged in a canister and the appropriate dose is delivered by a metered valve (eg supplied by Bespak, Valois or 3M, or alternatively by Aptar, Coster or Vari).
[0246] Topical administration to the lung can also be achieved by the use of non-pressurized formulations, such as aqueous solutions or suspensions. These can be administered by a nebulizer, for example a handheld, portable nebulizer, or a home or hospital (i.e., non-portable) nebulizer. The formulation may contain excipients such as water, buffers, tonicity adjusters, pH adjusters, surfactants, and cosolvents. Suspensions and aerosol formulations (whether pressurized or non-pressurized) typically have a D of, for example, 0.5 to 10 μm, e.g., about 1 to 5 μm. 50 The particle size distribution is D10 , D 50 and D 90 The particle size distribution can be expressed using the value D 50 The median is defined as the particle size in microns that divides the distribution in half. Measurements derived from laser diffraction are more accurately described as volume distributions, and therefore the D obtained using this procedure 50 The value is Dv 50 As used herein, the Dv value refers to the particle size distribution measured using laser diffraction. Similarly, the Dv value used in the context of laser diffraction is more meaningful as the median value of the volume distribution. 10 and D 90 The value is Dv 10 and Dv 90 This is interpreted as meaning the particle size where 10% of the distribution is D 10 below the value, and 90% of the distribution is D 90 Below the value.
[0247] Local administration to the lung can also be achieved by the use of dry powder formulations. Dry powder formulations typically have a mass mean diameter (MMAD) of 1 to 10 μm or a D of 0.5 to 10 μm, for example about 1 to 5 μm. 50 The powder of the compound of the present disclosure in micronized form can be prepared by a micronization process or a similar size reduction process. Micronization may be performed using a jet mill, such as that manufactured by Hosokawa Alpine. The resulting particle size distribution can be measured using laser diffraction (e.g., with a Malvern Mastersizer 2000S instrument). Formulations typically contain particles of generally relatively large particle size, e.g., a mass median diameter (MMAD) of 50 μm or more, e.g., 100 μm or more, or a D of 40 to 150 μm. 50The lactose component may be processed by micronization, sieving, grinding, compaction, agglomeration, or spray drying. Commercially available forms of lactose are available in various forms, e.g., Lactohale. (登録商標) (inhalation-grade lactose; DFE Pharma), InhaLac (登録商標) 70 (sieved lactose for dry powder inhalation; Meggle), Pharmatose ( 登録商標) (DFE Pharma) and Respitose (登録商標) (Sieved Inhalation Grade Lactose; DFE Pharma) products are also included. In one embodiment, the lactose component is selected from the group consisting of α-lactose monohydrate, α-lactose anhydrous, and amorphous lactose. Preferably, the lactose is α-lactose monohydrate.
[0248] Dry powder formulations may also contain other excipients. Thus, in one embodiment, a dry powder formulation according to the present disclosure includes magnesium stearate or calcium stearate. Such formulations may have excellent chemical and / or physical stability, especially if such formulations also contain lactose.
[0249] Dry powder formulations are typically delivered using dry powder inhaler (DPI) devices. Examples of dry powder delivery systems include SPINHALER®, DISKHALER®, TURBOHALER®, DISKUS®, SKYEHALER®, ACCUHALER®, and CLICKHALER®. Further examples of dry powder delivery systems include ECLIPSE, NEXT, ROTAHALER, HANDIHALER, AEROLISER, CYCLOHALER, BREEZHALER / NEOHALER, MONODOSE, FLOWCAPS, TWINCAPS, X-CAPS, TURBOSPIN, ELPENHALER, MIATHALER, TWISTHALER, NOVOLIZER, PRESSAIR, ELLIPTA, ORIEL dry powder inhaler, MICRODOSE, PULVINAL, EASYHALER, ULTRAHALER, TAIFUN, PULMOJET, OMNIHALER, GYROHALER, TAPER, CONIX, XCELOVAIR, and PROHALER.
[0250] In one embodiment, the compound of general formula (I) is provided as a micronized dry powder formulation, for example comprising a suitable grade of lactose.
[0251] Thus, in one aspect of the present invention there is provided a pharmaceutical composition comprising a compound of general formula (I) in granular form in combination with granular lactose, optionally including magnesium stearate.
[0252] In one embodiment, the compound of general formula (I) is provided as a micronized dry powder formulation comprising a suitable grade of lactose and magnesium stearate, which is loaded into a device such as a DISKUS. Suitably, such a device is a multi-dose device, for example, the formulation is loaded into blisters for use in a multi-unit dose device such as a DISKUS.
[0253] In another embodiment, the compound of general formula (I) is provided as a micronized dry powder formulation comprising a suitable grade of lactose filled into a hard shell capsule for use in a single dose device such as, for example, an AEROLISER.
[0254] In another embodiment, the compound of general formula (I) is provided as a micronized dry powder formulation comprising a suitable grade of lactose and magnesium stearate filled into a hard shell capsule for use in a single-dose device such as an AEROLISER.
[0255] In another embodiment, the compound of general formula (I) is provided as a micronized powder for use in an inhalation dosage form, the powder having a D of 0.5 to 10 μm, for example about 1 to 5 μm, produced by a size reduction process other than jet mill micronization, such as spray drying, spray freezing, microfluidization, high pressure homogenization, supercritical fluid crystallization, ultrasonic crystallization, or a combination of these methods, or other suitable particle formation method known in the art used to produce microparticles with an aerodynamic diameter of 0.5 to 10 μm. 50 The resulting particle size distribution can be measured using laser diffraction (e.g., by a Malvern Mastersizer 2000S instrument). The particles can contain the compound alone or in combination with other suitable excipients that can aid in processing. The resulting microparticles can form the final formulation for delivery to humans, or can optionally be further formulated with other suitable excipients to facilitate delivery in an acceptable dosage form.
[0256] The compound of the present invention can also be administered rectally in the form of suppositories or enemas, including aqueous or oily solutions, suspensions, emulsions, and foams.Such compositions are prepared according to standard procedures well known to those skilled in the art.For example, suppositories can be prepared by mixing the active ingredient with a conventional suppository base, such as cocoa butter or other glycerides.In this case, the drug is mixed with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore melts in the rectum to release the drug.Such materials are cocoa butter and polyethylene glycol.
[0257] Generally, for compositions intended to be administered topically to the eye in the form of eye drops or eye ointment, the total amount of compounds of general formula (I) will be from about 0.0001 to less than 4.0% (w / w).
[0258] Preferably, for topical administration to the eye, the compositions administered according to general formula (I) are formulated as solutions, suspensions, emulsions, and other dosage forms. Aqueous solutions are generally preferred due to ease of formulation and the ease with which patients can administer such compositions by instilling one to two drops of the solution into the affected eye. However, the compositions may also be suspensions, viscous or semi-viscous gels, or other types of solid or semi-solid compositions. Suspensions may be preferred for compounds that are poorly soluble in water.
[0259] An alternative method of ocular administration is intravitreal injection of a solution or suspension of a compound of general formula (I). Additionally, the compounds of general formula (I) can also be introduced by means of an ocular implant or insert.
[0260] The administered composition according to general formula (I) may also contain various other ingredients, including, but not limited to, isotonicity agents, buffers, surfactants, stabilizing polymers, preservatives, cosolvents, and viscosity-increasing agents. A suitable pharmaceutical composition according to general formula (I) comprises a compound of the present invention formulated with an isotonicity agent and a buffer. The pharmaceutical composition according to general formula (I) may optionally further contain a surfactant and / or a emollient and / or a stabilizing polymer.
[0261] Various tonicity adjusting agents can be used to adjust the tonicity of the composition, preferably to that of natural tears in ophthalmic compositions. For example, simple sugars such as sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose, fructose, and galactose, and / or simple polyols such as the sugar alcohols mannitol, sorbitol, xylitol, lactitol, isomaltitol, maltitol, and hydrogenated starch hydrolysates can be added to the composition to approximate physiological tonicity. The amount of such tonicity adjusting agents varies depending on the specific agent added. However, generally, the composition contains a sufficient amount of tonicity adjusting agent so that the final composition has an ophthalmically acceptable osmolality (generally about 150-450 mOsm, preferably 250-350 mOsm, and most preferably about 290 mOsm). Generally, the tonicity adjusting agent of the present invention is present in the range of 2-4% (w / w). Preferred tonicity adjusting agents of the present invention include simple sugars or sugar alcohols, such as D-mannitol.
[0262] An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate, or boric acid) can be added to the composition to prevent pH drift under storage conditions. Specific concentrations will vary depending on the agent used. Preferably, however, the buffer is selected to maintain a target pH within the range of pH 5-8, more preferably a target pH of pH 5-7.
[0263] Surfactants may optionally be used to deliver higher concentrations of the compound of formula (I). Surfactants function to solubilize the compound and stabilize colloidal dispersions, such as micellar solutions, microemulsions, emulsions, and suspensions. Examples of optional surfactants include polysorbates, poloxamers, polyosyl stearate 40, polyoxyl castor oil, tyloxapol, Triton, and sorbitan monolaurate. Preferred surfactants for use in the present invention have a hydrophilic / lipophilic balance (HLB) in the range of 12.4 to 13.2 and are acceptable for ophthalmic use, such as Triton X114 and tyloxapol.
[0264] An additional agent that can be added to the ophthalmic composition of the compound of general formula (I) is a emollient that functions as a stabilizing polymer. The stabilizing polymer should be an ionic / chargeable example that is preferred for topical ocular application, more specifically, a polymer that can exhibit a zeta potential of (-)10 to 50 mV for physical stability and has a negative charge on its surface that allows it to be dispersed in water (i.e., aqueous). A preferred stabilizing polymer of the present invention is a polyelectrolyte, or polyelectrolytes, from the family of crosslinked polyacrylates, such as Carbomer and Pemulen®, especially Carbomer 974p (polyacrylic acid), at 0.1 to 0.5% w / w.
[0265] Other compounds may be added to the ophthalmic composition of the compound of general formula (I) to increase the viscosity of the carrier. Examples of viscosity-increasing agents include, but are not limited to, polysaccharides such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextran, various polymers of the cellulose family, vinyl polymers, and acrylic acid polymers.
[0266] Topical ophthalmic products are typically packaged in multi-dose form. Therefore, a preservative is required to prevent microbial contamination during use. Suitable preservatives include benzalkonium chloride, chlorobutanol, benzododecinium bromide, methylparaben, propylparaben, phenylethyl alcohol, edentate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically used at levels of 0.001 to 1.0% w / v. Unit-dose compositions of general formula (I) are sterile but typically not preserved. Therefore, such compositions generally do not contain preservatives.
[0267] Parenteral formulations are generally sterile.
[0268] A physician or other person skilled in the art can determine the appropriate dosage of a compound of general formula (I), and therefore the amount of a compound of the invention to be included in any particular pharmaceutical formulation (whether in unit dosage form or not).
[0269] The compounds of general formula (I) may be used in combination with one or more other active agents useful in the treatment or prevention of respiratory diseases and conditions.
[0270] Additional active agents of this type may be included in the pharmaceutical compositions described above, or may be administered separately, either at the same time as the compound of general formula (I), or at an earlier or later time.
[0271] Thus, in a further aspect of the present invention, there is provided a product comprising a compound of general formula (I) and an additional agent useful for the treatment or prevention of a respiratory condition as a combined preparation for simultaneous, sequential or separate use in the treatment of a disease or condition affected by modulation of TMEM16A, in particular a respiratory disease or condition, such as one of the diseases and conditions mentioned above.
[0272] Compounds of general formula (I) may also be provided in combination with an additional agent useful for the treatment or prevention of a disease or condition affected by modulation of TMEM16A, in particular a respiratory disease or condition, such as a combined preparation for simultaneous, sequential or separate use in the treatment of one of the above diseases and conditions.
[0273] Suitable additional active agents that may be included in pharmaceutical compositions or combination preparations with compounds of general formula (I), (Ix), (IA), (IB), (IC), (ID) or (IE) include: Beta-2 adrenergic receptor agonists such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, indacaterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol, olodaterol, vilanterol and abedeterol; Antihistamines, for example histamine H1 receptor antagonists or H4 receptor antagonists such as loratadine, cetirizine, desloratadine, levocetirizine, fexofenadine, astemizole, azelastine and chlorpheniramine; dornase alfa; Corticosteroids such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, mometasone furoate, and fluticasone furoate; Leukotriene antagonists such as montelukast and zafirlukast; anticholinergic compounds, particularly muscarinic antagonists such as ipratropium, tiotropium, glycopyrrolate, aclidinium and umeclidinium; CFTR repair therapies (e.g., CFTR potentiators, correctors, or amplifiers) such as Ivacaftor, QBW251, Bamacaftor (VX659), Elexacaftor (VX445), VX561 / CPT-656, VX152, VX440, GLP2737, GLP2222, GLP2451, PTI438, PTI801, PTI808, FDL-169, and FDL-176, and CFTR correctors such as Lumacaftor and Tezacaftor or combinations thereof (e.g., the combination of Ivacaftor, Tezacaftor, and Elexacaftor); ENaC modulators, especially ENaC inhibitors; antibiotics; antiviral agents such as ribavirin and neuraminidase inhibitors such as zanamivir; antifungal agents such as PUR1900; Airway hydration agents (osmoloytes) such as hypertonic saline and mannitol (Bronchitol®); and Mucolytic agents, such as N-acetylcysteine.
[0274] When the additional active agent is an ENaC modulator, it can be an ENaC inhibitor such as amiloride, VX-371, AZD5634, QBW276, SPX-101, BI443651, BI1265162, and ETD001. Other suitable ENaC blockers are disclosed in our applications WO 2017 / 221008, WO 2018 / 096325, WO 2019 / 077340, and WO 2019 / 220147, and any of the exemplary compounds of these applications can be used in combination with compounds of general formula (I). Compounds particularly suitable for use in combination with compounds of general formula (I) include compounds having a cation selected from the following: 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)ethyl]-6-(4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}piperidine-1-carbonyl)-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)methyl]-6-{[2-(4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}piperidin-1-yl)ethyl]carbamoyl}-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)methyl]-5-[4-({bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}methyl)piperidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)methyl]-6-[(3R)-3-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}pyrrolidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)methyl]-6-[(3S)-3-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}pyrrolidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)methyl]-1,3-diethyl-6-{[(1r,4r)-4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}cyclohexyl]carbamoyl}-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)methyl]-1,3-diethyl-6-{[(1s,4s)-4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}cyclohexyl]carbamoyl}-1H-1,3-benzodiazol-3-ium; and a suitable anion, such as a halide, sulfate, nitrate, phosphate, formate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate. [Brief explanation of the drawings]
[0275] [Figure 1] FIG. 10 is an exemplary trace from a whole-cell patch clamp (Qpatch) TMEM16A potentiator assay as used in Biological Example 21, illustrating the methodology used in this assay. [Example]
[0276] General conditions: Mass spectra were performed on an LC-MS system using electrospray ionization. They were performed using either a Waters Acquity uPLC system or a Shimadzu LCMS-2010EV system equipped with a Waters PDA and ELS detector. [M+H]+ refers to the monoisotopic molecular weight.
[0277] NMR spectra were recorded on a Bruker Avance III HD 500 MHz equipped with a 5 mm Broad Band Inverse probe, a Bruker Avance III HD 250 MHz equipped with a 5 mm Broad Band Observed SmartProbe, and a 400 MHz Avance III HD Nanobay using the solvent as an internal deuterium lock. Unless otherwise stated, spectra were recorded at room temperature and referenced using the solvent peak.
[0278] With reference to the following examples, compounds of preferred embodiments were synthesized using methods described herein or other methods known in the art.
[0279] The various starting materials, intermediates, and compounds of the preferred embodiments can be isolated and purified, if necessary, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Unless otherwise specified, all starting materials are obtained from commercial suppliers and used without further purification. Salts can be prepared from compounds by known salt-forming procedures.
[0280] Compounds were purified by flash column chromatography on normal-phase silica on a Biotage® Isolera system using appropriate SNAP or Sfar cartridges and gradients. Alternatively, compounds were purified on reverse-phase silica using either a Biotage® Isolera or Biotage® Selekt system with appropriate SNAP C18 or Sfar C18 cartridges and reverse-phase eluents, or by preparative HPLC (where otherwise noted).
[0281] Preparative HPLC with acidic pH, early elution method Purification was performed on a Gilson LC system using a Waters Sunfire C18 column (30 mm x 100 mm, 10 μM; temperature: RT) and a gradient of 10 to 95% B (A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile) over 14.44 min, followed by 95% B over 2.11 min, with an injection volume of 1500 μL and a flow rate of 40 mL / min. UV spectra were recorded at 215 nm using a Gilson detector.
[0282] Preparative HPLC with acidic pH, standard elution method Purification by preparative HPLC (acidic pH, standard elution) was performed on a Gilson LC system using a Waters Sunfire C18 column (30 mm x 100 mm, 10 μM; temperature: RT) and a gradient of 30 to 95% B over 11 min (A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile), followed by 95% B over 2.11 min, with an injection volume of 1500 μL and a flow rate of 40 mL / min. UV spectra were recorded at 215 nm using a Gilson detector.
[0283] Preparative HPLC with basic pH, early elution method Purification by preparative HPLC (basic pH, fast elution) was performed on a Gilson LC system using a Waters Xbridge C18 column (30 mm x 100 mm, 10 μM; temperature: RT) and a gradient of 10 to 95% (A = 0.2% ammonium hydroxide in water; B = 0.2% ammonium hydroxide in acetonitrile) over 14.44 min, followed by 95% B over 2.11 min, with an injection volume of 1500 μL and a flow rate of 40 mL / min. UV spectra were recorded at 215 nm using a Gilson detector.
[0284] Preparative HPLC with basic pH, standard elution method Purification by preparative HPLC (basic pH, standard elution) was performed on a Gilson LC system using a Waters Xbridge C18 column (30 mm x 100 mm, 10 μM; temperature: RT) and a gradient of 30 to 95% (A = 0.2% ammonium hydroxide in water; B = 0.2% ammonium hydroxide in acetonitrile) over 11 min, followed by 95% B over 2.11 min, with an injection volume of 1500 μL and a flow rate of 40 mL / min. UV spectra were recorded at 215 nm using a Gilson detector.
[0285] Unless otherwise indicated, analytical HPLC conditions are as follows: Method A Column: Phenomenex Kinetix-XB C18 2.1 x 100 mm, 1.7 μm Column temperature: 40℃ Eluent: A: H2O + 0.1% formic acid, B: Acetonitrile + 0.1% formic acid Flow rate: 0.6mL / min Gradient: 0–5.3 min 5–100% B, 5.3–5.8 min 100% B, 5.8–5.82 min 100–5% B, 5.82–7.00 min 5% B Method C Column: Waters UPLC® BEH (商標) C18 2.1×100mm, 1.7μm Column temperature: 40℃ Eluent: A: 2 mM ammonium bicarbonate buffered to pH 10, B: acetonitrile Flow rate: 0.6mL / min Gradient: 0–5.3 min 5–100% B, 5.3–5.8 min 100% B, 5.8–5.82 min 100–5% B, B, 5.82–7.00 min 5% B Method E Column: Kinetex Core-Shell C18 2.1x50mm, 5μm Column temperature: 40℃ Eluent: A: H2O + 0.1% formic acid, B: Acetonitrile + 0.1% formic acid Flow rate: 1.2mL / min Gradient: 0-1.20 min 5-100% B, 1.20-1.30 min 100% B, 1.30-1.31 min 100-5% B, 1.31-1.7 min 5% B Method F Column: Phenomenex Gemini-NX C18 2.0 x 50 mm, 3 μm Column temperature: 40℃ Eluent: A: 2 mM ammonium bicarbonate buffered to pH 10, B: acetonitrile Flow rate: 1mL / min Gradient: 0-1.80 min 1-100% B, 1.80-2.10 min 100% B, 2.10-2.30 min 100-1% B, 2.30-3.50 min 1% B Method G Column: Waters UPLC® BEH (商標) C18, 2.1mm x 50mm, 1.7μm, Column temperature: 40℃ Eluent: A: H2O + 0.1% formic acid, B: Acetonitrile + 0.1% formic acid Flow rate: 0.9mL / min Gradient: 0-1.10 min 5-100% B, 1.10-1.35 min 100% B, 1.35-1.40 min 100-5% B, 1.40-1.50 min 5% B Method H Column: Kinetex Core-Shell C18 2.1x50mm, 5μm Column temperature: 40℃ Eluent: A: H2O + 0.1% formic acid, B: Acetonitrile + 0.1% formic acid Flow rate: 1.2mL / min Gradient: 0-1.83 min, 5-100% B, 1.83-2.25 min, 100% B, 2.25-2.26 min, 100-5% B, 2.26-2.8 min, 5% B Method I: Column: Waters UPLC® BEH (商標) C18 2.1×30mm, 1.7μm Column temperature: 40℃ Eluent: A: 2 mM ammonium bicarbonate buffered to pH 10, B: acetonitrile Flow rate: 1.0mL / min Gradient: 0-0.75 min 5-100% B, 0.75-0.85 min 100% B, 0.85-0.9 min 100-5% B, 0.9-1.0 min 5% B
[0286] The following examples are intended to illustrate the present invention and should not be construed as limitations thereon. Temperatures are given in degrees Celsius. Unless otherwise specified, all evaporations are carried out in vacuo, preferably at about 15 mmHg to 100 mmHg (= 20 to 133 mbar). The structures of final products, intermediates, and starting materials are confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS and NMR. Abbreviations used are conventional in the art. Unless defined, terms have their generally accepted meanings.
[0287] Abbreviation aq. aqueous solution br Broad Cy Cyclohexyl d doublet dd Double of doublets DIBAL Diisobutylaluminum hydride DCM dichloromethane DCE 1,2-dichloroethane DIPEA Diisopropylethylamine DMAP 4-dimethylaminopyridine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EtOH ethanol EtOAc ethyl acetate HATU 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HPLC High Pressure Liquid Chromatography IPA Isopropyl Alcohol MeCN acetonitrile MeOH Methanol MS mass spectrometry m multiplet min mL milliliter m / z mass-to-charge ratio NMR nuclear magnetic resonance Q-Phos 1,2,3,4,5 Pentaphenyl-1'-(di-tert-butylphosphino)ferrocene Rt retention time s singlet t triplet T3P® 1-Propanephosphonic Anhydride Solution TBAF Tetra-n-butylammonium fluoride TBTU N,N,N',N'-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate TEA TEA TFA trifluoroacetic acid THF tetrahydrofuran μL microliter
[0288] Preparation example Example 1 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide TIFF0007583022000065.tif35170
[0289] Step 1: Methyl 4-[[2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate TIFF0007583022000066.tif35170
[0290] To a stirred solution of 2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetic acid (Intermediate G) (120 mg, 0.5 mmol), methyl 4-aminopyridine-2-carboxylate (76 mg, 0.5 mmol), and DIPEA (96 μL, 0.55 mmol) in 1,4-dioxane (1 mL) was added a 50% T3P® solution in EtOAc (297 μL, 0.5 mmol), and the mixture was stirred at room temperature for 45 minutes. The resulting mixture was partitioned between EtOAc (20 mL) and water (20 mL). The organic portion was separated, dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0 to 100% EtOAc in heptane to afford the title compound as an off-white solid.
[0291] LC-MS (Method E): Rt 1.20 min; MS m / z 375.2=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,chloroform-d)δ 8.61(d,J=5.5Hz,1H),8.05-7.84(m,2H),7.60(s,1H),7.07(d,J=11.9Hz,1H),6. 77(d,J=6.6Hz,1H),3.99(s,3H),3.83(s,3H),3.73(d,J=1.0Hz,2H),1.36(s,9H).
[0292] Step 2: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid TIFF0007583022000067.tif35170
[0293] 1M BBr3 in DCM (0.21 mL, 2.24 mmol) was cooled (0 °C) and added dropwise to a stirred suspension of methyl 4-[[2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate (Step 1) (140 mg, 0.37 mmol) in DCM (4 mL). After 30 min, the ice bath was removed and the reaction mixture was stirred at room temperature for 6 h. The resulting mixture was concentrated in vacuo, and the residue was partitioned between EtOAc (10 mL) and saturated NaHCO3 (10 mL). The aqueous portion was separated, and the pH was adjusted to approximately 3 with 2 M aqueous HCl. The mixture was extracted with EtOAc (2 × 10 mL), and the combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give the title compound as an off-white solid.
[0294] LC-MS (Method E): Rt 0.98 min; MS m / z 347.1=[M+H]+ (94% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 11.26(s,1H),9.33(s,1H),8.62(d,J=6.1Hz,1H),8.40(d,J=2.1Hz,1H),8.00(dd,J=6 .1,2.1Hz,1H),6.88(d,J=11.9Hz,1H),6.74(d,J=6.9Hz,1H),3.72(s,2H),1.32(s,9H)
[0295] Step 3: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide
[0296] To a solution of 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxyphenyl)acetyl]amino]pyridine-2-carboxylic acid (Step 2) (80 mg, 0.21 mmol), 1-methylcyclopropanamine (15 mg, 0.21 mmol), and DIPEA (73 μL, 0.42 mmol) in DMF (1 mL) was added HATU (75 mg, 0.2 mmol), and the resulting mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated in vacuo, and the residue was partitioned between EtOAc (5 mL) and water (5 mL). The organic layer was washed with water (2 × 5 mL), brine (5 mL), dried over NaSO, and concentrated in vacuo. The crude material was purified by preparative HPLC (acidic pH, fast elution method), and the desired fractions were combined and lyophilized overnight to afford the title compound as an off-white powder.
[0297] LC-MS (Method A): Rt 3.51 min; MS m / z 400.2=[M+H]+ (96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.74(s,1H),9.29(s,1H),8.76(s,1H),8.44(d,J=5.5Hz,1H),8.17(d,J=2.0Hz,1H),7.80(dd,J=5.5,2.2Hz,1H),6.87 (d,J=11.9Hz,1H),6.73(d,J=6.9Hz,1H),3.64(s,2H),1.35(s,3H),1.31(s,9H),0.82-0.70(m,2H),0.66-0.55(m,2H).
[0298] The compounds of the following tabular examples (Table 1) were prepared in a manner similar to Example 1 by replacing 1-methylcyclopropanamine (Step 3) with the appropriate commercially available amine. [Table 1] TIFF0007583022000069.tif255170TIFF0007583022000070.tif255170TIFF0007583022000071.tif255170
[0299] Examples 1.3a and 1.3b Chiral separation of racemic 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanoethyl)pyridine-2-carboxamide (Example 1.3) using supercritical fluid chromatography [chiral phase column 7% MeOH:93% CO2, Chiralcel OJ-H at 15 ml / min] afforded the individual enantiomers.
[0300] Example 1.3a: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyanoethyl]pyridine-2-carboxamide or 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyanoethyl]pyridine-2-carboxamide TIFF0007583022000072.tif41170(R)-isomer TIFF0007583022000073.tif43170(S)-isomer
[0301] First eluting peak: SFC retention time = 3.48 min LC-MS (Method A): Rt 3.35 min; MS m / z 399.2=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),9.49(d,J=8.1Hz,1H),9.32(s,1H),8.53(d,J=5.5Hz,1H),8.25(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz, 1H),6.88(d,J=11.9Hz,1H),6.74(d,J=6.9Hz,1H),5.07-4.99(m,1H),3.65(s,2H),1.55(d,J=7.2Hz,3H),1.32(s,9H).
[0302] Example 1.3b: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyanoethyl]pyridine-2-carboxamide or 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyanoethyl]pyridine-2-carboxamide TIFF0007583022000074.tif43170(R)-isomer TIFF0007583022000075.tif42170(S)-isomer
[0303] Second eluting peak: SFC retention time = 4.36 min LC-MS (Method A): Rt 3.35 min; MS m / z 399.2=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.83(s,1H),9.49(d,J=8.1Hz,1H),9.33(s,1H),8.53(d,J=5.5Hz,1H),8.25(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz, 1H),6.88(d,J=11.9Hz,1H),6.74(d,J=6.9Hz,1H),5.07-4.99(m,1H),3.65(s,2H),1.55(d,J=7.2Hz,3H),1.32(s,9H).
[0304] Examples 1.6a and 1.6b Chiral separation of racemic 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide (Example 1.6) using supercritical fluid chromatography [chiral phase column 25% IPA:75% CO2, Chiralpak IC 25 cm at 4 ml / min] gave the individual enantiomers.
[0305] Example 1.6a: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide or 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide TIFF0007583022000076.tif37170(R)-isomer TIFF0007583022000077.tif36170(S)-isomer
[0306] First eluting peak: SFC retention time = 2.33 min LC-MS (Method A): Rt 3.16 min; MS m / z 429.3=[M+H]+ (98% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.84(s,1H),9.32(s,1H),8.74(s,1H),8.52(d,J=5.5Hz,1H),8.25(d,J=2.0Hz,1H),7.86(dd,J=5.5,2.1Hz,1H),6.88(d,J=11.9 Hz,1H),6.75(d,J=6.9Hz,1H),5.91(s,1H),3.82(d,J=10.8Hz,1H),3.73(d,J=10.9Hz,1H),3.66(s,2H),1.66(s,3H),1.32(s,9H).
[0307] Example 1.6b: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide or 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide TIFF0007583022000078.tif38170(R)-isomer TIFF0007583022000079.tif38170(S)-isomer
[0308] Second eluting peak: SFC retention time = 4.26 min LC-MS (Method A): Rt 3.16 min; MS m / z 429.3=[M+H]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.85(s,1H),9.30(s,1H),8.74(s,1H),8.52(d,J=5.5Hz,1H),8.25(d,J=2.0Hz,1H),7.86(dd,J=5.5,2.1Hz,1H),6.88(d,J=11.9 Hz,1H),6.75(d,J=6.9Hz,1H),5.91(s,1H),3.82(d,J=11.0Hz,1H),3.73(d,J=10.9Hz,1H),3.66(s,2H),1.66(s,3H),1.32(s,9H).
[0309] Example 2 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000080.tif38170
[0310] Step 1: 4-[[2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000081.tif60170
[0311] To a stirred solution of 2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetic acid (Intermediate B) (38 mg, 0.12 mmol), 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (29 mg, 0.12 mmol), and DIPEA (23 μL, 0.13 mmol) in 1,4-dioxane (0.5 mL) was added a 50% T3P® solution in EtOAc (71 μL, 0.12 mmol), and the reaction mixture was stirred at room temperature for 1.5 hours. The resulting mixture was partitioned between EtOAc (5 mL) and water (5 mL). The organic layer was separated, dried over NaSO, and concentrated in vacuo to give the title compound as an off-white solid.
[0312] LC-MS (Method E): Rt 1.24 min; MS m / z 546.3=[M+H]+ (93% at 215 nm) 1 H NMR(500MHz,MeOD)δ 8.49(d,J=5.3Hz,1H),8.19(s,1H),7.90(d,J=4.8Hz,1H),7.46-7.42(m,2H),7.37-7.26 (m,4H),7.02(d,J=6.0Hz,1H),5.12(s,2H),3.77(s,2H),1.57(s,6H),1.42-1.18(m,4H).
[0313] Step 2: 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0314] To a solution of 4-[[2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 1) (45 mg, 0.08 mmol) in EtOH (2 mL) was added 10% Pd—C (9 mg, 0.01 mmol). The mixture was placed under a hydrogen atmosphere and stirred for 2 hours. The resulting mixture was filtered through Celite® (filter material) and rinsed with EtOH (10 mL). The filtrate was concentrated in vacuo, and the crude material was purified by preparative HPLC (acidic pH, fast elution method) to afford the title compound as an off-white solid.
[0315] LC-MS (Method A): Rt 2.95 min; MS m / z 456.2=[M+H]+ (98% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),9.58(br s,1H),9.40(s,1H),8.51(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.85(dd ,J=5.5,2.2Hz,1H),7.11(d,J=11.4Hz,1H),6.73(d,J=6.6Hz,1H),5.63(br s,1H),3.68(s,2H),1.49(s,6H),1.35-1.27(m,2H),1.24-1.14(m,2H).
[0316] The title compound was also prepared according to the following method.
[0317] A cooled (0 °C) solution of 4-[[2-(2-fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Example 7.1) (1.0 g, 2.29 mmol) in IPA (20 mL) and DCM (4 mL) purged with air was treated with tris(2,2,6,6-tetramethyl-3,5-heptanedionato)manganese(III) (0.14 g, 0.23 mmol), followed by the dropwise addition of phenylsilane (0.56 mL, 4.57 mmol). The reaction mixture was stirred at room temperature for 2 hours with a continuous air purge. The reaction was quenched with 20% aqueous sodium thiosulfate solution (100 mL) and stirred at room temperature for 30 minutes. The resulting mixture was extracted with EtOAc (3 x 100 mL), and the combined organic extracts were washed with brine (100 mL), dried over MgSO4, and concentrated in vacuo. Purification by chromatography on silica eluting with 0-100% EtOAc in heptane, followed by 0-100% MeOH in EtOAc, gave a yellow solid. The solid was further purified by C18 reverse-phase chromatography eluting with 10-100% aqueous MeCN (+0.1% formic acid) to give a white solid. The solid was recrystallized from MeCN (12 mL) to give the title compound as a white solid.
[0318] LCMS (Method A-MSQ2, 7 min) Rt 2.92 min; MS m / z 456.2 = [M+H]+ (100% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.56(bs,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=1.9Hz,1H),7.84(dd,J=5.5,2.1Hz,1H),7.10 (d,J=11.4Hz,1H),6.72(d,J=6.6Hz,1H),5.63(bs,1H),3.67(s,2H),1.48(s,6H),1.35-1.23(m,2H),1.25-1.10(m,2H).
[0319] Example 2.1 N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000082.tif37170
[0320] The title compound was prepared from 2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetic acid (Intermediate B) and 4-amino-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Intermediate AB) in analogy to Steps 1 and 2 of Example 2.
[0321] LC-MS (Method A): Rt 2.57 min; MS m / z 415.3=[M+H]+(95% at 215 nm) (500 MHz,DMSO-d6)δ 10.83(s,1H),9.57(br s,1H),8.84(s,1H),8.53(d,J=5.5Hz,1H),8.24(d,J=2.1Hz,1H),7.86(dd,J=5.5,2.2Hz,1H),7. 11(d,J=11.4Hz,1H),6.73(d,J=6.7Hz,1H),5.63(s,1H),3.69(s,2H),1.73(s,6H),1.50(s,6H).
[0322] Example 2.2 N-tert-butyl-4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000083.tif36170
[0323] The title compound was prepared from 2-[5-benzyloxy-4-(1-cyano-1-methyl-ethyl)-2-fluoro-phenyl]acetic acid (Intermediate C) and 4-amino-N-tert-butyl-pyridine-2-carboxamide in analogy to Steps 1 and 2 of Example 2.
[0324] LC-MS (Method C): Rt 3.27 min; MS m / z 411.5=[MH]-(99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),10.10(s,1H),8.46(d,J=5.5Hz,1H),8.18(d,J=2.1Hz,1H),8.03(s,1H),7.80(dd,J=5 .5,2.2Hz,1H),7.04(d,J=11.0Hz,1H),6.87(d,J=6.7Hz,1H),3.72(s,2H),1.69(s,6H),1.40(s,9H).
[0325] Example 2.3 4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000084.tif36170
[0326] The title compound was prepared from 2-[5-benzyloxy-4-(1-cyano-1-methyl-ethyl)-2-fluoro-phenyl]acetic acid (Intermediate C) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to steps 1 and 2 of Example 2.
[0327] LC-MS (Method C): Rt 3.20 min; MS m / z 465.3=[M+H]+ (96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),10.05(br.s,1H),9.39(s,1H),8.51(d,J=5.4Hz,1H),8.21(s,1H),7.87-7.78(m,1H),7.04 (d,J=10.9Hz,1H),6.87(d,J=6.5Hz,1H),3.72(s,2H),1.69(s,6H),1.33-1.26(m,2H),1.20-1.12(m,2H).
[0328] Example 2.4 N-tert-butyl-4-[[2-[4-(1-cyanocyclopropyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000085.tif32170 The title compound was prepared from 2-[5-benzyloxy-4-(1-cyanocyclopropyl)-2-fluoro-phenyl]acetic acid (Intermediate D) and 4-amino-N-tert-butyl-pyridine-2-carboxamide in analogy to steps 1 and 2 of Example 2.
[0329] LC-MS (Method A): Rt 3.05 min; MS m / z 411.3=[M+H]+ (96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),9.96(br s,1H),8.46(d,J=5.5Hz,1H),8.18(d,J=2.1Hz,1H),8.03(s,1H),7.80(dd,J=5.5,2.2Hz,1H),7.08(d, J=10.1Hz,1H),6.85(d,J=6.5Hz,1H),3.71(s,2H),1.59-1.52(m,2H),1.40(s,9H),1.33-1.26(m,2H).
[0330] Example 2.5 N-(1-cyano-1-methyl-ethyl)-4-[[2-[4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000086.tif49170 The title compound was prepared from 2-[5-benzyloxy-4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluorophenyl]acetic acid (Intermediate E) and 4-amino-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Intermediate AB) in a manner similar to steps 1 and 2 of Example 2.
[0331] LC-MS (Method A): Rt 1.70 min; MS m / z 498.3=[M+H]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 11.56(s,1H),10.82(s,1H),8.84(s,1H),8.52(d,J=5.5Hz,1H),8.23(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),6.86(d,J= 12.1Hz,1H),6.71(d,J=7.1Hz,1H),3.66(s,2H),3.57-3.49(m,4H),2.64(s,2H),2.48-2.41(m,4H),1.72(s,6H),1.31(s,6H).
[0332] Example 2.6 4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000087.tif35170
[0333] The title compound was prepared from 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) and 2-[5-benzyloxy-2-fluoro-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetic acid (Intermediate L) in analogy to Steps 1 and 2 of Example 2.
[0334] LC-MS (Method A): Rt 2.99 min; MS m / z 470.2=[M+H]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.39(s,1H),9.38(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),6.90(d,J=12.1Hz,1 H),6.72(d,J=7.0Hz,1H),4.75(t,J=5.3Hz,1H),3.64(s,2H),3.60(d,J=5.0Hz,2H),1.32-1.28(m,2H),1.25(s,6H),1.21-1.16(m,2H).
[0335] The title compound was also prepared according to the following method.
[0336] Step 1: 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000088.tif39170
[0337] To a solution of 2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate U) (98%, 1.82 g, 7.5 mmol) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (96%, 2.11 g, 8.25 mmol) in DMF (40 mL) was added DIPEA (3.93 mL, 22.49 mmol), followed by a 50% T3P® solution in EtOAc (8.93 mL, 14.99 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was diluted with EtOAc (150 mL) and washed with brine (3 × 150 mL). The combined aqueous washes were extracted with EtOAc (80 mL), and the organic extract was washed with brine (3 × 80 mL). The organic extracts were combined, dried over Na2SO4 and concentrated in vacuo to give the title compound as a pale yellow solid.
[0338] LC-MS (Method E): Rt 1.24 min; MS m / z 466.2=[M+H]+ (92% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.84(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.19(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.4 5(d,J=8.9Hz,1H),7.31(d,J=5.8Hz,1H),3.83(s,2H),1.45(s,6H),1.32-1.28(m,2H),1.21-1.16(m,2H).
[0339] Step 2: 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0340] To a cooled (-78 °C) solution of 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 1) (92%, 3.46 g, 6.84 mmol) in THF (65 mL) was added 4 M LiBH4 in THF (1.88 mL, 7.53 mmol). The mixture was stirred for 30 min, then gradually warmed to room temperature and stirred for 4 h. The resulting mixture was poured into ice-cold 1 M HCl (150 mL), allowed to stand for 20 min, and then partitioned between EtOAc (200 mL) and water (100 mL). The phases were separated, and the aqueous portion was further extracted with EtOAc (200 mL). The combined organic extracts were washed with saturated NaHCO3 solution (2 x 150 mL), brine (150 mL), dried over Na2SO4, and concentrated in vacuo. The crude residue was suspended in EtOAc (ca. 19 mL), filtered, and the solid was washed with EtOAc (3 x 10 mL). The solid was dried under vacuum for 1 h and then azeotroped with MeCN (2 x 100 mL) to give a white solid. The filtrate from the EtOAc filtration was concentrated in vacuo to give a yellow solid, which was purified by C18 reverse-phase chromatography eluting with MeCN / water 10-100% (0.1% formic acid) to give an off-white solid. The solids from the EtOAc filtration and reverse-phase purification were combined and recrystallized from MeCN to give the title compound as a colorless crystalline solid.
[0341] LC-MS (Method A): Rt 2.96 min; MS m / z 470.2=[M+H]+ (99% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),9.57-9.20(m,2H),8.50(d,J=5.5Hz,1H),8.21(d,J=1.9Hz,1H),7.84(dd,J=5.5,2.1Hz,1H),6.90(d,J=12. 1Hz,1H),6.72(d,J=7.0Hz,1H),4.76(s,1H),3.65(s,2H),3.60(s,2H),1.32-1.28(m,2H),1.25(s,6H),1.21-1.16(m,2H).
[0342] Example 2.7 N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000089.tif36170
[0343] The title compound was prepared from 2-[5-benzyloxy-2-fluoro-4-(2,2,2 trifluoro-1-hydroxy-1-methyl-ethyl)phenyl]acetic acid (Intermediate BA) and 4-amino-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Intermediate AB) in analogy to Steps 1 and 2 of Example 2.
[0344] LC-MS (Method A): Rt 2.91 min; MS m / z 469.2=[M+H]+ (97% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.86(s,1H),8.84(s,1H),8.52(d,J=5.5Hz,1H),8.23(d,J=1.9Hz,1H),7.85(dd,J=5.5,2.2 Hz,1H),7.24(d,J=11.4Hz,1H),6.80(d,J=6.6Hz,1H),3.72(s,2H),1.79(s,3H),1.72(s,6H).
[0345] Example 2.8 4-[[2-[4-(1-cyclopropyl-1-hydroxy-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000090.tif39170
[0346] The title compound was prepared from 2-[5-benzyloxy-4-(1-cyclopropyl-1-hydroxy-ethyl)-2-fluorophenyl]acetic acid (Intermediate BB) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to Steps 1 and 2 of Example 2.
[0347] LC-MS (Method A): Rt 3.23 min; MS m / z 482.3=[M+H]+ (98% at 215 nm) 1 H NMR (500 MHz, DMSO-d6) δ 10.80(s,1H),9.61(s,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2 .0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.08(d,J=11.4Hz,1H),6.72(d,J=6 .7Hz,1H),5.36(s,1H),3.67(s,2H),1.55-1.48(m,4H),1.32-1.27(m,2H), 1.21-1.16(m,2H),0.48-0.41(m,1H),0.36-0.23(m,2H),0.19-0.13(m,1H).
[0348] Example 2.9 4-[[2-[4-(4-cyanotetrahydropyran-4-yl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000091.tif36170
[0349] The title compound was prepared from 2-[5-benzyloxy-4-(4-cyanotetrahydropyran-4-yl)-2-fluorophenyl]acetic acid (Intermediate M) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to Steps 1 and 2 of Example 2.
[0350] LC-MS (Method A): Rt 2.92 min; MS m / z 507.2=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.84(s,1H),10.16(s,1H),9.40(s,1H),8.51(d,J=5.5Hz,1H),8.21(d, J=2.1Hz,1H),7.84(dd,J=5.5,2.1Hz,1H),7.06(d,J=11.0Hz,1H),6.90(d ,J=6.7Hz,1H),4.01-3.93(m,2H),3.73(s,2H),3.68(m,2H),2.32-2.27(m ,2H),2.00(td,J=13.2,4.2Hz,2H),1.32-1.28(m,2H),1.21-1.16(m,2H).
[0351] Example 2.10 4-[[2-[2-Fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000092.tif37170
[0352] The title compound was prepared from 2-[5-benzyloxy-2-fluoro-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetic acid (Intermediate N) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to Steps 1 and 2 of Example 2.
[0353] LC-MS (Method A): Rt 3.41 min; MS m / z 522.4=[M+H]+ (95% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.86(s,1H),9.88(br.s,1H),9.38(s,1H),8.51(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),6.96(d,J=10.2Hz ,1H),6.88(d,J=6.3Hz,1H),4.75-4.65(m,1H),4.55-4.46(m,1H),3.74(s,2H),3.19-3.05(m,2H),1.34-1.27(m,2H),1.22-1.16(m,2H).
[0354] Example 2.11 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000093.tif32170 The title compound was prepared from 2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-propyl)phenyl]acetic acid (Intermediate BC) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to steps 1 and 2 of Example 2.
[0355] LC-MS (Method A): Rt 3.12 min; MS m / z 470.2=[M+H]+(100% at 215 nm) 1H NMR (500 MHz, DMSO-d6) δ 10.80(s,1H),9.58(s,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.0Hz ,1H),7.84(dd,J=5.5,2.2Hz,1H),7.06(d,J=11.5Hz,1H),6.70(d,J=6.7Hz,1H) ,5.43(s,1H),3.67(s,2H),1.95(dq,J=14.8,7.4Hz,1H),1.70(dq,J=14.5,7.2H z,1H),1.46(s,3H),1.33-1.27(m,2H),1.22-1.16(m,2H),0.69(t,J=7.4Hz,3H).
[0356] Examples 2.11a and 2.11b
[0357] Chiral separation of racemic 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Example 2.11) gave the individual enantiomers by chiral HPLC [chiral phase column 95% heptane:5% EtOH, Chiralcel OD-H, 4.6 x 250 mm, 5 μL, 0.5 mL / min].
[0358] Example 2.11a: 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide or 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide JPEG0007583022000094.jpg36170(R)-isomer JPEG0007583022000095.jpg36170(S)-isomer
[0359] First eluting peak: Chiral HPLC retention time = 44.37 min LC-MS (Method A): Rt 3.15 min; MS m / z 470.4=[M+H]+ (98% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),9.58(br.s,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.1 Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.06(d,J=11.5Hz,1H),6.70(d,J=6.7Hz,1H) ,5.45(br.s,1H),3.66(s,2H),1.95(dq,J=14.8,7.4Hz,1H),1.70(dq,J=14.4,7.2 Hz,1H),1.46(s,3H),1.36-1.25(m,2H),1.25-1.16(m,2H),0.69(t,J=7.4Hz,3H).
[0360] Example 2.11b: 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide or 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide JPEG0007583022000096.jpg36170(R)-isomer JPEG0007583022000097.jpg36170(S)-isomer
[0361] Second eluting peak: Chiral HPLC retention time = 50.81 min LC-MS (Method A): Rt 3.15 min; MS m / z 470.4=[M+H]+ (98% at 215 nm)
[0362] 1H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),9.60(br.s,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.0 Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.06(d,J=11.5Hz,1H),6.70(d,J=6.7Hz,1H) ,5.44(br.s,1H),3.67(s,2H),1.95(dq,J=14.7,7.4Hz,1H),1.70(dq,J=14.6,7.3 Hz,1H),1.46(s,3H),1.32-1.26(m,2H),1.23-1.15(m,2H),0.69(t,J=7.4Hz,3H).
[0363] Example 2.12 4-[[2-[5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000098.tif37170
[0364] The title compound was prepared from 2-[5-benzyloxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetic acid (Intermediate BD) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to steps 1 and 2 of Example 2.
[0365] LC-MS (Method A): Rt 3.00 min; MS m / z 452.2=[M+H]+(100% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 10.72(s,1H),9.50(s,1H),9.37(s,1H),8.49(d,J=5.5Hz,1H),8.21(d,J=1.9Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),7 .04(s,1H),6.63(s,1H),5.76(s,1H),3.61(s,2H),2.16(s,3H),1.48(s,6H),1.33-1.27(m,2H),1.22-1.15(m,2H).
[0366] Example 2.13 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclobutyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000099.tif36170
[0367] Step 1: [1-[2-benzyloxy-5-fluoro-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]cyclobutyl]methyl acetate TIFF0007583022000100.tif54170
[0368] To a solution of 2-[4-[1-(acetoxymethyl)cyclobutyl]-5-benzyloxy-2-fluorophenyl]acetic acid (Intermediate CA) (94%, 142 mg, 0.35 mmol) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (93 mg, 0.38 mmol) in 1,4-dioxane (2 mL) was added DIPEA (91 μL, 0.52 mmol), followed by a 50% T3P® solution in EtOAc (0.31 mL, 0.52 mmol), and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with EtOAc (10 mL) and washed sequentially with 1 M HCl (10 mL), saturated NaHCO3 solution (10 mL), and brine (10 mL). The organic portion was dried over Na2SO4 and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-50% EtOAc in heptane to afford the title compound as a pale yellow powder.
[0369] LC-MS (Method E): Rt 1.44 min; MS m / z 614.4=[M+H]+ (99% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.81(s,1H),9.38(s,1H),8.51(d,J=5.5Hz,1H),8.21(d,J=2.1Hz,1H),7.85(dd,J=5.5 ,2.2Hz,1H),7.46-7.41(m,2H),7.40-7.35(m,2H),7.34-7.29(m,1H),7.09(d,J=6.3Hz, 1H),6.82(d,J=10.4Hz,1H),5.04(s,2H),4.31(s,2H),3.76(s,2H),2.35-2.27(m,2H),2 .18-2.11(m,2H),2.07-1.97(m,1H),1.90(s,3H),1.78-1.70(m,1H),1.31-1.17(m,4H).
[0370] Step 2: 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclobutyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0371] To a solution of [1-[2-benzyloxy-5-fluoro-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]cyclobutyl]methyl acetate (Step 1) (99%, 135 mg, 0.22 mmol) in MeOH (1 mL) was added K2CO3 (33 mg, 0.24 mmol) and the mixture was stirred at room temperature for 2 hours. The resulting mixture was filtered through Celite® and washed with MeOH (1 mL). To the filtrate was added 10% Pd / C (14 mg, 0.01 mmol) and the mixture was placed under an H2 atmosphere and stirred for 2 hours. The resulting mixture was filtered through Celite® and washed thoroughly with MeOH. The filtrate was concentrated in vacuo and the crude material was purified by chromatography on silica eluting with 50-100% EtOAc in heptane to afford the title compound as a colorless powder.
[0372] LC-MS (Method A): Rt 3.10 min; MS m / z 482.3=[M+H]+ (94% at 215 nm) 1 H NMR (400 MHz, DMSO-d6) δ 10.79(s,1H),9.38(s,1H),9.01(s,1H),8.50(d,J=5.5Hz,1H),8.22(d,J=1.9H z,1H),7.84(dd,J=5.5,2.1Hz,1H),6.69(d,J=6.7Hz,1H),6.65(d,J=10.8Hz,1 H),4.84(t,J=5.4Hz,1H),3.65(s,2H),3.62(d,J=5.6Hz,2H),2.21-2.16(m,4H ),2.00-1.90(m,1H),1.74-1.67(m,1H),1.32-1.27(m,2H),1.21-1.17(m,2H).
[0373] Example 2.14 N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000101.tif37170
[0374] The title compound was prepared from 2-[5-benzyloxy-2-fluoro-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetic acid (Intermediate N) and 4-amino-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Intermediate AB) in analogy to Steps 1 and 2 of Example 2.
[0375] LC-MS (Method A): Rt 3.11 min; MS m / z 481.4=[M+H]+ (100% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.89(s,1H),9.83(s,1H),8.85(s,1H),8.53(d,J=5.5Hz,1H),8.24(d,J=2.0Hz,1H),7.86(dd,J=5.5,2.2Hz,1H),6.97(d ,J=10.1Hz,1H),6.88(d,J=6.3Hz,1H),4.73-4.66(m,1H),4.55-4.48(m,1H),3.76(s,2H),3.18-3.06(m,2H),1.72(s,6H).
[0376] Example 2.15 4-[[2-[2-Fluoro-5-hydroxy-4-[4-(hydroxymethyl)tetrahydropyran-4-yl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000102.tif42170
[0377] The title compound was prepared from 2-[4-[4-(acetoxymethyl)tetrahydropyran-4-yl]-5-benzyloxy-2-fluorophenyl]acetic acid (Intermediate CB) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to Steps 1 and 2 of Example 2.
[0378] LC-MS (Method A): Rt 2.56 min; MS m / z 512.1=[M+H]+ (100% at 215 nm) 1 H NMR (500 MHz, DMSO-d6) δ 10.82(s,1H),9.40(d,J=6.9Hz,2H),8.51(d,J=5.5Hz,1H),8.22(d,J=1.9Hz, 1H),7.84(dd,J=5.5,2.2Hz,1H),6.88(d,J=12.2Hz,1H),6.76(d,J=7.0Hz,1H ),4.61(t,J=5.2Hz,1H),3.70-3.61(m,6H),3.43-3.37(m,2H),2.26-2.17(m, 2H),1.83(ddd,J=13.3,9.3,3.6Hz,2H),1.33-1.27(m,2H),1.22-1.15(m,2H).
[0379] Example 2.16 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclopropyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000103.tif35170
[0380] Step 1: Methyl 1-[2-benzyloxy-4-(2-benzyloxy-2-oxo-ethyl)-5-fluoro-phenyl]cyclopropanecarboxylate TIFF0007583022000104.tif60170
[0381] Activated zinc (1.066 g, 16.31 mmol) in THF (54.35 mL) was heated at 65 °C and treated with bromine (70 μL, 1.22 mmol) and stirred until the red color dissipated. Methyl 1-bromocyclopropanecarboxylate (21.89 g, 12.23 mmol) was added, and the mixture was heated at 70 °C for 2 h. The mixture was then cooled to room temperature and allowed to settle to remove residual Zn dust.
[0382] A separate vessel was charged with Pd(dba) (234 mg, 0.41 mmol), Q-Phos (290 mg, 0.41 mmol), and benzyl 2-(5-benzyloxy-4-bromo-2-fluorophenyl)acetate (Intermediate S, Step 2) (3.5 g, 8.15 mmol) and placed under a nitrogen atmosphere. To this mixture transferred via syringe was added the freshly prepared Negishi reagent, and the reaction mixture was stirred at 65 °C for 3 h. The resulting mixture was concentrated in vacuo and purified by chromatography on silica eluting with 0-30% EtOAc in heptane (repeated twice) to afford the title compound as a pale pink solid.
[0383] LC-MS (Method I): Rt 0.77 min; MS m / z 466.3=[M+NH4]+ (97% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.40-7.31(m,10H),7.11-7.06(m,2H),5.14(s,2H),5.06(s,2H),3.76(s,2H),3.48(s,3H),1.47-1.41(m,2H),1.18-1.13(m,2H).
[0384] Step 2: 2-[2-fluoro-5-hydroxy-4-(1-methoxycarbonylcyclopropyl)phenyl]acetic acid TIFF0007583022000105.tif34170
[0385] A mixture of methyl 1-[2-benzyloxy-4-(2-benzyloxy-2-oxo-ethyl)-5-fluoro-phenyl]cyclopropanecarboxylate (Step 1) (97%, 3.64 g, 7.88 mmol) in EtOH (60 mL) was treated with 10% Pd / C (50% in water) (15.38 g, 0.72 mmol), placed under a hydrogen atmosphere, and stirred at room temperature for 4 hours. The resulting mixture was filtered through Celite®, washed with EtOAc, and concentrated in vacuo to afford the title compound as a pale yellow soft glass.
[0386] LC-MS (Method G): Rt 0.69 min; MS m / z 269.1=[M+H]+ (94% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 12.42(br.s,1H),9.36(s,1H),6.91(d,J=10.3Hz,1H),6.69(d,J=6.7Hz,1H),3.52(s,3H),3.49(s,2H),1.44-1.39(m,2H),1.12-1.06(m,2H).
[0387] Step 3: 2-(5-fluoro-2-oxo-spiro[benzofuran-3,1'-cyclopropan]-6-yl)acetic acid TIFF0007583022000106.tif39170
[0388] 2-[2-Fluoro-5-hydroxy-4-(1-methoxycarbonylcyclopropyl)phenyl]acetic acid (Step 2) (94%, 2.8 g, 9.81 mmol) in THF (10 mL) was treated with 1 M KOH (29.44 mL, 29.44 mmol) at room temperature and stirred for 2 h. The resulting mixture was treated with 1 M aqueous HCl (39.25 mL, 39.25 mmol) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried over Na SO and concentrated in vacuo. The residue was dissolved in THF (20 mL), treated with 4 M HCl in dioxane (3.46 mL, 98.12 mmol), and heated at 80 °C for 1 h. Additional 4 M HCl in dioxane (10 mL) was added, and stirring was continued at 80 °C for 1 h. After cooling to room temperature, the mixture was concentrated in vacuo to provide the title compound as an off-white solid.
[0389] LC-MS (Method E): Rt 0.98 min; (83% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 12.46(br.s,1H),7.27(d,J=5.8Hz,1H),7.12-7.08(m,1H),3.64(d,J=1.6Hz,2H),1.89-1.84(m,2H),1.76-1.71(m,2H).
[0390] Step 4: 4-[[2-(5-fluoro-2-oxo-spiro[benzofuran-3,1'-cyclopropan]-6-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000107.tif41170
[0391] 2-(5-Fluoro-2-oxo-spiro[benzofuran-3,1'-cyclopropan]-6-yl)acetic acid (Step 3) (83%, 1.860 g, 6.54 mmol) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (1.76 g, 7.19 mmol) in 1,4-dioxane (40 mL) were treated with DIPEA (3.42 mL, 19.61 mmol) and a 50% T3P® solution in EtOAc (7.78 mL, 13.07 mmol), and the mixture was stirred at room temperature for 45 minutes. The resulting mixture was partitioned between EtOAc (150 mL) and water (150 mL), and the phases were separated. The aqueous portion was back-extracted with EtOAc (150 mL), then the combined organic extracts were dried over Na.sub.2SO.sub.4 and concentrated in vacuo to give the title compound as a beige solid.
[0392] LC-MS (Method E): Rt 1.20 min; MS m / z 464.2=[M+H]+ (98% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.81(s,1H),9.38(s,1H),8.50(d,J=5.5Hz,1H),8.19(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.1Hz,1H),7.33(d,J=5.8Hz ,1H),7.12(d,J=9.0Hz,1H),3.83(s,2H),1.90-1.84(m,2H),1.78-1.73(m,2H),1.33-1.26(m,2H),1.21-1.16(m,2H).
[0393] Step 5: 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclopropyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0394] To a cooled (-78°C) solution of 4-[[2-(5-fluoro-2-oxo-spiro[benzofuran-3,1'-cyclopropan]-6-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 4) (98%, 3.12 g, 6.59 mmol) in THF (70 mL) was added dropwise 4M LiBH4 in THF (1.81 mL, 7.25 mmol). The mixture was stirred at -78°C for 10 minutes, then gradually warmed to room temperature and stirred at room temperature for 5 hours. The resulting mixture was cooled to 0°C in an ice bath and quenched by the dropwise addition of 1M HCl (70 mL). The resulting mixture was warmed to room temperature, diluted with EtOAc (300 mL) and water (230 mL), and the phases were separated. The aqueous portion was extracted with EtOAc (300 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo to give the crude product as a beige solid. The solid was recrystallized from EtOAc (approximately 25 mL) to give a white powdery solid. The mother liquor was concentrated in vacuo to give a yellow solid, which was purified by C18 reverse-phase chromatography eluting with MeCN / water 10-100% (0.1% formic acid) to give an off-white solid.
[0395] The material from the EtOAc crystallization and reverse-phase purification was combined in MeCN and concentrated in vacuo. The solid was azeotroped with MeCN and then recrystallized from MeCN and dried overnight in a high vacuum oven at about 40° C. to give the title compound as a white solid.
[0396] LC-MS (Method A): Rt 2.84 min; MS m / z 468.3=[M+H]+ (99% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 10.79(s,1H),9.38(s,1H),9.24(s,1H),8.51(d,J=5.5Hz,1H),8.21(d,J= 1.9Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),6.89(d,J=10.4Hz,1H),6.75(d,J =6.7Hz,1H),4.99(t,J=5.4Hz,1H),3.67(s,2H),3.47(d,J=5.3Hz,2H),1. 35-1.27(m,2H),1.23-1.14(m,2H),0.83-0.73(m,2H),0.68-0.58(m,2H).
[0397] Example 3 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)-5-fluoro-pyridine-2-carboxamide TIFF0007583022000108.tif38170
[0398] Step 1: N-(2-bromo-5-fluoro-4-pyridyl)-2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetamide TIFF0007583022000109.tif39170
[0399] The title compound was prepared from 2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetic acid (Intermediate G) and 2-bromo-5-fluoro-pyridin-4-amine in analogy to Step 1 of Example 1. DIPEA was replaced with TEA. LC-MS (Method E): Rt 1.38 min; MS m / z 413.0,415.0=[M+H]+(94% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.67(s,1H),8.41(d,J=2.6Hz,1H),8.38(d,J=5.8Hz,1H),6.98(d,J=6. 7Hz, 1H), 6.95 (d, J=11.8Hz, 1H), 3.87 (s, 2H), 3.78 (s, 3H), 1.31 (s, 9H).
[0400] Step 2: Methyl 4-[[2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxylate TIFF0007583022000110.tif38170
[0401] All reagents were loaded into a COware gas reactor system (a two-chamber glass apparatus) according to the following procedure;
[0402] Chamber A was charged with N-(2-bromo-5-fluoro-4-pyridyl)-2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetamide (Step 1) (500 mg, 1.21 mmol) and Pd(dppf)Cl (85 mg, 0.12 mmol), and the apparatus was flushed with nitrogen. Chamber B was charged with a solution of formic acid (320 μL, 8.47 mmol) and methanesulfonyl chloride (656 μL, 8.47 mmol) in degassed toluene (5 mL). A solution of TEA (423 μL, 2.42 mmol) in MeOH (5 mL) was then added to Chamber A, followed by TEA (2.96 mL, 16.94 mmol) in Chamber B to generate carbon monoxide. The COware apparatus was heated to 60 °C for 16 h. The mixture obtained from Chamber A was partitioned between EtOAc (100 mL) and water (100 mL). The phases were separated, and the aqueous portion was re-extracted with EtOAc (100 mL). The combined organic extracts were dried over Na2SO4, concentrated in vacuo, and the crude material was purified by chromatography on silica eluting with 0 to 100% EtOAc in heptane to afford the title compound as a pale beige foam.
[0403] LC-MS (Method E): Rt 1.25 min; MS m / z 393.1=[M+H]+ (94% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.67(s,1H),8.91(d,J=6.4Hz,1H),8.66(d,J=2.4Hz,1H),6.99(d,J=6.7Hz,1 H),6.96(d,J=11.8Hz,1H),3.87(s,2H),3.85(s,3H),3.79(s,3H),1.32(s,9H).
[0404] Step 3: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxylic acid TIFF0007583022000111.tif38170
[0405] 1M BBr3 in DCM (4.34 mL, 4.34 mmol) was added to a solution of methyl 4-[[2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxylate (Step 2) (98%, 348 mg, 0.87 mmol) in DCM (10 mL), and the mixture was stirred at room temperature for 4 hours. The resulting mixture was diluted with water (15 mL) and stirred at room temperature for 10 minutes. The volatile solvents were removed in vacuo, and the resulting mixture was diluted with EtOAc (50 mL) and 1:1 water:brine (30 mL). The phases were separated, and the aqueous portion was re-extracted with EtOAc (30 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give the title compound as an off-white solid.
[0406] LC-MS (Method E): Rt 1.08 min; MS m / z 365.1=[M+H]+ (95% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.61(s,1H),9.30(s,1H),8.90(d,J=6.5Hz,1H),8.64(d,J=2.4Hz,1H), 6.87(d,J=11.9Hz,1H),6.73(d,J=7.0Hz,1H),3.78(s,2H),1.32(s,9H).
[0407] Step 4: 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)-5-fluoro-pyridine-2-carboxamide
[0408] HATU (151 mg, 0.40 mmol) in DMF (3 mL) was added to a solution of 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxylic acid (step 3) (145 mg, 0.40 mmol), 2-amino-2-methyl-propanenitrile hydrochloride (72 mg, 0.6 mmol) and DIPEA (0.17 mL, 0.99 mmol), and the reaction mixture was stirred at room temperature for 2 h. The resulting mixture was diluted with EtOAc (20 mL) and water (20 mL), and the phases were separated. The combined organic portions were washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by preparative HPLC (acidic pH, standard elution method) to give the title compound as a white solid.
[0409] LC-MS (Method A): Rt 3.54 min; MS m / z 431.2=[M+H]+ (98% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.63(s,1H),9.31(s,1H),8.88(d,J=6.5Hz,1H),8.82(s,1H),8.61(d,J=2.4Hz,1H), 6.88(d,J=11.9Hz,1H),6.74(d,J=6.9Hz,1H),3.79(s,2H),1.71(s,6H),1.32(s,9H).
[0410] Example 4 N-(1-cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000112.tif41170
[0411] Step 1: 2-[2-deuterio-6-fluoro-3-methoxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetic acid TIFF0007583022000113.tif38170
[0412] A vessel containing 2-(2-fluoro-5-methoxy-phenyl)acetic acid (300 mg, 1.63 mmol) in DCE (16 mL) was treated with 1,1,1,3,3,3-hexadeuterio-2-deuteriooxy-2-(trideuteriomethyl)propane (1.23 mL, 13.03 mmol) and deuterium sulfate (0.71 mL, 13.03 mmol) and then stirred at room temperature for 3 hours. The resulting mixture was diluted with water (20 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 × 20 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo. The residue was dissolved in DCM (15 mL), treated with TFA (1.5 mL), stirred for 2 hours, and concentrated in vacuo. The resulting mixture was purified by chromatography on silica eluting with 0 to 100% EtOAc (+1% formic acid) in heptane (+1% formic acid) to afford the title compound as a colorless solid. (Note: NMR analysis showed 80% D incorporation into the ortho position of the phenol and 97% D incorporation into the tert-butyl group.)
[0413] LC-MS (Method E): Rt 1.18 min; (75% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.41(s,1H),7.08(d,J=9.4Hz,0.2H),6.92(d,J=11.7Hz,1H),3.77(s,3H),3.55(d,J=1.0Hz,2H),1.25(s,0.3H).
[0414] Step 2: Methyl 4-[[2-[2-deuterio-6-fluoro-3-methoxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxylate TIFF0007583022000114.tif40170
[0415] A mixture of methyl 4-aminopyridine-2-carboxylate (178 mg, 1.17 mmol) and 2-[2-deuterio-6-fluoro-3-methoxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetic acid (Step 1) (267 mg, 1.06 mmol) in 1,4-dioxane (10.7 mL) was treated with TEA (0.56 mL, 3.19 mmol) and a 50% T3P® solution in EtOAc (0.63 mL, 1.06 mmol), and the mixture was stirred for 16 hours. The resulting mixture was concentrated in vacuo, and the residue was dissolved in EtOAc (30 mL). The mixture was washed with saturated aqueous sodium bicarbonate (2 × 20 mL), dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane followed by 0-100% MeOH in EtOAc to afford the title compound as a colorless oil. (Note: NMR analysis showed 80% D incorporation into the ortho position of the phenol and 97% D incorporation into the tert-butyl group.)
[0416] LC-MS (Method E): Rt 1.17 min; MS m / z 385.1=[M+H]+ (69% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.81(s,1H),8.55(d,J=5.5Hz,1H),8.30(t,J=2.2Hz,1H),7.77(dd,J=5.5,2.1Hz,1H),6.99(d, J=6.65Hz,0.2H),6.95(d,J=11.7Hz,1H),3.87(s,3H),3.79(s,3H),3.75(s,2H),1.26(s,0.3H).
[0417] Step 3: 4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxylic acid TIFF0007583022000115.tif41170
[0418] Methyl 4-[[2-[2-deuterio-6-fluoro-3-methoxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxylate (Step 2) (69%, 471 mg, 0.85 mmol) in THF (4 mL) was treated with 1 M LiOH (4.23 mL, 4.23 mmol) and stirred for 2 h. The volatile solvents were removed in vacuo, and the aqueous phase was acidified to pH 1 by the addition of 1 M HCl. The resulting suspension was extracted with EtOAc (3 × 10 mL), and the combined organic extracts were concentrated in vacuo. The crude material was dissolved in DCM (8 mL), cooled in an ice bath, and treated with 1 M BBr in DCM (2.54 mL, 2.54 mmol). After stirring for 3 h, the reaction was quenched with water (10 mL), and the phases were separated. The aqueous layer was extracted with DCM (2 x 20 mL) and EtOAc (2 x 20 mL), and the combined organic extracts were concentrated in vacuo. The crude material was purified by C18 reverse-phase chromatography eluting with 10-100% MeCN in water to afford the title compound as a colorless solid. (Note: NMR analysis showed 80% D incorporation into the ortho position of the phenol and 97% D incorporation into the tert-butyl group.)
[0419] LC-MS (Method E): Rt 0.98 min; MS m / z 357.1=[M+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.79(s,1H),9.29(s,1H),8.54(d,J=5.5Hz,1H),8.27(s,1H),7.79(dd,J=5.5,2.1H z,1H),6.86(d,J=11.9Hz,1H),6.74(d,J=7.0Hz,0.2H),3.65(s,2H),1.26(s,0.3H).
[0420] Step 4: N-(1-cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide
[0421] 4-[[2-[2-Deuterio-6-fluoro-3-hydroxy-4-[2,2,2 trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxylic acid (Step 3) (50 mg, 0.14 mmol) in DMF (1.4 mL) was treated with 1-aminocyclopropanecarbonitrile hydrochloride (20 mg, 0.17 mmol), DIPEA (49 μL, 0.28 mmol), and HATU (50.7 mg, 0.13 mmol), and the mixture was stirred at room temperature for 2 h. Purification of the reaction mixture by preparative HPLC (acidic pH, fast elution method) afforded the title compound as a colorless solid.
[0422] (Note: NMR analysis showed 80% D incorporation into the ortho position of the phenol and 97% D incorporation into the tert-butyl group.)
[0423] LC-MS (Method C): Rt 3.38 min; MS m / z 421.3=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),9.67(s,1H),9.30(s,1H),8.51(d,J=5.5Hz,1H),8.24(d,J=2.1Hz,1H),7.86(dd,J=5.5,2.2Hz,1H), 6.87(d,J=11.9Hz,1H),6.75(d,J=6.9Hz,0.2H),3.66(s,2H),1.57-1.51(m,2H),1.37-1.30(m,2H),1.27(s,0.3H).
[0424] Example 5 N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclobutyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000116.tif35170
[0425] Step 1: Methyl 4-[[2-(2-fluoro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate TIFF0007583022000117.tif36170
[0426] To a solution of methyl 4-aminopyridine-2-carboxylate (3.64 g, 23.89 mmol) and 2-(2-fluoro-5-methoxy-phenyl)acetic acid (4 g, 21.72 mmol) in 1,4-dioxane (108.6 mL) was added TEA (9.48 mL, 54.3 mmol) and a 50% T3P® solution in EtOAc (51.67 mL, 43.44 mmol), and the mixture was stirred for 2 h. The resulting mixture was concentrated in vacuo, and the residue was dissolved in EtOAc (100 mL) and washed with saturated aqueous sodium bicarbonate (2 × 100 mL). The organic portion was dried over NaSO and concentrated in vacuo. Purification by chromatography on silica eluting with 0% to 100% EtOAc in heptane afforded the title compound as an orange gum.
[0427] LC-MS (Method E): Rt 1.00 min; MS m / z 319.1=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),8.55(d,J=5.4Hz,1H),8.30(d,J=1.8Hz,1H),7.77(dd,J=5.5,2.2Hz,1H),7.11(t,J=9.2H z,1H),6.96(dd,J=6.1,3.2Hz,1H),6.86(dt,J=8.9,3.7Hz,1H),3.87(s,3H),3.77(s,2H),3.73(s,3H).
[0428] Step 2: Methyl 4-[[2-[2-fluoro-5-methoxy-4-(1-methylcyclobutyl)phenyl]acetyl]amino]pyridine-2-carboxylate TIFF0007583022000118.tif39170
[0429] A solution of methyl 4-[[2-(2-fluoro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate (Step 1) (200 mg, 0.63 mmol) in DCE (2 mL) was treated with concentrated sulfuric acid (0.27 mL, 5.03 mmol), and the mixture was cooled to 0 °C. To this mixture, methylenecyclobutane (214 mg, 3.14 mmol) in DCE (2 mL) was added dropwise, and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with DCM (10 mL) and water (10 mL). The organic portion was separated, dried over Na SO , and concentrated in vacuo to give the title compound as a yellow solid.
[0430] LC-MS (Method E): Rt 1.22 min; MS m / z 387.1=[M+H]+ (77% at 215 nm)
[0431] Step 3: N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclobutyl)phenyl]acetyl]amino]pyridine-2-carboxamide
[0432] A 1 M solution of BBr3 in DCM (4.05 mL, 4.05 mmol) was added to a cooled (0 °C) stirred solution of methyl 3-[[2-[2-fluoro-5-methoxy-4-(1-methylcyclobutyl)phenyl]acetyl]amino]benzoate (260 mg, 0.67 mmol) under nitrogen over 2 minutes. The mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched with ice and stirred for 30 minutes. The organic layer was separated, dried over Na2SO4, and concentrated in vacuo to give a brown oil. The oil was dissolved in DMF (1 mL), and 2-amino-2-methyl-propanenitrile hydrochloride (36 mg, 0.29 mmol) and DIPEA (86 μL, 0.49 mmol) were added, followed by HATU (80.83 mg, 0.21 mmol), and the reaction mixture was stirred at room temperature overnight. The resulting mixture was diluted with EtOAc (10 mL) and water (10 mL). The organic layer was separated, dried over Na2SO4 and concentrated in vacuo. The crude material was purified by preparative HPLC (acidic pH, fast elution method) to afford the title compound as an off-white solid.
[0433] LC-MS (Method A): Rt 3.52 min; MS m / z 425.3=[M+H]+ (96% at 215 nm) 1 H NMR(500MHz,MeOH-d4)δ 8.47(d,J=5.5Hz,1H),8.19(d,J=1.9Hz,1H),7.94(dd,J=5.5,2.1Hz,1H),6.69-6.63(m,2H),3 .68(s,2H),2.43-2.30(m,2H),2.16-2.02(m,3H),1.80(s,6H),1.80-1.72(m,1H),1.45(s,3H).
[0434] Example 6 N-tert-butyl-4-[[2-(4-tert-butyl-5-hydroxy-2-isopropyl-phenyl)acetyl]amino]pyridine-2-carboxamide TIFF0007583022000119.tif39170
[0435] Step 1: 4-[[2-(2-bromo-4-tert-butyl-5-methoxy-phenyl)acetyl]amino-N-tert-butyl-pyridine-2-carboxamide TIFF0007583022000120.tif38170
[0436] The title compound was prepared analogously to Example 1, Step 1 from 2-(2-bromo-4-tert-butyl-5-methoxy-phenyl)acetic acid (Intermediate F) and 4-amino-N-tert-butyl-pyridine-2-carboxamide. LC-MS (Method E): Rt 1.42 min; MS m / z 476.1,478.1=[M+H]+(96% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.80(s,1H),8.45(d,J=5.5Hz,1H),8.17(d,J=1.8Hz,1H),8.03(s,1H),7.81(dd,J=5.5, 2.2Hz,1H),7.30(s,1H),7.09(s,1H),3.86(s,2H),3.81(s,3H),1.40(s,9H),1.32(s,9H).
[0437] Step 2: 4-[[2-(2-bromo-4-tert-butyl-5-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide TIFF0007583022000121.tif35170
[0438] The title compound was prepared from 4-[[2-(2-bromo-4-tert-butyl-5-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Step 1) and 1M BBr3 in DCM in analogy to Step 2 of Example 1. LC-MS (Method E): Rt 1.32 min; MS m / z 462.0,463.9=[M+H]+(96% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.66(s,1H),8.46(d,J=5.5Hz,1H),8.20(d,J=2.0Hz,1H),8.03(s,1H),7.8 0(dd,J=5.5,2.2Hz,1H),7.24(s,1H),6.83(s,1H),3.75(s,2H),1.40(s,9H),1.33(s,9H).
[0439] Step 3: N-tert-butyl-4-[[2-(4-tert-butyl-5-hydroxy-2-isopropyl-phenyl)acetyl]amino]pyridine-2-carboxamide
[0440] A mixture of 4-[[2-(2-bromo-4-tert-butyl-5-hydroxyphenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Step 2) (96%, 170 mg, 0.35 mmol), 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (119 mg, 0.71 mmol), potassium phosphate tripotassium (300 mg, 1.41 mmol), P(Cy) (40 mg, 0.14 mmol), and Pd(OAc) (16 mg, 0.07 mmol) was dissolved in degassed 10:1 toluene:water (2.2 mL) under nitrogen and heated at 100 °C for 4 h. The resulting mixture was concentrated in vacuo, and the residue was dissolved in EtOAc (10 mL). The mixture was washed with water (10 mL), and the aqueous washes were re-extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude mixture was filtered through a silica plug, washed with EtOAc, and concentrated in vacuo. The residue was dissolved in EtOH (2 mL) and treated with 10% Pd / C (38 mg, 0.35 mmol). The mixture was placed under a hydrogen atmosphere and stirred for 24 h. The resulting mixture was filtered through a Celite® plug, washed with EtOAc, and the filtrate was concentrated in vacuo. Purification by preparative HPLC (acidic pH, fast elution method) afforded the title compound as a colorless solid.
[0441] LC-MS (Method A): Rt 4.32 min; MS m / z 426.4=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.72(s,1H),9.03(s,1H),8.45(d,J=5.5Hz,1H),8.20(d,J=2.0Hz,1H),8.03(s,1H),7.81(dd,J=5.5,2.2Hz,1H), 7.03(s,1H),6.62(s,1H),3.64(s,2H),3.05(hept,J=6.9Hz,1H),1.40(s,9H),1.33(s,9H),1.12(d,J=6.8Hz,6H).
[0442] Example 7 N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000122.tif38170
[0443] Step 1: 4-[[2-(4-bromo-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide TIFF0007583022000123.tif35170
[0444] The title compound was prepared from 4-[[2-(4-bromo-2-fluoro-5-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Intermediate I) and 1 M BBr3 in DCM in analogy to Step 2 of Example 1. LC-MS (Method A): Rt 3.28 min; MS m / z 424.1,426.1=[M+H]+(93% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),10.15(s,1H),8.46(d,J=5.5Hz,1H),8.18(d,J=2.1Hz,1H),8.03(s,1H),7.79( dd,J=5.5,2.2Hz,1H),7.40(d,J=9.0Hz,1H),6.95(d,J=6.9Hz,1H),3.71(s,2H),1.40(s,9H).
[0445] Step 2: N-tert-butyl-4-[[2-(2-fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]pyridine-2-carboxamide TIFF0007583022000124.tif35170
[0446] The title compound was prepared from 4-[[2-(4-bromo-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Step 1) and 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in analogy to Step 1 of Example 8.
[0447] LC-MS (Method A): Rt 3.56 min; MS m / z 386.2=[M+H]+ (91% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.78(s,1H),9.43(s,1H),8.46(d,J=5.5Hz,1H),8.19(d,J=2.0Hz,1H),8.03(s,1H),7.81(dd,J=5.5,2.2Hz,1H),6.91 (d,J=10.6Hz,1H),6.80(d,J=6.7Hz,1H),5.22-5.19(m,1H),5.14-5.11(m,1H),3.69(s,2H),2.06(s,3H),1.40(s,9H).
[0448] Step 3: N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide
[0449] A solution of N-tert-butyl-4-[[2-(2-fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]pyridine-2-carboxamide (Step 2) (50 mg, 0.13 mmol) in water (2.5 mL) and 1,4-dioxane (5 mL) was treated with methanesulfonic acid (842 μL, 12.97 mmol) and stirred at 30° C. for 24 h. After standing at room temperature overnight, the mixture was partitioned between EtOAc (20 mL) and water (20 mL). The layers were separated, and the aqueous portion was further extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine (20 mL), dried over NaSO, and concentrated in vacuo. The crude material was purified by preparative HPLC (acidic pH, fast elution method) to afford the title compound as a white solid.
[0450] LC-MS (Method A): Rt 2.99 min; MS m / z 404.3=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,MeOH-d4)δ 8.43(dd,J=5.6,0.5Hz,1H),8.13(dd,J=2.2,0.5Hz,1H),7.90(dd,J=5.5,2.2Hz,1H), 7.00(d,J=11.2Hz,1H),6.73(d,J=6.6Hz,1H),3.70(s,2H),1.58(s,6H),1.47(s,9H).
[0451] Example 7.1 4-[[2-(2-fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000125.tif37170
[0452] Step 1: 4-[2-(4-bromo-2-fluoro-5-hydroxyphenyl)acetamido]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000126.tif33170
[0453] To a cooled (0 °C) solution of 4-[[2-(4-bromo-2-fluoro-5-methoxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate H) (19.5 g, 39.78 mmol) in DCM (250 mL) was added 1 M BBr in DCM (119.33 mL, 119.33 mmol) dropwise over 10 min. The reaction mixture was allowed to warm to room temperature and stirred for 2.5 h. The solvent was removed in vacuo and the crude material was suspended in EtOAc (350 mL) at 0 °C and treated with saturated NaHCO solution (550 mL). The mixture was stirred vigorously at room temperature for 20 min and the organic layer was separated. The aqueous layer was re-extracted with EtOAc (200 mL) and the combined organic extracts were dried over NaSO and concentrated in vacuo. The crude material was suspended in MeCN (300 mL) and the mixture was heated to 100° C. for 10 min. Water (300 mL) was added and heating was continued for 30 min. The resulting hot mixture was filtered and the solid was washed with MeCN (2×70 mL) and dried under high vacuum at 40° C. to give the title compound as a white solid.
[0454] LC-MS (Method E): Rt 1.16 min; MS m / z 476.2,478.1=[M+H]+(96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),10.17(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.20(d,J=2.0Hz,1H),7.83(dd,J=5.5,2. 2Hz,1H),7.40(d,J=9.0Hz,1H),6.95(d,J=6.9Hz,1H),3.71(s,2H),1.37-1.23(m,2H),1.22-1.15(m,2H).
[0455] Step 2: 4-[[2-(2-fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0456] A solution of 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (12.19 g, 72.57 mmol), Pd(OAc) (1.63 g, 7.26 mmol), 4-[[2-(4-bromo-2-fluoro-5-hydroxyphenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 1) (96%, 18.0 g, 36.29 mmol) in toluene (200 mL) and water (40 mL) was degassed with nitrogen for 10 minutes and then treated with P(Cy) (4.07 g, 14.51 mmol) and potassium phosphate tribasic (30.81 g, 145.14 mmol). The mixture was flushed with nitrogen, sealed, and heated at 100 °C overnight. The resulting mixture was concentrated in vacuo, and the crude residue was partitioned between EtOAc (200 mL) and water (200 mL). The organic portion was separated, dried over Na2SO4, filtered through a Celite® pad, and washed with 20% MeOH in DCM (100 mL). The filtrate was concentrated in vacuo, and the crude material was suspended in toluene (200 mL). The mixture was heated to reflux for 20 minutes, then cooled and allowed to stand at 0°C overnight. The resulting solid was filtered and washed with toluene (50 mL) and heptane (100 mL) to afford the title compound as an off-white solid.
[0457] The filtrate was concentrated in vacuo, and the crude material was dissolved in MeCN (200 mL). Additional material was obtained by concentrating the filtrate in vacuo and redissolving in MeCN (200 mL). 2,4,6-Trimercapto-s-triazine (1.5 g) and decolorizing carbon (3.0 g) were added, and the mixture was stirred at 20-25°C for 1 hour. Celite® (2.0 g) was added, and the mixture was stirred at 0-5°C for 1 hour. The precipitate was removed by suction filtration through a filter paper and washed with MeCN (100 mL). The filtrate was concentrated in vacuo, and the crude material was suspended in toluene (100 mL) and heated to reflux for 20 minutes. The mixture was cooled to room temperature and maintained at 0°C overnight. The resulting mixture was filtered, and the solid was washed with cold toluene (50 mL), followed by heptane (100 mL), and dried in a high vacuum oven at 40°C to afford the title compound as an off-white solid.
[0458] The filtrate was concentrated, and the crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane, followed by 0-100% MeOH in EtOAc to give additional material. The purified material from the purification steps was combined and further purified by C18 reverse-phase chromatography eluting with 10-100% aqueous MeCN (+0.1% formic acid). The resulting solid was recrystallized from MeCN (10 mL) to give the title compound as a white solid.
[0459] LC-MS (Method A): Rt 3.32 min; MS m / z 438.1=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.81(s,1H),9.45(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),6.91(d,J=10.6Hz,1 H),6.80(d,J=6.7Hz,1H),5.22-5.19(m,1H),5.14-5.11(m,1H),3.69(s,2H),2.11-2.01(m,3H),1.36-1.23(m,2H),1.25-1.11(m,2H).
[0460] Example 8 N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclopropyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000127.tif33170
[0461] Step 1: N-tert-butyl-4-[[2-(2-fluoro-4-isopropenyl-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide TIFF0007583022000128.tif37170
[0462] A solution of 4-[[2-(4-bromo-2-fluoro-5-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Intermediate I) (850 mg, 1.94 mmol), 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (729 μL, 3.88 mmol), and potassium phosphate tripotassium (1.65 g, 7.76 mmol) in toluene (6 mL) and water (0.6 mL) was degassed with nitrogen for 10 minutes and then treated with Pd(OAc) (87 mg, 0.39 mmol) and P(Cy) (217.54 mg, 0.78 mmol). The mixture was flushed with nitrogen, sealed, and heated at 100 °C for 3 hours. The resulting mixture was concentrated in vacuo, and the crude residue was partitioned between EtOAc (50 mL) and water (50 mL). The organic portion was separated, washed with brine (50 mL), dried over Na2SO4, and concentrated in vacuo. The resulting crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane, followed by 0-10% MeOH in EtOAc to afford the title compound as a yellow solid.
[0463] LC-MS (Method E): Rt 1.35 min; MS m / z 400.2=[M+H]+ (91% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.78(s,1H),8.45(d,J=5.5Hz,1H),8.17(d,J=2.1Hz,1H),8.03(s,1H),7.81(dd,J=5.5,2.2Hz,1H),7.03(d,J=6.4Hz, 1H),6.97(d,J=10.2Hz,1H),5.16-5.12(m,1H),5.11-5.08(m,1H),3.78(s,2H),3.76(s,3H),2.04(s,3H),1.39(s,9H).
[0464] Step 2: N-tert-butyl-4-[[2-[2-fluoro-5-methoxy-4-(1-methylcyclopropyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000129.tif39170
[0465] To a mixture of triethylammonium bis(catecholato)iodomethylsilicate (Intermediate J) (95%, 193 mg, 0.38 mmol) and (4,4'-di-t-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-kN)phenyl-kC]iridium(III) hexafluorophosphate (14 mg, 0.01 mmol) in anhydrous TEA (6.59 mL) under nitrogen was added a solution of N-tert-butyl-4-[[2-(2-fluoro-4-isopropenyl-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Step 1) (100 mg, 0.25 mmol) in anhydrous DMSO (1.5 mL). The reaction mixture was sealed with parafilm and irradiated in front of a Kessil A160WE Tuna Blue 40W LED lamp oven, with the temperature maintained at approximately 20-25 °C with a fan. Additional triethylammonium bis(catecholato)iodomethylsilicate (Intermediate J) (95%, 193 mg, 0.38 mmol) and (4,4'-di-t-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-kN)phenyl-kC]iridium(III) hexafluorophosphate (14 mg, 0.01 mmol) were added, the mixture was re-purged with nitrogen, and irradiated for an additional 8 h. The resulting mixture was diluted with EtOAc (10 mL) and HO (10 mL). A precipitate formed, which was removed by filtering through a 1 g Celite® Isolute cartridge and washing with EtOAc. The filtrate phases were separated and the organic portion was washed with brine (2 x 10 mL), dried over NaSO, and concentrated in vacuo. Purification by chromatography on silica eluting with 0-100% EtOAc in heptane, followed by C18 reverse-phase chromatography eluting with 10-100% MeCN (+0.1% formic acid) in HO (+0.1% formic acid) afforded the title compound as a yellow viscous oil.
[0466] LC-MS (Method E): Rt 1.33 min; MS m / z 414.1=[M+H]+ (97% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.77(s,1H),8.45(d,J=5.5Hz,1H),8.17(d,J=2.0Hz,1H),8.03(s,1H),7.81(dd,J=5.5,2.2Hz,1H),6.98(d,J=5.1H) z,1H),6.97-6.95(m,1H),3.80(s,3H),3.75(s,2H),1.40(s,9H),1.26(s,3H),0.69-0.65(m,2H),0.65-0.59(m,2H).
[0467] Step 3: N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclopropyl)phenyl]acetyl]amino]pyridine-2-carboxamide
[0468] 1M BCl in DCM (181 μL, 0.18 mmol) was added dropwise under nitrogen to a cooled (0 °C) solution of N-tert-butyl-4-[[2-[2-fluoro-5-methoxy-4-(1-methylcyclopropyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Step 2) (30 mg, 0.07 mmol) and tetra-n-butylammonium iodide (67 mg, 0.18 mmol) in DCM (1 mL), and the mixture was stirred at 0 °C for 2 h. Additional 1M BCl in DCM (72 μL, 0.07 mmol) was added, and stirring was continued for 30 min. The reaction was quenched with ice, and the organic layer was separated through a hydrophobic frit. The remaining aqueous layer was washed with DCM, and the organic portions were combined and concentrated in vacuo. The crude material was purified by C18 reverse phase chromatography eluting with 10-100% MeCN (+0.1% formic acid) in H2O (+0.1% formic acid) to afford the title compound as an off-white solid.
[0469] LC-MS (Method A): Rt 3.56 min; MS m / z 400.3=[M+H]+ (98% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.76(s,1H),9.17(s,1H),8.45(d,J=5.5Hz,1H),8.18(d,J=2.1Hz,1H),8.03(s,1H),7.80(dd,J=5.5,2.2Hz,1H),6.87 (d,J=10.4Hz,1H),6.73(d,J=6.7Hz,1H),3.64(s,2H),1.40(s,9H),1.26(s,3H),0.69-0.63(m,2H),0.63-0.55(m,2H).
[0470] Example 9 N-(1-cyanocyclopropyl)-4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000130.tif33170
[0471] Step 1: Methyl 4-[[2-[2-fluoro-5-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetyl]amino]pyridine-2-carboxylate TIFF0007583022000131.tif42170
[0472] Under nitrogen, a mixture of methyl 4-[[2-(4-bromo-2-fluoro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate (Intermediate I, Step 1) (94%, 4.5 g, 10.65 mmol), bis(pinacolato)diboron (4.06 g, 15.97 mmol), KOAc (4.42 g, 31.95 mmol), and Pd(dppf)Cl (779 mg, 1.06 mmol) in 1,4-dioxane (45 mL) was heated at 80° C. for 4 h. Additional bis(pinacolato)diboron (4.06 g, 15.97 mmol) was added, and the mixture was heated at 80° C. for an additional 3.5 h. Additional Pd(dppf)Cl (779 mg, 1.06 mmol) was then added, and the mixture was heated at 80° C. overnight. The resulting mixture was filtered through Celite® (filter material) and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane followed by 0-10% MeOH in EtOAc to afford the title compound as a dark brown viscous oil.
[0473] LC-MS (Method E): Rt 1.11 min; MS m / z 445.2=[M+H]+ (62% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.81(s,1H),8.55(d,J=5.5Hz,1H),8.29(d,J=1.8Hz,1H),7.77(dd,J=5.5,2.2Hz,1H),7.20 (d,J=9.6Hz,1H),7.01(d,J=5.7Hz,1H),3.87(s,3H),3.81(s,2H),3.73(s,3H),1.27(s,12H).
[0474] Step 2: Methyl 4-[[2-[2-fluoro-5-methoxy-4-[1-(trifluoromethyl)vinyl]phenyl]acetyl]amino]pyridine-2-carboxylate TIFF0007583022000132.tif38170
[0475] Under nitrogen, a mixture of methyl 4-[[2-[2-fluoro-5-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetyl]amino]pyridine-2-carboxylate (Step 1) (4.5 g, 10.13 mmol), CsCO (3.96 g, 12.16 mmol), and Pd(dppf)Cl (827 mg, 1.01 mmol) was dissolved in degassed monoglyme (45.5 mL) and degassed deionized water (13 mL). 2-Bromo-3,3,3-trifluoroprop-1-ene (2.36 mL, 22.28 mmol) was added, and the mixture was heated at 80 °C overnight. The resulting mixture was diluted with EtOAc (150 mL) and water (150 mL). The organic portion was separated, washed with brine (150 mL), dried over NaSO, and concentrated in vacuo. Purification by chromatography on silica eluting with 0-100% EtOAc in heptane, followed by 0-20% MeOH in EtOAc, followed by C18 reverse-phase chromatography eluting with 10-100% MeCN (+0.1% formic acid) in HO (+0.1% formic acid) afforded the title compound as a colorless viscous oil.
[0476] LC-MS (Method G): Rt 0.83 min; MS m / z 413.2=[M+H]+ (91% at 215 nm)
[0477] Step 3: Methyl 4-[[2-[2-fluoro-5-methoxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxylate TIFF0007583022000133.tif39170
[0478] The title compound was prepared from methyl 4-[[2-[2-fluoro-5-methoxy-4-[1-(trifluoromethyl)vinyl]phenyl]acetyl]amino]pyridine-2-carboxylate (Step 2) and triethylammonium bis(catecholato)iodomethylsilicate (Intermediate J) in analogy to Step 2 of Example 8.
[0479] LC-MS (Method A): Rt 3.22 min; MS m / z 427.2=[M+H]+ (42% at 215 nm) 1 H NMR(500MHz,chloroform-d)δ 8.62(s,1H),8.01(d,J=2.1Hz,1H),7.94-7.91(m,1H),7.65(s,1H),7.18(d,J=9.8Hz,1H),6. 86-6.82(m,1H),3.99(s,3H),3.85(s,3H),3.74(s,2H),1.40-1.36(m,2H),1.01-0.97(m,2H).
[0480] Step 4: 4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxylic acid TIFF0007583022000134.tif32170
[0481] The title compound was prepared from methyl 4-[[2-[2-fluoro-5-methoxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxylate (Step 3) and 1 M BBr in DCM in analogy to Step 2 of Example 1.
[0482] LC-MS (Method E): Rt 0.96 min; MS m / z 399.1=[M+H]+ (76% at 215 nm) 1 H NMR (500 MHz, DMSO-d6) δ 10.89 (s, 1H), 9.62 (s, 1H), 8.57-8.53 (m, 1H), 8.28 (d, J = 2.0 Hz, 1H), 7.83-7.79 (m, 1H), 7.07 (d, J = 9.4 Hz, 1H), 6.84 (d, J = 6.6 Hz, 1H), 3.72 (s, 2H), 1.32-1.29 (m, 2H), 1.06-1.02 (m, 2H). [No acid-OH group observed]
[0483] Step 5: N-(1-cyanocyclopropyl)-4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxamide To a solution of 4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxylic acid (Step 4) (42%, 63 mg, 0.07 mmol) in DMF (1.5 mL) was added DIPEA (23 μL, 0.13 mmol), 1-aminocyclopropanecarbonitrile hydrochloride (9 mg, 0.08 mmol), followed by HATU (24 mg, 0.06 mmol), and the mixture was stirred under nitrogen at room temperature for 2 hours. Additional 1-aminocyclopropanecarbonitrile hydrochloride (9 mg, 0.08 mmol), DIPEA (23 μL, 0.13 mmol), followed by HATU (24 mg, 0.06 mmol) were added, and the reaction mixture was stirred overnight. The resulting mixture was concentrated in vacuo, and the crude material was purified by preparative HPLC (acidic pH, fast elution method) to afford the title compound as a tan solid.
[0484] LC-MS (Method A): Rt 3.08 min; MS m / z 463.2=[M+H]+ (94% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.85(s,1H),9.68(s,1H),9.62(s,1H),8.50(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),7 .07(d,J=10.0Hz,1H),6.84(d,J=6.6Hz,1H),3.71(s,2H),1.55-1.51(m,2H),1.35-1.28(m,4H),1.07-1.01(m,2H).
[0485] Example 10 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide TIFF0007583022000135.tif34170
[0486] Step 1: Methyl 4-[[2-(4-tert-butyl-2-chloro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate TIFF0007583022000136.tif40170
[0487] To a stirred solution of 2-(4-tert-butyl-2-chloro-5-methoxy-phenyl)acetic acid (Intermediate K) (1.68 g, 6.54 mmol), methyl 4-aminopyridine-2-carboxylate (1.19 g, 7.85 mmol), and DIPEA (1.49 mL, 8.51 mmol) in 1,4-dioxane (40 mL) was added a 50% T3P® solution in EtOAc (5.06 mL, 8.51 mmol). The reaction mixture was stirred at room temperature for 45 minutes and then partitioned between EtOAc (200 mL) and water (200 mL). The resulting suspension was washed with 1 M aqueous HCl (100 mL), followed by 20% aqueous NaOH (2 × 100 mL). The organic layer was separated, dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 20-100% EtOAc in heptane to give the title compound as an off-white powder.
[0488] LC-MS (Method E): Rt 1.25 min; MS m / z 391.1,393.1=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),8.55(d,J=5.45Hz,1H),8.31(d,J=2.0Hz,1H),7.77(dd,J=5.5,2.1Hz ,1H),7.16(s,1H),7.08(s,1H),3.86(s,3H),3.85(s,2H),3.81(s,3H),1.32(s,9H).
[0489] Step 2: 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid TIFF0007583022000137.tif34170
[0490] 1M BBr3 in DCM (63.71 mL, 63.71 mmol) was added dropwise to a cooled (0 °C) stirred suspension of methyl 4-[[2-(4-tert-butyl-2-chloro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate (Step 1) (4.15 g, 10.62 mmol) in DCM (8 mL). After 30 min, the ice bath was removed and the reaction mixture was stirred at room temperature for 18 h. The resulting mixture was concentrated in vacuo and the crude residue was partitioned between EtOAc (100 mL) and water (100 mL). The organic layer was separated and the aqueous layer was back-extracted with EtOAc (50 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The residue was suspended in 1:1 MeCN:water (50 mL), filtered, and washed with 1:1 MeCN:water. The solid was dried under vacuum to give the title compound.
[0491] LC-MS (Method E): Rt 1.02 min; MS m / z 363.0,365.0=[M+H]+(100% at 215 nm)
[0492] Step 3: 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide
[0493] To a solution of 4-[[2-(4-tert-butyl-2-chloro-5-hydroxyphenyl)acetyl]amino]pyridine-2-carboxylic acid (Step 2) (2.5 g, 6.89 mmol) in DMF (25 mL) was added 2-amino-2-methyl-propanenitrile hydrochloride (914 mg, 7.58 mmol), DIPEA (2.41 mL, 13.78 mmol), followed by HATU (2.62 g, 6.89 mmol), and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with EtOAc and washed sequentially with 1 M HCl (150 mL), saturated NaHCO solution (150 mL), and brine (150 mL). The organic portion was dried over NaSO and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0–100% EtOAc in heptane to afford the title compound as a colorless powder.
[0494] LC-MS (Method A): Rt 3.65 min; MS m / z 429.2,431.2=[M+H]+(99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.85(s,1H),9.64(s,1H),8.85(s,1H),8.52(d,J=5.5Hz,1H),8.24(d,J=2.0Hz,1H),7.8 5(dd,J=5.5,2.1Hz,1H),7.09(s,1H),6.82(s,1H),3.75(s,2H),1.72(s,6H),1.33(s,9H).
[0495] Example 10.1 4-[[2-(4-tert-butyl-2-chloro-5-hydroxyphenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000138.tif35170
[0496] The title compound was prepared similarly to Example 10 by substituting 1-(trifluoromethyl)cyclopropanamine hydrochloride for 2-amino-2-methyl-propanenitrile hydrochloride (step 3).
[0497] LC-MS (Method A): Rt 3.92 min; MS m / z 470.2,472.2=[M+H]+(98% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.81(s,1H),9.62(s,1H),9.38(s,1H),8.51(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.84(d d,J=5.5,2.2Hz,1H),7.09(s,1H),6.82(s,1H),3.74(s,2H),1.33(s,9H),1.30-1.14(m,4H).
[0498] Example 10.2 4-[[2-(4-tert-butyl-2-chloro-5-hydroxyphenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide TIFF0007583022000139.tif35170
[0499] The title compound was prepared similarly to Example 10 by substituting 1-aminocyclopropanecarbonitrile hydrochloride for 2-amino-2-methyl-propanenitrile hydrochloride (step 3).
[0500] LC-MS (Method A): Rt 3.50 min; MS m / z 427.2,429.2=[M+H]+(97% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.82(br s,1H),9.66(s,1H),9.63(br s,1H),8.50(d,J=5.7Hz,1H),8.24(d,J=1.8Hz,1H),7.85(dd,J=5.5,2.2Hz,1H) ,7.09(s,1H),6.82(s,1H),3.75(s,2H),1.56-1.50(m,2H),1.39-1.27(m,11H).
[0501] Example 11 4-[[2-[2-fluoro-5-hydroxy-4-(3-hydroxy-1,1-dimethylpropyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000140.tif46170
[0502] Step 1: 4-[[2-(6-fluoro-4,4-dimethyl-2-oxo-chroman-7-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000141.tif47170
[0503] The title compound was prepared from 2-(6-fluoro-4,4-dimethyl-2-oxo-chroman-7-yl)acetic acid (Intermediate P) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to Step 1 of Example 2.
[0504] LC-MS (Method G): Rt 0.96 min; MS m / z 480.2=[M+H]+ (93% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.84(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.19(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.28 (d,J=10.2Hz,1H),7.15(d,J=6.4Hz,1H),3.80(s,2H),2.73(s,2H),1.34-1.21(m,8H),1.21-1.17(m,2H).
[0505] Step 2: 4-[[2-[2-fluoro-5-hydroxy-4-(3-hydroxy-1,1-dimethyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0506] To a stirred and cooled (-78 °C) solution of 4-[[2-(6-fluoro-4,4-dimethyl-2-oxo-chroman-7-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 1) (93%, 345 mg, 0.67 mmol) in THF (10 mL) was added 4 M LiBH4 in THF (201 μL, 0.8 mmol) and the mixture was stirred at -78 °C for 1 h and then at room temperature overnight.
[0507] The reaction was quenched with water (20 mL) and diluted with EtOAc (10 mL). The organic layer was separated, dried over Na2SO4, and concentrated in vacuo. The crude residue was purified by C18 reverse-phase chromatography eluting with 10-100% MeCN in water (0.1% formic acid) to afford the title compound as a white solid.
[0508] LC-MS (Method A): Rt 2.98 min; MS m / z 484.2=[M+H]+ (98% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.81(s,1H),9.39(s,1H),9.30(s,1H),8.50(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),6.82(d,J=12.0Hz,1H) ),6.73(d,J=7.0Hz,1H),4.16(t,J=4.9Hz,1H),3.65(s,2H),3.20-3.10(m,2H),2.03-1.91(m,2H),1.38-1.22(m,8H),1.21-1.12(m,2H).
[0509] Example 12 N-(4-cyanotetrahydropyran-4-yl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000142.tif43170
[0510] Step 1: Methyl 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylate TIFF0007583022000143.tif41170
[0511] DIPEA (9.0 mL, 51.53 mmol) and a 50% solution of T3P® in EtOAc (20.0 mL, 33.6 mmol) were added simultaneously to a stirred solution of 2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate U) (4.0 g, 16.79 mmol) and methyl 4-aminopyridine-2-carboxylate (2.55 g, 16.79 mmol) in DMF (60 mL), and the mixture was stirred at room temperature for 2 hours. The resulting mixture was diluted with EtOAc (60 mL) and washed with brine (100 mL). The aqueous layer was extracted with EtOAc (2 × 75 mL), and the combined organic extracts were washed with brine (2 × 100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by chromatography on silica eluting with 0-100% EtOAc in heptane, followed by azeotroping the product fractions with EtOAc (3×100 mL) to give the title compound as a beige powder.
[0512] LC-MS (Method G): Rt 0.81 min; MS m / z 373.2=[M+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.85(br.s,1H),8.56(d,J=5.4Hz,1H),8.30(d,J=1.9Hz,1H),7.77(dd,J=5.5,2.1Hz,1 H),7.44(d,J=8.9Hz,1H),7.30(d,J=5.8Hz,1H),3.86(s,3H),3.83(s,2H),1.45(s,6H).
[0513] Step 2: 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylic acid TIFF0007583022000144.tif41170
[0514] To a solution of methyl 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylate (Step 1) (2.0 g, 5.37 mmol) in THF (22 mL) was added a solution of lithium hydroxide hydrate (1.13 g, 26.86 mmol) in water (22 mL), and the reaction mixture was stirred at room temperature for 1 h. The pH of the resulting mixture was adjusted to pH 1 using 2 M KHSO4 (approximately 45 mL), and stirring was continued at room temperature for 1 h. Dioxane (100 mL) was added to aid solubility, and the mixture was heated to 50 °C overnight. The mixture was extracted with EtOAc / MeCN (1:1, 4 × 100 mL), and the combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude residue was dissolved in 4 M HCl in dioxane (15 mL) and heated to 80 °C for 1 h. The resulting emulsion was allowed to cool to room temperature, concentrated in vacuo, and azeotroped with EtOAc:MeCN (1:1, 2×100 mL) to give the title compound as an off-white solid.
[0515] LC-MS (Method E): Rt 0.93 min; MS m / z 359.1=[M+H]+ (97% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 11.26(br.s,1H),8.60(d,J=5.9Hz,1H),8.36(d,J=2.1Hz,1H),7.95(dd,J=5.9,2 .2Hz,1H),7.45(d,J=8.9Hz,1H),7.32(d,J=5.8Hz,1H),3.89(s,2H),1.45(s,6H).
[0516] Step 3: N-(4-cyanotetrahydropyran-4-yl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide
[0517] To a solution of 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylic acid (Step 2) (87%, 150 mg, 0.36 mmol), 4-aminotetrahydropyran-4-carbonitrile (51 mg, 0.40 mmol), and HATU (166 mg, 0.44 mmol) in DMF (3 mL) was added DIPEA (89 μL, 0.51 mmol), and the mixture was stirred at room temperature overnight. Additional HATU (166 mg, 0.44 mmol), 4-aminotetrahydropyran-4-carbonitrile (51 mg, 0.40 mmol), and DIPEA (89 μL, 0.51 mmol) were added, and stirring was continued for another 1 h. The resulting mixture was diluted with EtOAc (8 mL), washed with water (8 mL), brine (2 × 8 mL), dried over NaSO, and concentrated in vacuo. The crude residue was dissolved in THF (3 mL) and cooled to -78 °C. 4 M LiBH4 in THF (0.10 mL, 0.40 mmol) was added dropwise, and stirring was continued with gradual warming to room temperature over 45 min. The resulting mixture was recooled to 0 °C, and the reaction was quenched by the dropwise addition of 1 M HCl (5 mL). The mixture was diluted with EtOAc (10 mL), and the phases were separated. The aqueous layer was extracted with EtOAc (10 mL), and the combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by C18 reverse-phase chromatography, eluting with 10–100% MeCN in water (+0.1% formic acid), to afford the title compound as a beige solid.
[0518] LC-MS (Method A): Rt 2.54 min; MS m / z 471.4=[M+H]+(100% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.83(s,1H),9.39(s,1H),9.02(s,1H),8.54(d,J=5.5Hz,1H),8.24(d,J= 2.0Hz,1H),7.86(dd,J=5.5,2.2Hz,1H),6.90(d,J=12.1Hz,1H),6.72(d,J =7.0Hz,1H),4.77(t,J=5.3Hz,1H),3.87(dt,J=12.1,3.8Hz,2H),3.65(s, 2H),3.62-3.55(m,4H),2.40-2.33(m,2H),2.11-2.03(m,2H),1.25(s,6H).
[0519] Example 12.1 4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[3-(trifluoromethyl)oxetan-3-yl]pyridine-2-carboxamide TIFF0007583022000145.tif37170
[0520] The title compound was prepared from 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylic acid (Step 2 of Example 12) and 3-(trifluoromethyl)oxetan-3-amine hydrochloride in analogy to Step 3 of Example 12.
[0521] LC-MS (Method A): Rt 2.75 min; MS m / z 486.3=[M+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.82(s,1H),9.89(s,1H),9.38(s,1H),8.55(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.87(dd,J=5.5,2.1Hz,1H),6.91(d,J= 12.1Hz,1H),6.73(d,J=7.0Hz,1H),4.93(d,J=7.9Hz,2H),4.79-4.69(m,3H),3.66(s,2H),3.61(d,J=3.3Hz,2H),1.26(s,6H).
[0522] Example 12.2 4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide TIFF0007583022000146.tif38170
[0523] The title compound was prepared from 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylic acid (Step 2 of Example 12) and (1S,2S)-2-aminocyclopentanol hydrochloride in analogy to Step 3 of Example 12.
[0524] LC-MS (Method A): Rt 2.37 min; MS m / z 446.3=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,Methanol-d4)δ 8.46(d,J=5.5Hz,1H),8.34(br.s,1H),8.18(d,J=1.9Hz,1H),7.89(dd,J=5.5,2.2Hz,1H),6.95(d,J=12.0Hz,1H),6.71(d,J=6.8Hz,1H) ,4.16-4.08(m,2H),3.79(s,2H),3.69(s,2H),2.23-2.15(m,1H),2.05-1.97(m,1H),1.89-1.73(m,2H),1.70-1.58(m,2H),1.34(s,6H).
[0525] Example 12.3 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide TIFF0007583022000147.tif36170
[0526] 4-[[2-(5-Fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylic acid ((Example 12, Step 2) (87%, 172 mg, 0.42 mmol) and DIPEA (0.22 mL, 1.26 mmol) were suspended in DMF (2 mL) and treated with HATU (191 mg, 0.5 mmol) followed by 2-amino-2-methyl-propan-1-ol (49 mg, 0.54 mmol) and the reaction mixture was stirred at room temperature for 2 h. The resulting mixture was diluted with EtOAc (25 mL), washed with water (2 × 20 mL), brine (2 × 20 mL), dried over NaSO and concentrated in vacuo. The crude intermediate was dissolved in THF (10 mL) and cooled to −78° C. 4M in THF LiBH4 (157 μL, 0.63 mmol) was added and stirring was continued with gradual warming to room temperature. After stirring for an additional 1.5 h, the resulting mixture was recooled to 0 °C and the reaction was quenched by the dropwise addition of 1 M HCl (10 mL). The mixture was diluted with EtOAc (20 mL) and water (20 mL), and the phases were separated. The aqueous portion was further extracted with EtOAc (2 × 10 mL), and the combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative HPLC (acidic pH, fast elution method) to give a solid that was dried in a vacuum oven at 40 °C to give the title compound as a colorless solid.
[0527] LCMS (Method A) Rt 2.43 min; MS m / z 434.3=[M+H]+(100% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 10.76(s,1H),9.37(s,1H),8.45(d,J=5.5Hz,1H),8.25(s,1H),8.19(d,J=1.9Hz,1H),7.80(dd,J=5.5,2.2Hz,1H),6.90(d,J=12.1Hz,1H),6.72 (d,J=7.0Hz,1H),5.13(t,J=5.5Hz,1H),4.77-4.70(m,1H),3.64(s,2H) ,3.60(d,J=3.7Hz,2H),3.44(d,J=5.5Hz,2H),1.33(s,6H),1.25(s,6H).
[0528] Example 12.4 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide TIFF0007583022000148.tif36170
[0529] To a solution of 4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxylic acid (Example 12, Step 2) (87%, 160 mg, 0.39 mmol) and DIPEA (0.24 mL, 1.36 mmol) in DMF (3 mL), HATU (177 mg, 0.47 mmol) was added, followed by (1-aminocyclobutyl)methanol hydrochloride (70 mg, 0.51 mmol), and the mixture was stirred at room temperature for 40 min. The resulting mixture was diluted with EtOAc (20 ml) and water (20 mL), and the phases were separated. The organic portion was washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo. The crude intermediate was dissolved in THF (3 mL) and cooled to -78 °C. 4M LiBH4 in THF (107 μL, 0.43 mmol) was added dropwise, and the mixture was stirred while gradually warming to room temperature over 40 min. The resulting mixture was recooled to 0 °C, and the reaction was quenched by the dropwise addition of 1M HCl (5 mL). The mixture was diluted with EtOAc (10 mL), and the phases were separated. The aqueous portion was further extracted with EtOAc (10 mL), and the combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative HPLC (acidic pH, fast elution method) to afford the title compound as a colorless solid.
[0530] LC-MS (Method A): Rt 2.43 min; MS m / z 446.3=[M+H]+(100% at 215 nm) 1H NMR (500MHz, DMSO-d6) δ 10.79(s,1H),9.34(br.s,1H),8.48(d,J=5.5Hz,1H),8.41(s,1H),8.19(d,J=2. 0Hz,1H),7.82(dd,J=5.5,2.2Hz,1H),6.91(d,J=12.1Hz,1H),6.73(d,J=7.0Hz,1 H),5.01(t,J=5.5Hz,1H),4.76(br.s,1H),3.65(s,2H),3.62(d,J=5.4Hz,2H),3. 61(s,2H),2.09-2.01(m,2H),1.89-1.80(m,1H),1.79-1.66(m,1H),1.26(s,6H).
[0531] Example 13 4-[[2-[2-Fluoro-5-hydroxy-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000149.tif33170
[0532] Step 1: 4-[[2-(5-benzyloxy-4-bromo-2-fluoro-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000150.tif58170
[0533] The title compound was prepared from 2-(5-benzyloxy-4-bromo-2-fluoro-phenyl)acetic acid (Intermediate S) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to Step 1 of Example 2.
[0534] LC-MS (Method G): Rt 1.13 min; MS m / z 566.1,568.0=[M+H]+(100% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 10.82(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.19(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.56(d,J=8.9Hz,1H) ,7.50-7.46(m,2H),7.42-7.36(m,2H),7.35-7.28(m,2H),5.16(s,2H),3.79(s,2H),1.33-1.27(m,2H),1.23-1.15(m,2H).
[0535] Step 2: 4-[[2-[5-benzyloxy-4-(3,6-dihydro-2H-pyran-4-yl)-2-fluorophenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000151.tif60170
[0536] A solution of 4-[[2-(5-benzyloxy-4-bromo-2-fluorophenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 1) (220 mg, 0.39 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (163 mg, 0.78 mmol), and potassium phosphate tripotassium (330 mg, 1.55 mmol) in toluene (5 mL) and water (0.5 mL) was degassed with nitrogen for 10 minutes and then treated with Pd(OAc) (17 mg, 0.08 mmol) and P(Cy) (44 mg, 0.16 mmol). The mixture was sparged with nitrogen for an additional 5 minutes, sealed, and heated at 100 °C for 5 hours. The resulting mixture was concentrated in vacuo, and the residue was partitioned between EtOAc (25 mL) and water (25 mL). The layers were separated, and the organic portion was washed with brine (25 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane to give the title compound.
[0537] LC-MS (Method E): Rt 1.35 min; MS m / z 570.3=[M+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.80(s,1H),9.39(s,1H),8.51(d,J=5.4Hz,1H),8.20(d,J=1.8Hz,1H),7.85(dd, J=5.5,2.2Hz,1H),7.46-7.34(m,4H),7.34-7.28(m,1H),7.15(d,J=6.4Hz,1H),7. 00(d,J=10.3Hz,1H),5.99-5.95(m,1H),5.07(s,2H),4.19-4.15(m,2H),3.77(s,2 H),3.74(t,J=5.4Hz,2H),2.43-2.38(m,2H),1.33-1.27(m,2H),1.22-1.17(m,2H).
[0538] Step 3: 4-[[2-[5-benzyloxy-2-fluoro-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000152.tif54170
[0539] A solution of 4-[[2-[5-benzyloxy-4-(3,6-dihydro-2H-pyran-4-yl)-2-fluorophenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 2) (100%, 170 mg, 0.3 mmol) in IPA (5 mL) and DCM (1 mL) was purged with air for 10 minutes. The mixture was cooled to 0 °C, and tris(2,2,6,6-tetramethyl-3,5-heptanedionato)manganese(III) (18 mg, 0.03 mmol) was added, followed by phenylsilane (74 μL, 0.6 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. The reaction was quenched with 20% aqueous sodium thiosulfate (20 mL) and stirred at room temperature for 30 minutes. The resulting mixture was extracted with EtOAc (2 x 25 mL), and the combined organic extracts were washed with brine (20 mL), dried over MgSO4, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane to afford the title compound as an off-white solid.
[0540] LC-MS (Method E): Rt 1.26 min; MS m / z 588.3=[M+H]+ (79% at 215 nm) 1 H NMR (500 MHz, DMSO-d6) δ 10.80(s,1H),9.38(s,1H),8.51(d,J=5.5Hz,1H),8.20(d,J=1.9Hz,1H),7.84 (dd,J=5.5,2.2Hz,1H),7.52-7.48(m,2H),7.41-7.34(m,3H),7.32-7.28(m,1H ),7.13(d,J=6.3Hz,1H),5.15(s,2H),5.11(s,1H),3.79-3.71(m,4H),3.66(dd ,J=10.7,5.2Hz,2H),2.68-2.57(m,2H),1.35-1.28(m,4H),1.21-1.17(m,2H).
[0541] Step 4: 4-[[2-[2-fluoro-5-hydroxy-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0542] The title compound was prepared from 4-[[2-[5-benzyloxy-2-fluoro-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 3) and 10% Pd—C in analogy to Step 2 of Example 2.
[0543] LC-MS (Method A): Rt 2.71 min; MS m / z 498.2=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.81(s,1H),9.57(s,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H) ,7.18(d,J=11.5Hz,1H),6.76(d,J=6.6Hz,1H),5.35(s,1H),3.77-3.72(m,2H),3.70-3.65(m,4H),2.46(obscured m,2H),1.36(d,J=12.9Hz,2H),1.32-1.27(m,2H),1.21-1.16(m,2H).
[0544] Example 14 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000153.tif35170
[0545] Step 1: Methyl 2-[5-chloro-2-methoxy-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]-2-methyl-propanoate TIFF0007583022000154.tif37170
[0546] To a stirred solution of 2-[2-chloro-5-methoxy-4-(2-methoxy-1,1-dimethyl-2-oxo-ethyl)phenyl]acetic acid (Intermediate T Step 5) (771 mg, 2.56 mmol), 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (629 mg, 2.56 mmol) and TEA (672 μL, 3.85 mmol) in 1,4-dioxane (10 mL) was added a 50% T3P® solution in EtOAc (2.29 mL, 3.85 mmol) and the reaction mixture was stirred at ambient temperature for 1 hour.
[0547] The resulting mixture was concentrated in vacuo, and the crude residue was dissolved in EtOAc (20 mL), washed with NaHCO (15 mL), brine (15 mL), dried over NaSO, and concentrated in vacuo. The crude residue was purified by chromatography on silica eluting with 0-100% EtOAc in heptane to afford the title compound as an off-white solid.
[0548] LC-MS (Method G): Rt 1.05 min; MS m / z 528.1,530.1=[M+H]+(99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.87(s,1H),9.40(s,1H),8.51(d,J=5.5Hz,1H),8.21(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),7.28(s ,1H),7.11(s,1H),3.89(s,2H),3.73(s,3H),3.55(s,3H),1.42(s,6H),1.32-1.30(m,2H),1.21-1.19(m,2H).
[0549] Step 2: 4-[[2-(5-chloro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000155.tif38170
[0550] 1M BBr3 in DCM (2.81 mL, 2.81 mmol) was added dropwise to a solution of methyl 2-[5-chloro-2-methoxy-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]-2-methyl-propanoate (Step 1) (494 mg, 0.94 mmol) in DCM (12 mL) under N2, and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with water (20 mL) and extracted with DCM (30 mL). The organic extract was dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by C18 reverse-phase chromatography eluting with 10–100% water (+0.1% formic acid) / MeCN (+0.1% formic acid) to afford the title compound as an off-white solid.
[0551] LC-MS (Method G): Rt 1.02 min; MS m / z 482.2,484.1=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.86(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.19(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz ,1H),7.67(s,1H),7.38(s,1H),3.94(s,2H),1.46(s,6H),1.32-1.28(m,2H),1.21-1.17(m,2H).
[0552] Step 3: 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0553] To a cooled (-78 °C) solution of 4-[[2-(5-chloro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 2) (197 mg, 0.41 mmol) in THF (4 mL) was added 4 M LiBH in THF (0.11 mL, 0.45 mmol). The resulting mixture was stirred for 5 min and then allowed to warm gradually to room temperature over 1 h.
[0554] The mixture was poured onto ice-cold 1 M HCl (50 mL), allowed to stand for 20 minutes, and then diluted with EtOAc (50 mL) and water (20 mL). The phases were separated, and the aqueous portion was extracted with EtOAc (50 mL). The combined organic extracts were washed with saturated NaHCO solution (2 × 50 mL), brine (50 mL), dried over NaSO, and concentrated in vacuo. The crude residue was purified by C18 reverse-phase chromatography, eluting with 10–100% water (+0.1% formic acid) / MeCN (+0.1% formic acid), to afford the title compound as an off-white solid.
[0555] LC-MS (Method A): Rt 3.12 min; MS m / z 486.2,488.1=[M+H]+(99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),9.69(s,1H),9.40(s,1H),8.51(d,J=5.5Hz,1H),8.23(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),7 .13(s,1H),6.80(s,1H),4.77(s,1H),3.75(s,2H),3.61(s,2H),1.33-1.28(m,2H),1.26(s,6H),1.22-1.17(m,2H).
[0556] Example 14.1 4-[[2-[5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000156.tif36170
[0557] Step 1: Methyl 2-[5-bromo-2-methoxy-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]-2-methyl-propanoate TIFF0007583022000157.tif40170
[0558] The title compound was prepared from 2-[2-bromo-5-methoxy-4-(2-methoxy-1,1-dimethyl-2-oxo-ethyl)phenyl]acetic acid (Intermediate Q) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) in analogy to Step 1 of Example 14.
[0559] LC-MS (Method H): Rt 1.53 min; MS m / z 573.4=[M+H]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.87(s,1H),9.40(s,1H),8.51(d,J=5.5Hz,1H),8.21(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),7.41(s ,1H),7.12(s,1H),3.90(s,2H),3.72(s,3H),3.55(s,3H),1.42(s,6H),1.32-1.29(m,2H),1.22-1.16(m,2H).
[0560] Step 2: Methyl 2-[2-methoxy-5-methyl-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]-2-methyl-propanoate TIFF0007583022000158.tif40170
[0561] Methyl 2-[5-bromo-2-methoxy-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]-2-methylpropanoate (Step 1) (75%, 655 mg, 0.86 mmol) was dissolved in 1,4-dioxane (15 mL), and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (50%, 0.29 mL, 1.03 mmol), Pd(dppf)Cl (31 mg, 0.04 mmol), and KCO (237 mg, 1.72 mmol) were added. The reaction mixture was degassed for 5 min and left stirring at 110 °C for 18 h. The resulting mixture was diluted with EtOAc (40 mL), washed with water (30 mL), brine (30 mL), dried over Na2SO4, and concentrated in vacuo. Purification by C18 reverse-phase chromatography eluting with 0-100% MeCN in water afforded the title compound.
[0562] LC-MS (Method G): Rt 1.01 min; MS m / z 508.30=[M+H]+ (79% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.77(s,1H),9.38(s,1H),8.50(d,J=5.5Hz,1H),8.20(d,J=2.0Hz,1H),7.86(dd,J=5.5,2.1Hz,1H),7.06(s,1H),6 .90(s,1H),3.72(s,2H),3.67(s,3H),3.52(s,3H),2.22(s,3H),1.39(s,6H),1.32-1.28(m,2H),1.21-1.15(m,2H).
[0563] Step 3: N-[1-(trifluoromethyl)cyclopropyl]-4-[[2-(3,3,5-trimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxamide TIFF0007583022000159.tif37170
[0564] The title compound was prepared from methyl 2-[2-methoxy-5-methyl-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]-2-methyl-propanoate (Step 2) and 1 M BBr in DCM in analogy to Step 2 of Example 14.
[0565] LC-MS (Method G): Rt 1.02 min; MS m / z 462.2=[M+H]+ (93% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.20(d,J=1.9Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),7 .28(s,1H),7.16(s,1H),3.79(s,2H),2.27(s,3H),1.42(s,6H),1.32-1.27(m,2H),1.21-1.16(m,2H).
[0566] Step 4: 4-[[2-[5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0567] The title compound was prepared from N-[1-(trifluoromethyl)cyclopropyl]-4-[[2-(3,3,5-trimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxamide (Step 3) and 4M LiBH4 in analogy to Step 3 of Example 14.
[0568] LC-MS (Method A): Rt 3.04 min; MS m / z 466.3=[M+H]+ (98% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.73(s,1H),9.39(s,1H),9.15(s,1H),8.50(d,J=5.5Hz,1H),8.22(d,J=1.9Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),6.92(s ,1H),6.64(s,1H),4.71(s,1H),3.59(s,2H),3.58(s,2H),2.15(s,3H),1.32-1.28(m,2H),1.25(s,6H),1.21-1.17(m,2H).
[0569] Example 15 N-(3,3-difluoro-1-methyl-cyclobutyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000160.tif45170
[0570] 4-Amino-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide (Intermediate AE) (67 mg, 0.28 mmol) and 2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate U) (60 mg, 0.25 mmol) in DMF (2.5 mL) were treated with DIPEA (0.13 mL, 0.74 mmol) and a 50% T3P® solution in EtOAc (0.59 mL, 0.49 mmol), and the mixture was stirred for 3 hours. The resulting mixture was diluted with EtOAc (20 mL), washed with brine (2 × 20 mL), dried over NaSO, and concentrated in vacuo. The residue was dissolved in THF (2.5 mL), cooled to −78 ° C, and treated with 4 M LiBH in THF (60 μL, 0.25 mmol). The mixture was warmed to 0°C and stirred for 4 hours. The reaction was quenched by dropwise addition to an ice-cold solution of 1M HCl and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with saturated aqueous sodium bicarbonate (30 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by preparative HPLC (acidic pH, fast elution method) to afford the title compound as a colorless solid.
[0571] LC-MS (Method A): Rt 3.02 min; MS m / z 466.3=[M+H]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.78(s,1H),9.39(br.s,1H),9.04(s,1H),8.49(d,J=5.5Hz,1H),8.18(d,J=1.9Hz,1H),7.83(dd,J=5.5,2.2Hz,1H),6.90(d,J=12.1Hz ,1H),6.72(d,J=7.0Hz,1H),4.75(br.s,1H),3.65(s,2H),3.60(s,2H),3.12-3.00(m,2H),2.74-2.64(m,2H),1.52(s,3H),1.25(s,6H).
[0572] Example 15.1 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide TIFF0007583022000161.tif37170
[0573] The title compound was prepared from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Intermediate AD) and 2-(5-chloro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate T) in analogy to Example 15.
[0574] LC-MS (Method A): Rt 3.07 min; MS m / z 444.3,446.3=[M+H]+(100% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),9.68(s,1H),8.48(d,J=5.5Hz,1H),8.33(s,1H),8.21(d,J=1.9Hz,1H),7.83(dd,J=5.5,2.2Hz, 1H),7.12(s,1H),6.80(s,1H),4.76(s,1H),3.74(s,2H),3.61(s,2H),3.22(s,1H),1.64(s,6H),1.25(s,6H).
[0575] Example 15.2 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide TIFF0007583022000162.tif42170
[0576] The title compound was prepared from 4-amino-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide (Intermediate AE) and 2-(5-chloro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate T) in analogy to Example 15.
[0577] LC-MS (Method A): Rt 3.18 min; MS m / z 482.3,484.3=[M+H]+(99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.68(s,1H),9.04(s,1H),8.49(d,J=5.5Hz,1H),8.19(d,J=1.9Hz,1H),7.83(dd,J=5.5,2.2Hz,1H),7.12(s,1H),6.8 0(s,1H),4.76(t,J=5.2Hz,1H),3.74(s,2H),3.61(d,J=4.9Hz,2H),3.12-3.00(m,2H),2.74-2.63(m,2H),1.52(s,3H),1.25(s,6H).
[0578] Example 15.3 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(difluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000163.tif39170
[0579] The title compound was prepared analogously to Example 15 from 2-(5-chloro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate T) and 4-amino-N-[1-(difluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate AC).
[0580] LC-MS (Method A): Rt 2.96 min; MS m / z 468.2,470.2=[M+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.80(s,1H),9.68(s,1H),9.08(s,1H),8.49(d,J=5.5Hz,1H),8.21(d,J=2.1Hz,1H),7.83(dd,J=5.5,2.1Hz,1H),7.12(s,1H), 6.80(s,1H),6.08(t,J=57.1Hz,1H),4.75(s,1H),3.74(s,2H),3.61(s,2H),1.25(s,6H),1.11-1.05(m,2H),1.06-0.99(m,2H).
[0581] Example 15.4 N-[1-(Difluoromethyl)cyclopropyl]-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000164.tif36170
[0582] The title compound was prepared analogously to Example 15 from 2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate U) and 4-amino-N-[1-(difluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate AC).
[0583] LC-MS (Method A): Rt 2.78 min; MS m / z 452.3=[M+H]+ (94% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.38(br.s,1H),9.09(s,1H),8.49(d,J=5.5Hz,1H),8.21(d,J=1.9Hz,1H),7.83(dd,J=5.5,2.2Hz,1H),6.90(d,J=12.1Hz,1H) ,6.72(d,J=7.0Hz,1H),6.08(t,J=57.1Hz,1H),4.75(br.s,1H),3.64( s,2H),3.60(s,2H),1.25(s,6H),1.11-1.05(m,2H),1.05-1.00(m,2H).
[0584] Example 16 N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000165.tif37170
[0585] Step 1: N-(1,1-dimethylprop-2-ynyl)-4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxamide TIFF0007583022000166.tif43170
[0586] A solution of 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Intermediate AD) (176 mg, 0.87 mmol), DIPEA (0.21 mL, 1.18 mmol), 2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate U) (94%, 200 mg, 0.79 mmol) and a 50% T3P® solution in EtOAc (0.56 mL, 0.95 mmol) in DMF (5 mL) was stirred at room temperature overnight. The resulting mixture was diluted with EtOAc (10 mL) and washed with brine (20 mL). The organic portion was dried over NaSO and concentrated in vacuo to give the title compound as a white solid, which was used in the next step without further purification.
[0587] LC-MS (Method G): Rt 0.98 min; MS m / z 424.3=[M+H]+ (92% at 215 nm)
[0588] Step 2: N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide
[0589] To a cooled (-78°C) stirred solution of N-(1,1-dimethylprop-2-ynyl)-4-[[2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetyl]amino]pyridine-2-carboxamide (Step 1) (92%, 330 mg, 0.72 mmol) in THF (10 mL) was added 4 M LiBH in THF (215 μL, 0.86 mmol), and the mixture was stirred at -78°C for 1 h and then at room temperature for 3 h. The resulting mixture was cooled to 0°C, and the reaction was quenched with 1 M HCl (10 mL). The mixture was diluted with EtOAc (10 mL), and the layers were separated. The aqueous portion was re-extracted with EtOAc (2 x 10 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo. The crude product was purified by C18 reverse phase chromatography eluting with 10-100% MeCN in water (+0.1% formic acid) followed by recrystallization from MeCN to give the title compound as a white solid.
[0590] LC-MS (Method C): Rt 2.97 min; MS m / z 426.5=[MH]-(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.79(s,1H),9.37(bs,1H),8.48(d,J=5.5Hz,1H),8.32(s,1H),8.20(d,J=1.9Hz,1H),7.83(dd,J=5.5,2.2Hz,1H),6.90 (d,J=12.1Hz,1H),6.72(d,J=7.0Hz,1H),4.75(bs,1H),3.65(s,2H),3.60(s,2H),3.21(s,1H),1.65(s,6H),1.25(s,6H).
[0591] Example 16.1 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide TIFF0007583022000167.tif38170
[0592] The title compound was prepared from 2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate U) and 4-amino-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Intermediate AF) in analogy to steps 1 and 2 of Example 16.
[0593] LC-MS (Method A): Rt 2.66 min; MS m / z 460.3=[M+H]+(100% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 10.79(s,1H),9.38(s,1H),8.49(d,J=5.6Hz,1H),8.20(d,J=1.8Hz,1H),8.12(s,1H),7.83(dd,J=5.5,2.2Hz,1H),6.91(d,J=12.1Hz,1H),6 .73(d,J=7.0Hz,1H),4.75(br.s,1H),3.70-3.57(m,6H),3.55-3.47(m ,2H),2.24-2.16(m,2H),1.68-1.58(m,2H),1.43(s,3H),1.26(s,6H).
[0594] Example 16.2 N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide TIFF0007583022000168.tif37170
[0595] The title compound was prepared from 2-(5-fluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate U) and 4-amino-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Intermediate AB) in analogy to steps 1 and 2 of Example 16.
[0596] LC-MS (Method A): Rt 2.65 min; MS m / z 429.4=[M+H]+ (98% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.83(s,1H),9.39(s,1H),8.84(s,1H),8.52(d,J=5.5Hz,1H),8.23(d,J=2.0Hz,1H),7.86(dd,J=5.5,2.2Hz,1H) ,6.90(d,J=12.1Hz,1H),6.73(d,J=7.0Hz,1H),4.75(s,1H),3.66(s,2H),3.60(s,2H),1.72(s,6H),1.25(s,6H).
[0597] Example 16.3 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide TIFF0007583022000169.tif37170
[0598] The title compound was prepared from 2-(5-fluoro-3-methyl-2-oxo-3H-benzofuran-6-yl)acetic acid (Intermediate UA) and 4-amino-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Intermediate AF) in analogy to Steps 1 and 2 of Example 16.
[0599] LC-MS (Method A): Rt 2.34 min; MS m / z 446.3=[M+H]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.25(s,1H),8.49(d,J=5.5Hz,1H),8.20(d,J=1.9Hz,1H),8.12(s,1H) ),7.82(dd,J=5.5,2.2Hz,1H),6.88(d,J=11.0Hz,1H),6.75(d,J=6.8Hz,1H),4.64( t,J=5.3Hz,1H),3.68-3.61(m,4H),3.57-3.48(m,3H),3.38-3.34(m,1H),3.18-3.0 8(m,1H),2.24-2.17(m,2H),1.67-1.59(m,2H),1.43(s,3H),1.13(d,J=7.0Hz,3H).
[0600] Example 16.4 4-[[2-[2,6-difluoro-3-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000170.tif39170
[0601] The title compound was prepared from 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) and 2-(5,7-difluoro-3,3-dimethyl-2-oxo-benzofuran-6-yl)acetic acid (Intermediate V) in analogy to Steps 1 and 2 of Example 16.
[0602] LC-MS (Method A): Rt 3.04 min; MS m / z 488.3=[M+H]+ (99% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 10.88(s,1H),9.51(br.s,1H),9.38(s,1H),8.51(d,J=5.6Hz,1H),8.18(d,J=2.1Hz,1H),7.84(dd,J=5.5,2.2Hz,1 H),6.82(dd,J=11.8,1.7Hz,1H),5.07(br.s,1H),3.77(s,2H),3.63(s,2H),1.32-1.24(m,8H),1.22-1.15(m,2H).
[0603] Example 17 4-[[2-[2-Fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000171.tif41170
[0604] Step 1: 4-[[2-[5-benzyloxy-4-[1-[[tert-butyl(dimethyl)silyl]oxymethyl]-2,2,2-trifluoroethyl]-2-fluorophenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0605] tert-Butyl-chloro-dimethyl-silane (41 mg, 0.27 mmol) was added to a mixture of 2-[5-benzyloxy-2-fluoro-4-[2,2,2 trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetic acid (Intermediate R) (51 mg, 0.14 mmol) and imidazole (23 mg, 0.34 mmol) in DMF (1.5 mL), and the resulting mixture was stirred at room temperature overnight. Additional imidazole (23 mg, 0.34 mmol) and tert-butyl-chloro-dimethyl-silane (41 mg, 0.27 mmol) were added, and stirring was continued for another 30 minutes. Additional imidazole (46 mg) and tert-butyl-chloro-dimethyl-silane (82 mg) were added, and stirring was continued for another 30 minutes. The resulting mixture was diluted with EtOAc (10 mL) and saturated ammonium chloride solution (10 mL), and the phases were separated. The aqueous portion was extracted with EtOAc (10 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo. The residue was dissolved in 1,4-dioxane (1.5 mL) and treated with 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (40 mg, 0.16 mmol), DIPEA (47.95 μL, 0.27 mmol), followed by a 50% T3P® solution in EtOAc (0.1 mL, 0.16 mmol), and the resulting mixture was stirred at room temperature for 45 minutes. The resulting mixture was diluted with EtOAc (15 mL) and water (15 mL), and the phases were separated. The aqueous portion was extracted with EtOAc (10 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0 to 50% EtOAc in heptane to afford the title compound as a colorless oil.
[0606] LC-MS (Method H): Rt 2.10 min; MS m / z 714.5=[M+H]+ (98% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.84(s,1H),9.40(s,1H),8.51(d,J=5.5Hz,1H),8.20(d,J=1.9Hz,1H),7.84(dd,J=5.5, 2.2Hz,1H),7.45-7.41(m,2H),7.40-7.35(m,2H),7.35-7.30(m,1H),7.28(d,J=10.4Hz,1 H),7.25(d,J=6.4Hz,1H),5.15.15-5.08(m,2H),4.21-4.11(m,1H),4.07-4.01(m,1H),3. 98-3.93(m,1H),3.80(s,2H),1.31-1.17(m,4H),0.80(s,9H),-0.02(s,3H),-0.04(s,3H).
[0607] Step 2: 4-[[2-[2-fluoro-5-hydroxy-4-[2,2,2 trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0608] 4M HCl in dioxane (0.5 mL, 2.0 mmol) was added to a mixture of 4-[[2-[5-benzyloxy-4-[1-[[tert-butyl(dimethyl)silyl]oxymethyl]-2,2,2-trifluoroethyl]-2-fluoro-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 1) (46 mg, 0.06 mmol) in MeOH (0.5 mL). The mixture was stirred at room temperature for 15 minutes, then azeotroped with EtOH (2 × 5 mL) and concentrated in vacuo. The residue was dissolved in EtOH (3 mL) and placed under a nitrogen atmosphere. 10% Pd / C (6.85 mg, 0.01 mmol) was added, and the reaction mixture was stirred under a hydrogen atmosphere for 2 hours. The resulting mixture was filtered through a Celite® pad and rinsed with 9:1 EtOAc:MeOH. The filtrate was concentrated in vacuo and the crude material was purified by C18 reverse phase chromatography eluting with 10-100% MeCN / water (+0.1% formic acid) to afford the title compound as an off-white solid.
[0609] LC-MS (Method A): Rt 2.91 min; MS m / z 510.0=[M+H]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.84(s,1H),9.80(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.21(d,J =2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.08(d,J=10.6Hz,1H),6.87(d ,J=6.7Hz,1H),5.11(t,J=4.9Hz,1H),4.11-4.00(m,1H),3.93-3.86(m,1 H),3.82-3.75(m,1H),3.71(s,2H),1.33-1.25(m,2H),1.24-1.15(m,2H).
[0610] Example 18 4-[[2-[2-chloro-6-fluoro-3-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000172.tif34170
[0611] N-chlorosuccinimide (59 mg, 0.44 mmol) was added to a mixture of 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Example 2) (100 mg, 0.22 mmol) in DMF (2 mL), and the mixture was stirred at room temperature for 18 hours. Additional N-chlorosuccinimide (59 mg, 0.44 mmol) was added, and stirring was continued for 24 hours. The resulting mixture was diluted with EtOAc (10 mL) and 1:1 brine:water (10 mL), and the phases were separated. The organic portion was dried over Na2SO4 and concentrated in vacuo to give the crude product as a yellow oil. The oil was purified by C18 reverse phase chromatography eluting with 10-100% MeCN / water (+0.1% formic acid) to give the title compound as an off-white solid.
[0612] LC-MS (Method A): Rt 3.16 min; MS m / z 490.3=[M+H]+(100% at 215 nm) 1 H NMR (500MHz, DMSO-d6) δ10.93(s,1H), 9.39(s,1H), 8.50(d,J=5.5Hz,1H), 8.18(d,J=2.0Hz,1H), 7.83(d,J =5.5,2.2Hz,1H), 7.06(d,J=10.8Hz,1H), 3.88(s,2H), 1.52(s,6H), 1.32-1.26(m,2H), 1.21-1.15(m,2H).
[0613] Example 19 4-[[2-[2-chloro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000173.tif35170
[0614] Step 1: 4-[[2-[5-benzyloxy-2-chloro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000174.tif54170
[0615] To a solution of 2-[5-benzyloxy-2-chloro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetic acid (Intermediate BE) (150 mg, 0.45 mmol), 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (100 mg, 0.41 mmol), and DIPEA (178 μL, 1.02 mmol) in 1,4-dioxane (1 mL) was added a 50% T3P® solution in EtOAc (364 μL, 0.61 mmol), and the mixture was stirred at ambient temperature for 2 h and then allowed to stand over the weekend. The resulting mixture was partitioned between DCM (5 mL) and water (5 mL), and the organics were separated by filtration through a hydrophobic PTFE fritted tube. The filtrate was concentrated in vacuo and the residue was purified by chromatography on silica eluting with 0-100% EtOAc in heptane followed by 0-100% MeOH in EtOAc to afford the title compound as a pale yellow powdery solid.
[0616] LC-MS (Method G): Rt 1.05 min; MS m / z 562.2,564.2=[M+H]+(91% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.83(s,1H),9.40(s,1H),8.52(d,J=5.6Hz,1H),8.21(d,J=2.0Hz,1H),7.85(dd,J=5.5,2.2Hz,1H),7.59(s,1H),7.49-7.44(m,2H),7.4 3-7.37(m,2H),7.36-7.31(m,1H),7.19(s,1H),5.15(s,1H),5.11(s, 2H),3.86(s,2H),1.47(s,6H),1.33-1.28(m,2H),1.22-1.17(m,2H).
[0617] Step 2: 4-[[2-[2-chloro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0618] Under a nitrogen atmosphere, degassed EtOH (3.5 mL) was added to 4-[[2-[5-benzyloxy-2-chloro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (196 mg, 0.35 mmol) (Step 1) and 10% Pd / C (20 mg, 0.35 mmol), the mixture was purged with nitrogen, and then placed under a hydrogen atmosphere for 60 minutes. An additional 10% Pd / C (20 mg, 0.35 mmol) was added, and the reaction was again purged with nitrogen and placed under a hydrogen atmosphere for an additional 65 minutes. The resulting mixture was diluted with MeOH (approximately 10 mL), filtered through Celite®, and washed with additional MeOH. The filtrate was concentrated in vacuo, and the residue was purified by chromatography on silica eluting with 0-100% EtOAc in heptane and 0-100% MeOH in EtOAc, followed by preparative HPLC (acidic pH, fast elution method) using water / MeCN with 0.1% formic acid. The combined product fractions were concentrated in vacuo to remove most of the organic solvent, and the aqueous residue was treated with saturated aqueous NaHCO (10 mL). The mixture was extracted with EtOAc (2 x 15 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo to give the title compound as a white crystalline solid.
[0619] LC-MS (Method A): Rt 3.11 min; MS m / z 472.2,474.2=[M+H]+(100% at 215 nm) UPLC(MSQ1,7MIN_HIRES_UPLC)100%;Rt 3.11 min;MS m / z 472.2,474.2=[M+H]+ 1H NMR(500MHz,DMSO-d6)δ 10.82(s,1H),9.40(s,1H),8.51(d,J=5.5Hz,1H),8.22(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz ,1H),7.35(s,1H),6.79(s,1H),3.76(s,2H),1.49(s,6H),1.33-1.28(m,2H),1.22-1.17(m,2H).
[0620] Example 20 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000175.tif36170
[0621] Step 1: Methyl 2-[2-benzyloxy-5-fluoro-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]propanoate
[0622] A solution of [(E)-1-methoxyprop-1-enoxy]-trimethylsilane (130 μL, 0.71 mmol) in degassed DMF (2 mL) was treated with 4-[[2-(5-benzyloxy-4-bromo-2-fluoro-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Example 13, Step 1) (200 mg, 0.35 mmol), ZnF (37 mg, 0.35 mmol) and Pd( t To the mixture was added Bu3)2 (18 mg, 0.04 mmol) under nitrogen, and the resulting mixture was heated to 80 °C for 16 h. The resulting mixture was diluted with EtOAc (20 mL), washed with water (2 × 20 mL), brine (2 × 20 mL), dried over Na2SO4, and concentrated in vacuo. The resulting crude material was purified by chromatography on silica eluting with 0 to 100% EtOAc in heptane to afford the title compound as a white solid.
[0623] LC-MS (Method G): Rt 1.09 min; MS m / z 574.2=[M+H]+ (83% at 215 nm) 1H NMR (500 MHz, DMSO-d6) δ 10.82(s,1H),9.39(s,1H),8.51(d,J=5.5Hz,1H),8.20(d,J=2.0Hz,1H),7.84( dd,J=5.5,2.2Hz,1H),7.43-7.35(m,4H),7.33-7.29(m,1H),7.14(d,J=6.3Hz, 1H),7.06(d,J=10.2Hz,1H),5.10-5.04(m,2H),3.98(q,J=7.2Hz,1H),3.77(s, 2H),3.51(s,3H),1.37(d,J=7.2Hz,3H),1.32-1.28(m,2H),1.21-1.17(m,2H).
[0624] Step 2: 4-[[2-[5-benzyloxy-2-fluoro-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000176.tif54170
[0625] A cooled (−78° C.) solution of methyl 2-[2-benzyloxy-5-fluoro-4-[2-oxo-2-[[2-[[1-(trifluoromethyl)cyclopropyl]carbamoyl]-4-pyridyl]amino]ethyl]phenyl]propanoate (Step 1) (83%, 100 mg, 0.14 mmol) in THF (10 mL) under an inert atmosphere was treated with a solution of 2.4 M LiAlH4 in THF (121 μL, 0.29 mmol), and the mixture was stirred at −78° C. for 1.5 h and then warmed to 0° C. The reaction was quenched with water and allowed to warm to room temperature. The resulting mixture was diluted with water (25 mL) and EtOAc (25 mL). The layers were separated, and the organic portion was washed with saturated Rochelle's salt solution (10 mL), brine (10 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by C18 reverse-phase chromatography eluting with 10-100% MeCN / water (+0.1% formic acid). The product fractions were concentrated in vacuo to give a colorless oil. The oil was azeotroped with MeOH and concentrated under high vacuum to give the title compound as a pale yellow solid.
[0626] LC-MS (Method G): Rt 1.00 min; MS m / z 546.2=[M+H]+(90% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.79(s,1H),9.39(s,1H),8.50(d,J=5.5Hz,1H),8.19(d,J=2.0Hz,1H) ,7.84(dd,J=5.5,2.2Hz,1H),7.47-7.41(m,2H),7.40-7.35(m,2H),7.35 -7.28(m,1H),7.08(d,J=6.5Hz,1H),7.00(d,J=10.8Hz,1H),5.07(s,2H),4.66-4.61(m,1H),3.74(s,2H),3.58-3.52(m,1H),3.30-3.22(partial obscured m,2H),1.32-1.26(m,2H),1.22-1.17(m,2H),1.14(d,J=7.0Hz,3H).
[0627] Step 3: 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[0628] The title compound was prepared from 4-[[2-[5-benzyloxy-2-fluoro-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Step 2) and 10% Pd—C in analogy to Step 2 of Example 2.
[0629] LC-MS (Method A): Rt 2.70 min; MS m / z 456.3=[M+H]+ (96% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),9.38(s,1H),9.26(s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.0Hz,1H) ,7.84(dd,J=5.5,2.2Hz,1H),6.87(d,J=11.0Hz,1H),6.75(d,J=6.7Hz,1H),4.66-4.6 1 (m, 1H), 3.65 (s, 2H), 3.57-3.51 (m, 1H), 3.17-3.08 (m, 1H), 1.32-1.28 (m, 2H), 1.21-1.16 (m, 2H), 1.13 (d, J = 7.0 Hz, 3H). The signal at approximately 3.3-3.4 is hidden under the water peak but was observed by HSQC (bottom). Examples 20a and 20b
[0630] Chiral separation of racemic 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Example 20) using supercritical fluid chromatography [15% IPA:85% CO, Chiralpak AD-H 10x250 mm column, 15 mL / min] afforded the individual enantiomers.
[0631] Example 20a: 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide or 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide JPEG0007583022000177.jpg37170(R)-isomer JPEG0007583022000178.jpg37170(S)-isomer
[0632] First eluting peak: SFC retention time = 17.13 min LC-MS (Method A): Rt 2.69 min; MS m / z 456.3=[M+H]+ (91% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),9.39(s,1H),9.21(br.s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.0Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),6.87 (d,J=11.0Hz,1H),6.74(d,J=6.8Hz,1H),4.65(br.s,1H),3.65(s,2H),3.53(dd,J=10.2,5.6Hz,1H),3.40-3.30(obscured m,1H),3.14-3.10(m,1H),1.32-1.28(m,2H),1.21-1.17(m,2H),1.13(d,J=7.0Hz,3H).
[0633] Example 20b: 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide or 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide JPEG0007583022000179.jpg37170(R)-isomer JPEG0007583022000180.jpg37170(S)-isomer
[0634] Second eluting peak: SFC retention time = 20.28 min LC-MS (Method A): Rt 2.69 min; MS m / z 456.3=[M+H]+ (99% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.80(s,1H),9.39(s,1H),9.25(br.s,1H),8.50(d,J=5.5Hz,1H),8.21(d,J=2.1Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),6.87 (d,J=11.0Hz,1H),6.74(d,J=6.7Hz,1H),4.65(br.s,1H),3.65(s,2H),3.53(dd,J=10.2,5.6Hz,1H),3.40-3.30(obscured m,1H),3.15-3.10(m,1H),1.31-1.28(m,2H),1.20-1.17(m,2H),1.13(d,J=7.0Hz,3H).
[0635] Preparation of intermediates Intermediate A 4-Amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000181.tif25170
[0636] 4-Aminopyridine-2-carboxylic acid (1 g, 7.24 mmol) in DMF (36.2 mL) was treated with TEA (3.68 mL, 26.43 mmol), 1-(trifluoromethyl)cyclopropanamine hydrochloride (1.29 g, 7.96 mmol), followed by TBTU (3.14 g, 9.77 mmol) and stirred at room temperature for 4 days. The resulting mixture was filtered, and the solid was washed with DMF (2 × 30 mL). The filtrate was concentrated in vacuo, and the crude residue was dissolved in EtOAc (300 mL) and washed with saturated NaHCO3 solution (2 × 300 mL). The aqueous portion was re-extracted with EtOAc (30 mL), and the combined organic extracts were washed with brine (2 × 160 mL), dried over Na2SO4, and concentrated in vacuo. Purification by C18 reverse-phase column chromatography eluting with 10–100% MeCN in water afforded the title compound as an off-white solid.
[0637] LC-MS (Method F): Rt 1.32 min; MS m / z 246.1=[M+H]+(100% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 9.13(s,1H),8.02(d,J=5.6Hz,1H),7.20(d,J=2.3Hz,1H),6.61(dd,J=5.6,2.4Hz,1H),6.36(s,2H),1.32-1.22(m,2H),1.21-1.11(m,2H).
[0638] Intermediate AB 4-Amino-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide JPEG0007583022000182.jpg27170
[0639] The title compound was prepared similarly to Intermediate A from 4-aminopyridine-2-carboxylic acid and 2-amino-2-methyl-propanenitrile hydrochloride.
[0640] LC-MS (Method E): Rt 0.35 min; MS m / z 205.0=[M+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 8.60(s,1H),8.03(d,J=5.6Hz,1H),7.21(d,J=2.3Hz,1H),6.62(dd,J=5.6,2.4Hz,1H),6.40(s,2H),1.70(s,6H).
[0641] intermediate AC 4-Amino-N-[1-(difluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000183.tif27170
[0642] The title compound was prepared analogously to Intermediate A from 4-aminopyridine-2-carboxylic acid and 1-(difluoromethyl)cyclopropanamine hydrochloride.
[0643] LC-MS (Method I): Rt 0.39 min; MS m / z 228.0=[M+H]+(100% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 8.85(s,1H),8.00(d,J=5.6Hz,1H),7.19(d,J=2.1Hz,1H),6.60(dd,J=5.6,2.4Hz ,1H),6.36(s,2H),6.05(t,J=57.2Hz,1H),1.09-1.03(m,2H),1.03-0.97(m,2H).
[0644] Intermediate AD 4-Amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide TIFF0007583022000184.tif28170
[0645] The title compound was prepared similarly to Intermediate A from 4-aminopyridine-2-carboxylic acid and 2-methylbut-3-yn-2-amine.
[0646] LC-MS (Method I): Rt 0.42 min; MS m / z 203.9=[M+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 8.23(s,1H),7.99(d,J=5.6Hz,1H),7.19(d,J=2.3Hz,1H),6.58(dd,J=5.6,2.4Hz,1H),6.36(s,2H),3.19(s,1H),1.62(s,6H).
[0647] Intermediate AE 4-Amino-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide TIFF0007583022000185.tif32170
[0648] The title compound was prepared analogously to Intermediate A from 3,3-difluoro-1-methyl-cyclobutanamine hydrochloride and 4-aminopyridine-2-carboxylic acid.
[0649] LC-MS (Method G): Rt 0.63 min; MS m / z 242.2=[M+H]+ (98% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 8.79(s,1H),8.01(d,J=5.6Hz,1H),7.18(d,J=2.2Hz,1H),6.59(dd,J=5.6,2. 4Hz, 1H), 6.32 (br.s, 2H), 3.11-2.96 (m, 2H), 2.72-2.59 (m, 2H), 1.50 (s, 3H).
[0650] Intermediate AF 4-Amino-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide TIFF0007583022000186.tif28170
[0651] The title compound was prepared similarly to Intermediate A from 4-methyltetrahydropyran-4-amine hydrochloride and 4-aminopyridine-2-carboxylic acid.
[0652] LC-MS (Method I): Rt 0.36 min; MS m / z 236.0=[M+H]+ (93% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 8.08(s,1H),8.00(d,J=5.6Hz,1H),7.18(d,J=2.2Hz,1H),6.58(dd,J=5.6,2.4Hz,1H),6.34(s ,2H),3.67-3.60(m,2H),3.51-3.45(m,2H),2.18-2.12(m,2H),1.63-1.56(m,2H),1.39(s,3H).
[0653] Intermediate B 2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetic acid TIFF0007583022000187.tif58170
[0654] Step 1: (3-Bromo-4-fluoro-phenyl)acetate TIFF0007583022000188.tif42170
[0655] A cooled (0 °C) solution of 3-bromo-4-fluorophenol (5 g, 26.18 mmol) and TEA (6.86 mL, 49.22 mmol) in DCM (100 mL) was treated dropwise with acetyl chloride (2.61 mL, 36.65 mmol), and the mixture was stirred at room temperature for 45 minutes. The resulting mixture was diluted with DCM (100 mL) and washed sequentially with 0.5 M HCl (120 mL), water (120 mL), saturated NaHCO (120 mL), and brine (120 mL). The organic portion was dried over NaSO and concentrated in vacuo to give the title compound as a tan solid.
[0656] LC-MS (Method E): Rt 1.14 min (85% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.59(dd,J=6.0,2.8Hz,1H),7.43(t,J=8.8Hz,1H),7.26-7.17(m,1H),2.26(s,3H).
[0657] Step 2: 1-(4-bromo-5-fluoro-2-hydroxy-phenyl)ethanone TIFF0007583022000189.tif33170
[0658] A mixture of (3-bromo-4-fluoro-phenyl)acetate (Step 1) (90%, 6.3 g, 24.33 mmol) and aluminum trichloride (5.84 g, 43.8 mmol) was stirred at 165 °C for 3 h. The melt was allowed to cool to room temperature, and the resulting solid was suspended in DCM (100 mL). 2 N HCl (100 mL) was added, and the insoluble material was removed by filtration through Celite® (filter material). The layers were separated, and the aqueous portion was re-extracted with DCM (60 mL). The combined organic extracts were washed with water (140 mL), brine (140 mL), dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-30% EtOAc in heptane to give the title compound as an off-white solid.
[0659] LC-MS (Method E): Rt 1.17 min (96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 11.62(s,1H),7.79(d,J=9.4Hz,1H),7.33(d,J=5.8Hz,1H),2.61(s,3H).
[0660] Step 3: 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)ethanone TIFF0007583022000190.tif54170
[0661] Benzyl bromide (3.23 mL, 27.19 mmol) was added to a stirred mixture of 1-(4-bromo-5-fluoro-2-hydroxy-phenyl)ethanone (Step 2) (96%, 5.5 g, 22.66 mmol) and K2CO3 (7.83 g, 56.65 mmol) in DMF (25 mL), and the mixture was stirred at 80 °C for 1 h. The resulting mixture was allowed to cool to room temperature and partitioned between EtOAc (150 mL) and water (150 mL). The aqueous layer was further extracted with EtOAc (100 mL). The combined organic extracts were washed with water (2 × 150 mL), brine (150 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0–60% EtOAc in heptane to afford the title compound as an off-white solid.
[0662] LC-MS (Method E): Rt 1.35 min (87% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.65(d,J=5.5Hz,1H),7.55-7.46(m,3H),7.44-7.40(m,2H),7.39-7.35(m,1H),5.26(s,2H),2.49(s,3H).
[0663] Step 4: 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)propan-2-ol TIFF0007583022000191.tif49170
[0664] To a solution of 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)ethanone (Step 3) (90%, 100 mg, 0.28 mmol) in THF (1 mL) stirred at −78° C. was added bromo(methyl)magnesium (3 M in EtO) (121 μL, 0.36 mmol). The dry ice bath was removed, and the mixture was stirred at room temperature for 1 h. The resulting mixture was diluted with saturated aqueous NH4Cl (10 mL) and EtOAc (10 mL). The organic layer was separated, dried over Na2SO4, and concentrated in vacuo to give the title compound as a pale yellow solid.
[0665] LC-MS (Method E): Rt 1.31 min; MS m / z 320.9,322.9 [M+H-H2O]+ (95% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.57-7.27(m,7H),5.23(s,1H),5.14(s,2H),1.45(s,6H).
[0666] Step 5: 2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetic acid
[0667] To a stirred solution of potassium 3-ethoxy-3-oxopropanoate (75 mg, 0.44 mmol) and 2-(2-benzyloxy-4-bromo-5-fluorophenyl)propan-2-ol (Step 4) (100 mg, 0.29 mmol) in toluene (2 mL) was added DMAP (3.6 mg, 0.03 mmol). The resulting mixture was degassed for 5 minutes. Diallyldipalladium dichloride (2.2 mg, 0.01 mmol) and BINAP (11.0 mg, 0.02 mmol) were added, and the sealed reaction mixture was stirred at 140° C. for 3.5 hours. The resulting mixture was concentrated in vacuo, and the residue was dissolved in THF (3 mL). Insoluble material was removed by filtration, and the filtrate was diluted with MeOH (0.5 mL) and treated with 2 M aqueous LiOH (0.44 mL, 0.88 mmol). The resulting mixture was stirred at room temperature for 16 hours. The mixture was diluted with 2M NaOH (10 mL) and extracted with EtOAc (3 × 10 mL). The organic extracts were discarded, and the aqueous portion was acidified to pH 3 with 2M aqueous HCl. The mixture was extracted with EtOAc (3 × 10 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo to give the title compound as an off-white solid.
[0668] LC-MS (Method E): Rt 1.10 min; MS m / z 301.0 [M+H-H2O]+ (93% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.40(s,1H),7.49-7.45(m,2H),7.45-7.40(m,2H),7.37-7.33(m,1H),7.31(d,J=11 .5Hz,1H),7.05(d,J=6.3Hz,1H),5.08(s,1H),5.06(s,2H),3.57(s,2H),1.46(s,6H).
[0669] Intermediate BA 2-[5-benzyloxy-2-fluoro-4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)phenyl]acetic acid TIFF0007583022000192.tif58170
[0670] Step 1: [1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2,2,2-trifluoro-1-methyl-ethoxy]-trimethyl-silane TIFF0007583022000193.tif53170
[0671] To a solution of trimethyl(trifluoromethyl)silane (257 μL, 1.74 mmol) in THF (1 mL) stirred at −50° C. was added a solution of 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)ethanone (Step 3 of Intermediate B) (90%, 500 mg, 1.39 mmol) in THF (1 mL), followed by the addition of TBAF (2.5 mg, 0.01 mmol). The reaction mixture was stirred at −50° C. for 30 minutes and then warmed to room temperature for 1 hour. The resulting mixture was diluted with EtOAc (10 mL) and water (10 mL). The organic layer was separated, washed with water (10 mL), dried over NaSO, and concentrated in vacuo to give the title compound as a yellow oil.
[0672] LC-MS (Method H): Rt 2.03 min; (85% at 215 nm) 1 H NMR (500 MHz, chloroform-d) δ 7.38 (d, J = 10.3 Hz, 1H), 7.31-7.11 (m, 5H), 6.99 (d, J = 5.7 Hz, 1H), 4.88 (s, 2H), 1.79 (s, 3H), 0.05 (s, 9H).
[0673] Step 2: 2-[5-benzyloxy-2-fluoro-4-(2,2,2 trifluoro-1-hydroxy-1-methyl-ethyl)phenyl]acetic acid
[0674] The title compound was prepared from [1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2,2,2-trifluoro-1-methyl-ethoxy]-trimethyl-silane (Step 1) and potassium 3-ethoxy-3-oxo-propanoate, analogous to Step 5 of Intermediate B.
[0675] LC-MS (Method E): Rt 1.18 min; MS m / z 743.2 [2M-H]-(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.60(s(br),1H),7.47-7.39(m,5H),7.37-7.31(m,1H),7.19(d,J=6.4Hz,1H),6.59(s,1H),5.10-5.03(m,2H),3.61(s,2H),1.78(s,3H).
[0676] Intermediate BB 2-[5-benzyloxy-4-(1-cyclopropyl-1-hydroxy-ethyl)-2-fluorophenyl]acetic acid TIFF0007583022000194.tif57170
[0677] The title compound was prepared from 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)ethanone (Step 3 of Intermediate B) and bromo(cyclopropyl)magnesium solution (1M in Me-THF) in analogy to Steps 4 and 5 of Intermediate B.
[0678] LC-MS (Method E): Rt 1.23 min; MS m / z 345.1 [M+H]+ (86% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.47(s(br),1H),7.49-7.45(m,2H),7.43-7.39(m,2H),7.36-7.32(m,1H),7.23(d,J=11.5Hz,1H),7.06(d,J=6.4Hz,1H),5. 08(s,2H),4.64(s,1H),3.56(s,2H),1.64-1.58(m,1H),1.54(s,3H),0.50-0.42(m,1H),0.24-0.16(m,2H),0.06-0.00(m,1H).
[0679] intermediate BC 2-[5-benzyloxy-2-fluoro-4-(1-hydroxy-1-methyl-propyl)phenyl]acetic acid TIFF0007583022000195.tif50170
[0680] The title compound was prepared from 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)ethanone (Step 3 of Intermediate B) and bromo(ethyl)magnesium solution (1M in THF) in analogy to Steps 4 and 5 of Intermediate B.
[0681] LC-MS (Method E): Rt 1.17 min; MS m / z 315.1 [M+H-H2O]+ (96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.43(br.s,1H),7.47-7.39(m,4H),7.37-7.32(m,1H),7.28(d,J=11.6Hz,1H),7.04(d,J=6.3Hz,1H),5.05(s,2H),4.85( s,1H),3.59-3.54(m,2H),2.02(dq,J=14.8,7.4Hz,1H),1.65(dq,J=14.5,7.3Hz,1H),1.44(s,3H),0.61(t,J=7.4Hz,3H).
[0682] Intermediate BD 2-[5-benzyloxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetic acid TIFF0007583022000196.tif59170
[0683] Step 1: 1-(2-benzyloxy-4-bromo-5-methyl-phenyl)ethanone TIFF0007583022000197.tif59170
[0684] The title compound was prepared from 1-(4-bromo-2-hydroxy-5-methyl-phenyl)ethanone and bromomethylbenzene in analogy to Step 3 of Intermediate B.
[0685] LC-MS (Method G): Rt 1.18 min; MS m / z 319.0,321.0=[M+H]+(98% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.56-7.46(m,4H),7.45-7.39(m,2H),7.38-7.33(m,1H),5.24(s,2H),2.48(s,3H),2.30(s,3H).
[0686] Step 2: 2-(2-benzyloxy-4-bromo-5-methyl-phenyl)propan-2-ol TIFF0007583022000198.tif54170
[0687] A cooled (0 °C) suspension of cerium trichloride (2.27 g, 9.21 mmol) in THF (100 mL) was treated with 3 M methylmagnesium bromide in ether (3.07 mL, 9.21 mmol) and stirred for 1 h. 1-(2-benzyloxy-4-bromo-5-methyl-phenyl)ethanone (Step 1) (98%, 2 g, 6.14 mmol) was added in one portion, and the reaction mixture was stirred at 0 °C for 90 min. The reaction was quenched by the addition of water (150 mL), followed by EtOAc (100 mL). The organics were separated, washed with water (100 mL), brine (100 mL), dried over Na SO , and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0–100% EtOAc in heptane to afford the title compound as a colorless oil.
[0688] LC-MS (Method G): Rt 1.16 min; MS m / z 317.1,319.1=[M-H2O+H]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.54(s,1H),7.47-7.39(m,4H),7.37-7.31(m,1H),7.22(s,1H),5.12(s,2H),5.02(s,1H),2.27(s,3H),1.45(s,6H).
[0689] Step 3: 2-[5-benzyloxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetic acid
[0690] The title compound was prepared from 2-(2-benzyloxy-4-bromo-5-methyl-phenyl)propan-2-ol (Step 2) and potassium 3-ethoxy-3-oxo-propanoate in analogy to Step 5 of Intermediate B.
[0691] LC-MS (Method G): Rt 0.87 min; MS m / z 297.2=[M-H2O+H]+ (95% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 12.32(br.s,1H),7.49-7.44(m,2H),7.44-7.38(m,2H),7.38-7.31(m,2H),6 .92(s,1H),5.05(s,2H),4.86(s,1H),3.52(s,2H),2.16(s,3H),1.46(s,6H).
[0692] Intermediate BE 2-[5-benzyloxy-2-chloro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetic acid TIFF0007583022000199.tif59170
[0693] Step 1: (3-Bromo-4-chloro-phenyl)acetate TIFF0007583022000200.tif47170
[0694] A cooled (ice bath) solution of 3-bromo-4-chlorophenol (5.0 g, 24.1 mmol) and TEA (6.31 mL, 36.15 mmol) in DCM (75 mL) was treated dropwise with acetyl chloride (2.4 mL, 33.74 mmol) in DCM (25 mL) and stirred at room temperature for 1 h. The resulting mixture was washed with 0.5 M HCl (100 mL), 1:1 saturated NaHCO / water (100 mL), dried over NaSO, and concentrated in vacuo to give the title compound as a brown oil.
[0695] LC-MS (Method E): Rt 1.22 min; no ionization (90% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 7.68(d,J=8.9Hz,1H),7.66(d,J=2.8Hz,1H),7.23(dd,J=8.7,2.7Hz,1H),2.27(s,3H).
[0696] Step 2: 1-(4-bromo-5-chloro-2-hydroxy-phenyl)ethanone TIFF0007583022000201.tif36170
[0697] Under nitrogen, a mixture of (3-bromo-4-chloro-phenyl)acetate (Step 1) (6.35 g, 25.47 mmol) and aluminum trichloride (6.11 g, 45.84 mmol) was heated to 165 °C for 3 h. The resulting melt was cooled to 130 °C, toluene (50 mL) was added, and the mixture was heated to reflux to dissolve the solids for 1 h. The resulting mixture was cooled to room temperature, then EtOAc (10 mL) and 0.5 M HCl (40 mL) were added, and the mixture was stirred with a secondary stirrer. The organics were separated, and the aqueous layer was re-extracted with EtOAc (20 mL). The combined organic extracts were washed with brine, dried over NaSO, and concentrated in vacuo. The residue was treated with heptane (25 mL), and the resulting suspension was filtered, washed with additional heptane, and dried under vacuum to afford the title compound as a tan crystalline solid.
[0698] LC-MS (Method E): Rt 1.26 min; no ionization (96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 11.76(s,1H),7.97(s,1H),7.41(s,1H),2.62(s,3H).
[0699] Step 3: 1-(2-benzyloxy-4-bromo-5-chloro-phenyl)ethanone TIFF0007583022000202.tif61170
[0700] 1-(4-Bromo-5-chloro-2-hydroxy-phenyl)ethanone (Step 2) (96%, 3.56 g, 13.69 mmol) and 1-(4-bromo-5-chloro-2-hydroxy-phenyl)ethanone (78%, 2.35 g, 7.33 mmol) were dissolved in DMF (30 mL) and treated with KCO (11.62 g, 84.1 mmol) and benzyl bromide (4.5 mL, 37.85 mmol). The reaction mixture was stirred at room temperature for 18 h. The resulting mixture was filtered through Celite®, washed with MeOH, and the filtrate was concentrated in vacuo. The residue was partitioned between 4:1 EtOAc / heptane (150 mL) and water (100 mL). The organic portion was separated, washed with water (100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by chromatography on silica eluting with a gradient of 0-30% EtOAc in heptane. The product fractions were concentrated in vacuo and the residue was recrystallized from 1:1 TBME / heptane (20 mL) to give the title compound as a brown crystalline solid.
[0701] LC-MS (Method G): Rt 1.19 min; (76% at 215 nm) 1 H NMR (500 MHz, chloroform-d) δ 7.83 (s, 1H), 7.44-7.40 (m, 5H), 7.32 (s, 1H), 5.14 (s, 2H), 2.55 (s, 3H).
[0702] Step 4: 2-(2-benzyloxy-4-bromo-5-chloro-phenyl)propan-2-ol TIFF0007583022000203.tif58170
[0703] A cooled (-78 °C) solution of 1-(2-benzyloxy-4-bromo-5-chloro-phenyl)ethanone (Step 3) (1.29 g, 3.8 mmol) in THF (25 mL) was treated with methylmagnesium bromide (3 M in EtO) (1.65 mL, 4.94 mmol) and allowed to warm to room temperature with stirring for 1.5 h. The resulting mixture was cooled to 0 °C and treated with 10% aqueous NH4Cl (10 mL) and EtOAc (10 mL). The organic portion was separated, dried over Na2SO4, and concentrated in vacuo. The crude material was purified by chromatography on basic silica eluting with a gradient of 0 to 50% EtOAc in heptane to afford the title compound as a tan oil that crystallized on standing.
[0704] LC-MS (Method G): Rt 1.17 min; MS m / z 337.0,339.0=[M+H-H2O]+(68% at 215 nm) 1 H NMR (500 MHz, chloroform-d) δ 7.47 (s, 1H), 7.45-7.36 (m, 5H), 7.21 (s, 1H), 5.10 (s, 2H), 3.45 (s, 1H), 1.58 (s, 6H).
[0705] Step 5: 2-[5-benzyloxy-2-chloro-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetic acid
[0706] 2-(2-Benzyloxy-4-bromo-5-chloro-phenyl)propan-2-ol (Step 4) (1.04 g, 2.91 mmol), potassium 3-ethoxy-3-oxopropanoate (991 mg, 5.82 mmol), diallyldipalladium dichloride (106 mg, 0.29 mmol), BINAP (362 mg, 0.58 mmol), and DMAP (36 mg, 0.29 mmol) were suspended in toluene (9.7 mL) and heated to 140 °C in a sealed tube for 18 h. The reaction solvent was concentrated in vacuo, and the resulting residue was treated with MeOH (20 mL) and 2 M aqueous LiOH solution (4.37 mL, 8.73 mmol) and then stirred at room temperature for 3 h. Additional 2 M aqueous LiOH solution (4.37 mL, 8.73 mmol) and MeOH (10 mL) were added, and stirring was continued for an additional 2 h. The mixture was concentrated in vacuo to remove the bulk of the organics, and the aqueous residue was diluted with water (20 mL) and DCM (30 mL). The aqueous portion was separated, washed with DCM, and acidified with 2 M KHSO (25 mL). The mixture was extracted with DCM (2 × 30 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane, followed by 0-100% MeOH in EtOAc. The product fractions were concentrated in vacuo, and the residue was dissolved in 1:1 DMSO / MeOH (1.2 mL). Purification of the crude material by preparative HPLC (acidic pH, fast elution method) afforded the title compound as a white crystalline solid.
[0707] LC-MS (Method E): Rt 1.12 min; MS m / z 316.9,318.9=[M+H-H2O]+(100% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.57(s,1H),7.50-7.45(m,2H),7.45-7.39(m,2H),7.38-7.33(m,1H),7.15(s,1H),5.11(s,1H),5.09(s,2H),3.65(s,2H),1.45(s,6H).
[0708] Intermediate C 2-[5-benzyloxy-4-(1-cyano-1-methyl-ethyl)-2-fluorophenyl]acetic acid TIFF0007583022000204.tif58170
[0709] Step 1: Methyl 4-bromo-5-fluoro-2-triisopropylsilyloxy-benzoate TIFF0007583022000205.tif48170
[0710] A stirred mixture of methyl 4-bromo-5-fluoro-2-hydroxybenzoate (3 g, 12.05 mmol), TEA (3.69 mL, 26.5 mmol), and DMAP (147 mg, 1.2 mmol) in DCM (20 mL) under nitrogen was treated dropwise with triisopropylsilyl chloride (3.09 mL, 14.46 mmol), and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with water (20 mL), and the organic layer was separated, dried over NaSO, and concentrated in vacuo to give the title compound as a yellow oil.
[0711] LC-MS (Method H): Rt 2.09 min; MS m / z 405.1,407.1=[M+H]+(97% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.61(d,J=8.8Hz,1H),7.12(d,J=5.6Hz,1H),3.81-3.74(m,3H),1.29(hept,J=7.3Hz,3H),1.05(d,J=7.6Hz,18H).
[0712] Step 2: (4-Bromo-5-fluoro-2-triisopropylsilyloxy-phenyl)methanol TIFF0007583022000206.tif50170
[0713] A stirred solution of methyl 4-bromo-5-fluoro-2-triisopropylsilyloxy-benzoate (Step 1) (76%, 5.4 g, 10.12 mmol) in THF (100 mL) was treated with 4M LiBH4 in THF (7.59 mL, 30.37 mmol) and the mixture was stirred at room temperature overnight.
[0714] The mixture was cooled (0°C) and the reaction was carefully quenched with ice (20 mL) with stirring for 30 minutes, then allowed to warm to room temperature. EtOAc (20 mL) was added, and the organic layer was separated, dried over Na2SO4, and concentrated in vacuo. The crude material was purified by chromatography on silica (Biotage® Isolera 55 g KP-NH) eluting with 0-100% EtOAc in heptane to afford the title compound as a yellow oil.
[0715] LC-MS (Method H): Rt 1.60 min; MS m / z 400.1=[M+Na]+ (90% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.28(d,J=9.5Hz,1H),6.92(d,J=5.7Hz,1H),5.32(t,J=5.2Hz,1H),4.48(d,J=4.4Hz,2H),1.28(dq,J=14.5,7.5Hz,3H),1.09-1.03(m,18H).
[0716] Step 3: [5-Bromo-2-(chloromethyl)-4-fluoro-phenoxy]-triisopropyl-silane TIFF0007583022000207.tif50170
[0717] A cooled (0°C) stirred solution of (4-bromo-5-fluoro-2-triisopropylsilyloxy-phenyl)methanol (4.8 g, 12.72 mmol) and DMF (941 µL, 12.14 mmol) in DCM (80 mL) was treated dropwise with thionyl chloride (2.24 mL, 30.88 mmol) in DCM (40 mL) and the mixture was stirred at room temperature for 2 h.
[0718] The solvent was removed in vacuo, and the residue was diluted with EtOAc (100 mL). The mixture was washed with saturated NaHCO (100 mL), brine (30 mL), dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane to afford the title compound as a yellow oil.
[0719] LC-MS (Method H): Rt 2.12 min (87% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.51(d,J=9.0Hz,1H),7.02(d,J=5.8Hz,1H),4.66(s,2H),1.35(hept,J=7.4Hz,3H),1.08(d,J=7.5Hz,18H).
[0720] Step 4: 2-(4-bromo-5-fluoro-2-hydroxy-phenyl)acetonitrile TIFF0007583022000208.tif32170
[0721] Sodium cyanide (576 mg, 11.75 mmol) in DMF (20 mL) was added to a solution of [5-bromo-2-(chloromethyl)-4-fluoro-phenoxy]-triisopropyl-silane (Step 3) (3.1 g, 7.83 mmol), and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with EtOAc (20 mL), washed with saturated aqueous sodium carbonate (30 mL), brine (50 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane to afford the title compound as a yellow solid.
[0722] LC-MS (Method E): Rt 1.04 min; MS m / z 227.8, 229.8 = [MH] (98% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 10.43(s,1H),7.30(d,J=9.1Hz,1H),7.08(d,J=6.1Hz,1H),3.78(s,2H).
[0723] Step 5: 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)acetonitrile TIFF0007583022000209.tif53170
[0724] Benzyl bromide (614 μL, 5.16 mmol) was added to a stirred mixture of 2-(4-bromo-5-fluoro-2-hydroxy-phenyl)acetonitrile (Step 4) (990 mg, 4.3 mmol) and K2CO3 (1.49 g, 10.76 mmol) in DMF (10 mL), and the mixture was stirred at 80 °C for 1 h. The resulting mixture was allowed to cool to room temperature and partitioned between EtOAc (20 mL) and water (50 mL). The layers were separated, and the aqueous portion was further extracted with EtOAc (10 mL). The combined organic extracts were washed with brine (50 mL), dried over Na2SO4, and concentrated in vacuo. Purification by chromatography on silica eluting with 0 to 100% EtOAc in heptane afforded the title compound as a yellow oil.
[0725] LC-MS (Method E): Rt 1.30 min (68% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.56-7.45(m,3H),7.46-7.37(m,3H),7.40-7.32(m,1H),5.22(s,2H),3.90(s,2H).
[0726] Step 6: 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2-methyl-propanenitrile TIFF0007583022000210.tif54170
[0727] To a cooled (0° C.) solution of 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)acetonitrile (0.51 g, 1.59 mmol) in DMF (10 mL) under nitrogen was added methyl iodide (100%, 0.2 mL, 3.19 mmol), followed by NaH (60% dispersion in mineral oil, 127 mg, 3.19 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The resulting mixture was carefully poured onto ice (20 mL), EtOAc (20 mL) was added, and the mixture was stirred for 20 minutes. The organic portion was separated, dried over Na2SO4, and concentrated in vacuo. Residual DMF was removed by drying in a high vacuum oven at 40° C. overnight to give the title compound as a yellow oil.
[0728] LC-MS (Method E): Rt 1.37 min; MS m / z 347.9,350.0=[M+H]+(66% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.56(m,2H),7.53(d,J=6.0Hz,1H),7.45-7.38(m,2H),7.38-7.32(m,2H),5.27(s,2H),1.69(s,6H).
[0729] Step 7: 2-[5-benzyloxy-4-(1-cyano-1-methyl-ethyl)-2-fluorophenyl]acetic acid
[0730] The title compound was prepared from potassium 3-ethoxy-3-oxo-propanoate and 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2-methyl-propanenitrile (step 6) in analogy to step 5 of intermediate B.
[0731] LC-MS (Method E): Rt 1.20 min; MS m / z 328.0=[M+H]+(48% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 12.50(s,1H),7.61-7.54(m,2H),7.45-7.37(m,2H),7.39-7.31(m,1H),7.24(d ,J=6.5Hz,1H),7.15(d,J=10.9Hz,1H),5.19(s,2H),3.62(s,2H),1.69(s,6H).
[0732] Intermediate CA 2-[4-[1-(acetoxymethyl)cyclobutyl]-5-benzyloxy-2-fluorophenyl]acetic acid TIFF0007583022000211.tif56170
[0733] Step 1: 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclobutanecarbonitrile TIFF0007583022000212.tif54170
[0734] To a cooled (0° C.) suspension of NaH (60% dispersion in mineral oil, 394 mg, 9.84 mmol) in DMF (15 mL) was added a solution of 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)acetonitrile (Intermediate C Step 5) (1.5 g, 4.69 mmol) in DMF (5 mL). The mixture was stirred for 15 min and then treated dropwise over 10 min with a solution of 1,3-dibromopropane (523 μL, 5.15 mmol) in DMF (5 mL). The mixture was allowed to warm to room temperature and stirred for 2 h. The reaction was quenched with saturated aqueous NH4Cl (100 mL) and extracted with DCM (100 mL). The combined organic extracts were washed with brine (100 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-50% TBME in heptane to give the title compound as a colorless crystalline solid.
[0735] LC-MS (Method G): Rt 1.18 min; MS m / z 360.1,362.0=[M+H]+(99% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 7.53-7.46(m,3H),7.45-7.39(m,2H),7.39-7.32(m,2H),5.21(s,2H),2.67-2.53(m,4H),2.29-2.17(m,1H),1.92-1.83(m,1H).
[0736] Step 2: 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclobutanecarbaldehyde TIFF0007583022000213.tif55170
[0737] To a cooled (-78°C) solution of 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclobutanecarbonitrile (Step 1) (99%, 556 mg, 1.53 mmol) in THF (7.5 mL) was added 1.2 M DIBAL in toluene (1.91 mL, 2.29 mmol), and the mixture was warmed to 0°C and maintained at 0°C overnight. The resulting mixture was cooled to -78°C, treated with an additional 0.5 equivalents of 1.2 M DIBAL in toluene, and warmed to -40°C. The reaction was quenched by the addition of 1 M HCl (2 mL) at -30°C, then warmed to room temperature and stirred for 30 minutes. The resulting mixture was diluted with EtOAc (30 mL) and washed with saturated NaHCO3 (30 mL) solution and brine (30 mL). The organics were dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by chromatography on silica eluting with 0-50% TBME in heptane to give the title compound as a colorless oil that crystallized on standing at room temperature.
[0738] LC-MS (Method G): Rt 1.23 min; (97% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 9.61(s,1H),7.42-7.30(m,6H),7.26(d,J=9.4Hz,1H),5.07(s,2H),2.40-2.32(m,2H),2.00-1.90(m,1H),1.86-1.78(m,1H),2.56-2.45(obscured) m,2H)
[0739] Step 3: [1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclobutyl]methanol TIFF0007583022000214.tif54170
[0740] To a cooled (0 °C) solution of 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclobutanecarbaldehyde (step 2) (97%, 200 mg, 0.53 mmol) in MeOH (2.5 mL) was added NaBH (21 mg, 0.56 mmol) and the mixture was stirred for 30 min. The reaction was quenched by adding saturated NaHCO solution (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with brine (30 mL), dried over NaSO, and concentrated to give the title compound as a colorless oil that crystallized upon standing at room temperature.
[0741] LC-MS (Method G): Rt 1.17 min; MS m / z 363.1, 365.1 = [MH] (99% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.45-7.38(m,4H),7.36-7.32(m,1H),7.29(d,J=5.9Hz,1H),6.88(d,J=9.7Hz,1H),5.07(s,2H),4. 62(t,J=5.8Hz,1H),3.62(d,J=5.7Hz,2H),2.25-2.11(m,4H),1.97-1.89(m,1H),1.74-1.66(m,1H).
[0742] Step 4: [1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclobutyl]methyl acetate TIFF0007583022000215.tif57170
[0743] To a solution of [1-(2-benzyloxy-4-bromo-5-fluorophenyl)cyclobutyl]methanol (Step 3) (99%, 191 mg, 0.52 mmol), TEA (99 μL, 0.57 mmol), and DMAP (6.32 mg, 0.05 mmol) in DCM (3 mL) was added acetic anhydride (54 μL, 0.57 mmol), and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with DCM (20 mL), washed with 1 M HCl (15 mL), brine (15 mL), dried over Na SO , and concentrated in vacuo to give the title compound as a colorless oil.
[0744] LC-MS (Method E): Rt 1.55 min; (95% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.45-7.38(m,4H),7.36-7.31(m,2H),6.98(d,J=9.6Hz,1H),5.09(s,2H),4.31(s,2H),2 .33-2.25(m,2H),2.17-2.10(m,2H),2.07-1.98(m,1H),1.88(s,3H),1.78-1.69(m,1H).
[0745] Step 5: tert-butyl 2-[4-[1-(acetoxymethyl)cyclobutyl]-5-benzyloxy-2-fluorophenyl]acetate TIFF0007583022000216.tif56170
[0746] To a solution of [1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclobutyl]methyl acetate (Step 4) (170 mg, 0.42 mmol) in THF (1.5 mL) was added Pd(dba) (12 mg, 0.02 mmol) and Q-Phos (15 mg, 0.02 mmol). The mixture was degassed for 5 min, then 0.5 M bromo-(2-tert-butoxy-2-oxo-ethyl)zinc (1.25 mL, 0.63 mmol) in THF was added, and the mixture was heated at 60 °C for 2 h. After cooling to room temperature, the resulting mixture was diluted with EtOAc (10 mL), washed with saturated NaHCO (10 mL) solution, brine (10 mL), dried over NaSO, and concentrated in vacuo. The crude residue was purified by chromatography on silica eluting with 0-50% TBME in heptane to give the title compound as a pale orange oil.
[0747] LC-MS (Method E): Rt 1.57 min; MS m / z 465.2 [M+Na]+ (72% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.45-7.38(m,4H),7.35-7.31(m,1H),7.00(d,J=6.4Hz,1H),6.79(d,J=10.5Hz,1H),5.02(s,2H),4.31(s,2H),3. 56(s,2H),2.34-2.26(m,2H),2.17-2.11(m,2H),2.05-1.97(m,1H),1.88(s,3H),1.77-1.70(m,1H),1.40(s,9H).
[0748] Step 6: 2-[4-[1-(acetoxymethyl)cyclobutyl]-5-benzyloxy-2-fluorophenyl]acetic acid
[0749] To a cooled (0° C.) solution of tert-butyl 2-[4-[1-(acetoxymethyl)cyclobutyl]-5-benzyloxy-2-fluoro-phenyl]acetate (step 5) (90%, 192 mg, 0.39 mmol) in DCM (1.5 mL) was added TFA (0.5 mL, 6.53 mmol), and the mixture was warmed to room temperature and stirred for a further 2 h. The resulting mixture was concentrated in vacuo, and the crude product was azeotroped with DCM to give the title compound as an orange oil.
[0750] LC-MS (Method E): Rt 1.31 min; MS m / z 409.1 [M+Na]+ (94% at 215 nm)
[0751] Intermediate CB 2-[4-[4-(acetoxymethyl)tetrahydropyran-4-yl]-5-benzyloxy-2-fluorophenyl]acetic acid TIFF0007583022000217.tif55170
[0752] Step 1: 4-(2-benzyloxy-4-bromo-5-fluoro-phenyl)tetrahydropyran-4-carbonitrile TIFF0007583022000218.tif54170
[0753] The title compound was prepared analogously to Step 6 of Intermediate C from 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)acetonitrile (Step 5 of Intermediate C) and 1-bromo-2-(2-bromoethoxy)ethane.
[0754] LC-MS (Method G): Rt 1.11 min; MS m / z 390.1,392.1=[M+H]+(95% at 215 nm) 1H NMR(400MHz,chloroform-d)δ 7.52-7.50(m,1H),7.45-7.35(m,4H),7.18(d,J=5.8Hz,1H),7.09(d,J=9.5Hz,1H),5.18(s, 2H),4.06-3.99(m,2H),3.91(td,J=12.2,1.6Hz,2H),2.36-2.27(m,2H),2.09-1.99(m,2H).
[0755] Step 2: [4-(2-benzyloxy-4-bromo-5-fluoro-phenyl)tetrahydropyran-4-yl]methanol TIFF0007583022000219.tif54170
[0756] To a solution of 4-(2-benzyloxy-4-bromo-5-fluoro-phenyl)tetrahydropyran-4-carbonitrile (Step 1) (1.85 g, 4.74 mmol) in DCM (50 mL) stirred at −78° C. was added 1 M DIBAL in hexanes (5.21 mL, 5.21 mmol) dropwise, and the mixture was stirred at −78° C. for 1 h. The reaction was quenched by the dropwise addition of MeOH, diluted with saturated aqueous Rochelle's salt (10 mL), water (30 mL), and the phases were separated. The organic phase was washed with 1 M HCl (30 mL), dried over NaSO, and concentrated in vacuo. The crude solid was dissolved in DCM (50 mL), re-treated with 1 M DIBAL in hexanes (5.21 mL, 5.21 mmol) at −78° C., and left stirring overnight. Additional 1 M DIBAL in hexane (3.0 mL, 3.0 mmol) was added at −78° C. and stirred for 40 min. The reaction was quenched by the dropwise addition of MeOH, resulting in the formation of a “hydrogel-like” material. The mixture was further diluted with DCM (30 mL), physically disrupted, filtered through a sintered funnel, and concentrated in vacuo. The filter cake was dissolved in 1 M NaOH (200 mL) and stirred for 2 h. The aqueous layer was extracted with TBME (2×100 mL), and the combined organic extracts were concentrated in vacuo. Purification by chromatography on silica eluting with 0–100% EtOAc in heptane afforded the title compound as an off-white gum.
[0757] LC-MS (Method G): Rt 1.02 min; MS m / z 395.1,397.2=[M+H]+(78% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.46-7.28(m,6H),7.16(d,J=11.2Hz,1H),5.12(s,2H),4.49(t,J=5.6Hz,1H) ,3.71-3.58(m,4H),3.43-3.35(m,2H),2.23-2.14(m,2H),1.84-1.75(m,2H).
[0758] Step 3: [4-(2-benzyloxy-4-bromo-5-fluoro-phenyl)tetrahydropyran-4-yl]methyl acetate TIFF0007583022000220.tif57170
[0759] To a cooled (0 °C) solution of [4-(2-benzyloxy-4-bromo-5-fluoro-phenyl)tetrahydropyran-4-yl]methanol (Step 2) (574 mg, 1.45 mmol) in DCM (10 mL) was added TEA (507 μL, 2.9 mmol), followed by DMAP (17.73 mg, 0.15 mmol) and acetic anhydride (274 μL, 2.9 mmol). The reaction mixture was warmed to room temperature and stirred overnight. The resulting mixture was diluted with DCM (20 mL) and washed with water (2 × 15 mL). The organic portion was dried over NaSO and concentrated in vacuo. Purification by C18 reverse-phase chromatography eluting with 10–100% MeCN in water (+0.1% formic acid) afforded the title compound as a pale yellow gum.
[0760] LC-MS (Method E): Rt 1.42 min; (100% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 7.47-7.38(m,5H),7.39-7.31(m,1H),7.25(d,J=11.0Hz,1H),5.14(s,2H),4.37(s,2H),3.65(ddd, J=11.5,5.7,3.6Hz,2H),3.41(ddd,J=11.5,8.9,2.5Hz,2H),2.27-2.19(m,2H),1.87-1.77(m,5H).
[0761] Step 4: tert-butyl 2-[4-[4-(acetoxymethyl)tetrahydropyran-4-yl]-5-benzyloxy-2-fluoro-phenyl]acetate TIFF0007583022000221.tif58170
[0762] The title compound was prepared from [4-(2-benzyloxy-4-bromo-5-fluoro-phenyl)tetrahydropyran-4-yl]methyl acetate (Step 3) and 0.5M bromo-(2-tert-butoxy-2-oxo-ethyl)zinc in THF analogously to Intermediate CA Step 5.
[0763] LC-MS (Method G): Rt 1.17 min; MS m / z 495.2=[M+Na]+ (99% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.48-7.43(m,2H),7.43-7.37(m,2H),7.38-7.30(m,1H),7.10(d,J=6.7Hz,1H),7.05(d,J=11.9Hz,1H),5.07(s,2H) ,4.37(s,2H),3.69-3.60(m,2H),3.58(s,2H),3.46-3.36(m,2H),2.29-2.19(m,2H),1.88-1.78(m,5H),1.40(s,9H).
[0764] Step 5: 2-[4-[4-(acetoxymethyl)tetrahydropyran-4-yl]-5-benzyloxy-2-fluoro-phenyl]acetic acid
[0765] The title compound was prepared from tert-butyl 2-[4-[4-(acetoxymethyl)tetrahydropyran-4-yl]-5-benzyloxy-2-fluoro-phenyl]acetate (Step 4) and TFA analogously to Intermediate CA Step 6.
[0766] LC-MS (Method G): Rt 0.91 min; MS m / z 439.2=[M+Na]+ (99% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.51(br.s,1H),7.48-7.43(m,2H),7.43-7.38(m,2H),7.38-7.31(m,1H),7.14(d,J=6.7Hz,1H),7.04(d,J=11.8Hz,1H),5.06 (s,2H),4.37(s,2H),3.65(ddd,J=11.3,5.5,3.5Hz,2H),3.59(s,2H),3.46-3.38(m,2H),2.27-2.19(m,2H),1.87-1.79(m,5H).
[0767] Intermediate D 2-[5-benzyloxy-4-(1-cyanocyclopropyl)-2-fluorophenyl]acetic acid TIFF0007583022000222.tif58170
[0768] Step 1: 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclopropanecarbonitrile TIFF0007583022000223.tif54170
[0769] To solid potassium hydroxide (210 mg, 3.75 mmol) was added 60% aqueous potassium hydroxide (779 mg, 3.28 mmol), followed by 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)acetonitrile (Step 5 of Intermediate C) (500 mg, 1.56 mmol) and tetrabutylammonium bromide (5 g, 15.62 mmol). The resulting mixture was treated dropwise with 1,2-dibromoethane (0.27 mL, 3.12 mmol) (an exotherm was observed; the temperature was maintained at 50 °C with external cooling), and stirring was continued at 50 °C overnight. The resulting mixture was diluted with water (15 mL) and extracted with EtOAc (2 × 10 mL). The organic extracts were combined, dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0 to 100% EtOAc in heptane to afford the title compound as a yellow solid.
[0770] LC-MS (Method E): Rt 1.33 min (100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.55(d,J=7.1Hz,2H),7.48(d,J=5.9Hz,1H),7.47-7.39(m,3H),7.35(t,J=7.3Hz,1H),5.28(s,2H),1.64-1.58(m,2H),1.41-1.35(m,2H).
[0771] Step 2: 2-[5-benzyloxy-4-(1-cyanocyclopropyl)-2-fluorophenyl]acetic acid
[0772] The title compound was prepared from 1-(2-benzyloxy-4-bromo-5-fluoro-phenyl)cyclopropanecarbonitrile (Step 1) and potassium 3-ethoxy-3-oxo-propanoate in a similar manner to Step 5 of Intermediate B, using mesitylene as the solvent, replacing toluene.
[0773] LC-MS (Method E): Rt 1.12 min; MS m / z 326.1=[M+H]+ (71% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 12.55(s,1H),7.57(d,J=7.1Hz,2H),7.45-7.38(m,2H),7.38-7.32(m,1H),7.20(d,J=9.8Hz ,1H),7.17(d,J=6.4Hz,1H),5.20(s,2H),3.60(s,2H),1.62-1.55(m,2H),1.38-1.32(m,2H).
[0774] Intermediate E 2-[5-benzyloxy-4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluorophenyl]acetic acid TIFF0007583022000224.tif56170
[0775] Step 1: 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2-methyl-propanal TIFF0007583022000225.tif54170
[0776] To a solution of 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2-methyl-propanenitrile (Step 6 of Intermediate C) (80% pure, 1 g, 2.30 mmol) in DCM (20 mL) at −78° C. was added 1 M DIBAL in hexanes (6.03 mL, 6.03 mmol). The mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction was quenched with 1 M HCl (50 mL) and stirred for 30 min. The organic layer was separated, dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0–30% EtOAc in heptane to afford the title compound as a white solid.
[0777] LC-MS (Method E): Rt 1.40 min (99% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 9.46(s,1H),7.46(d,J=6.0Hz,1H),7.44-7.37(m,1H),7.41-7.28(m,5H),5.12(s,2H),1.31(s,6H).
[0778] Step 2: 4-[2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2-methyl-propyl]morpholine TIFF0007583022000226.tif54170
[0779] To a solution of 2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2-methyl-propanal (Step 1) (520 mg, 1.48 mmol) and AcOH (127 μL, 2.22 mmol) in THF (10 mL) was added morpholine (256 μL, 2.96 mmol) and sodium triacetoxyborohydride (377 mg, 1.78 mmol), and the resulting mixture was stirred at room temperature for 16 h. The resulting mixture was diluted with EtOAc (10 mL) and saturated sodium bicarbonate solution (20 mL). The phases were separated, and the organic portion was washed with brine (20 mL), dried over NaSO, and concentrated in vacuo. The crude material was purified by chromatography on silica eluting with 0-100% EtOAc in heptane to afford the title compound as a colorless oil.
[0780] LC-MS (Method E): Rt 0.99 min; MS m / z 422.1,424.1=[M+H]+(100% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.52-7.46(m,2H),7.43(t,J=7.5Hz,2H),7.40-7.33(m,1H),7.34(d,J=6.2Hz,1H),7.14(d, J=10.9Hz,1H),5.12(s,2H),3.40-3.34(m,4H),2.59(s,2H),2.21-2.11(m,4H),1.26(s,6H).
[0781] Step 3: 2-[5-benzyloxy-4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluorophenyl]acetic acid
[0782] The title compound was prepared from 4-[2-(2-benzyloxy-4-bromo-5-fluoro-phenyl)-2-methyl-propyl]morpholine (Step 1) and potassium 3-ethoxy-3-oxo-propanoate in a similar manner to Step 5 of Intermediate B, substituting mesitylene for toluene as the solvent.
[0783] LC-MS (Method E): Rt 0.90 min; MS m / z 402.5=[M+H]+ (83% at 215 nm) 1 H NMR(400MHz,DMSO-d6)δ 7.54-7.47(m,2H),7.47-7.38(m,2H),7.40-7.31(m,1H),7.05(d,J=6.7Hz,1H),6.93(d,J=11.8H z,1H),5.04(s,2H),3.51(s,2H),3.42-3.34(m,4H),2.60(s,2H),2.22-2.10(m,4H),1.26(s,6H).
[0784] Intermediate F 2-(2-Bromo-4-tert-butyl-5-methoxy-phenyl)acetic acid TIFF0007583022000227.tif38170
[0785] Step 1: (4-tert-butyl-3-methoxy-phenyl)methanol TIFF0007583022000228.tif27170
[0786] 1 M borane in THF (134.45 mL, 134.45 mmol) was added to a stirred solution of 4-tert-butyl-3-methoxy-benzoic acid (10 g, 48.02 mmol) in THF (100 mL), and the mixture was stirred at 50 °C for 1 h. After cooling to room temperature, the resulting mixture was carefully quenched with MeOH (10 mL), and the volatile solvents were removed in vacuo. Additional MeOH (10 mL) was added, and the mixture was concentrated in vacuo to give the title compound as a pale yellow oil.
[0787] LC-MS (Method E): Rt 1.14 min (97% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.14(d,J=7.9Hz,1H),6.94(s,1H),6.81(d,J=7.8Hz,1H),5.12(s,1H),4.46(s,2H),3.79(s,3H),1.32(s,9H).
[0788] Step 2: 1-tert-butyl-4-(chloromethyl)-2-methoxybenzene TIFF0007583022000229.tif28170
[0789] Thionyl chloride (6.09 mL, 83.88 mmol) in DCM (40 mL) was added dropwise to a cooled (0 °C) solution of (4-tert-butyl-3-methoxy-phenyl)methanol (Step 1) (97%, 8.4 g, 41.94 mmol) and DMF (3.25 mL, 41.94 mmol) in DCM (80 mL), and the mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated in vacuo, and the residue was partitioned between EtOAc (100 mL) and saturated NaHCO (100 mL). The phases were separated, and the organic portion was washed with brine (30 mL), dried over NaSO, and concentrated in vacuo to give the title compound as a yellow oil.
[0790] LC-MS (Method E): Rt 1.38 min (79% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.20(d,J=7.9Hz,1H),7.04(d,J=1.7Hz,1H),6.94(dd,J=7.9,1.7Hz,1H),4.71(s,2H),3.81(s,3H),1.32(s,9H).
[0791] Step 3: 2-(4-tert-butyl-3-methoxy-phenyl)acetonitrile TIFF0007583022000230.tif30170
[0792] Sodium cyanide (1.88 g, 38.33 mmol) was added to a solution of 1-tert-butyl-4-(chloromethyl)-2-methoxy-benzene (Step 2) (79%, 8.6 g, 31.94 mmol) in DMF (100 mL), and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with EtOAc (100 mL), washed with saturated aqueous sodium carbonate (300 mL), brine (50 mL), dried over NaSO, and concentrated in vacuo to give the title compound as a brown oil.
[0793] LC-MS (Method E): Rt 1.25 min (84% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 7.21(d,J=7.9Hz,1H),6.94(d,J=1.5Hz,1H),6.86(dd,J=7.9,1.7Hz,1H),3.95(s,2H),3.81(s,3H),1.31(s,9H).
[0794] Step 4: 2-(4-tert-butyl-3-methoxy-phenyl)acetic acid TIFF0007583022000231.tif31170
[0795] To a solution of 2-(4-tert-butyl-3-methoxy-phenyl)acetonitrile (Step 3) (84%, 8.0 g, 33.06 mmol) in water (50 mL) was added lithium hydroxide hydrate (9.27 g, 165.29 mmol), and the mixture was heated to reflux overnight. After cooling to room temperature, the resulting mixture was acidified with concentrated HCl solution and extracted with DCM (2 x 30 mL). The combined organic extracts were dried over NaSO and concentrated in vacuo to give the title compound as a pale yellow solid.
[0796] LC-MS (Method E): Rt 1.13 min (88% at 215 nm) 1H NMR(400MHz,DMSO-d6)δ 12.27(s,1H),7.13(d,J=7.9Hz,1H),6.86(d,J=1.6Hz,1H),6.75(dd,J=7.9,1.7Hz,1H),3.78(s,3H),3.50(s,2H),1.31(s,9H).
[0797] Step 5: 2-(2-bromo-4-tert-butyl-5-methoxy-phenyl)acetic acid
[0798] 2-(4-tert-Butyl-3-methoxy-phenyl)acetic acid (Step 4) (340 mg, 1.53 mmol) in acetic acid (2.19 mL) was treated with bromine (176 μL, 3.06 mmol) and stirred for 90 minutes. The reaction was quenched with saturated aqueous sodium thiosulfate, and the resulting mixture was diluted with water (10 mL) and extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over NaSO and concentrated in vacuo. The crude material was purified by C18 reverse-phase chromatography, eluting with 10–100% MeCN in water, to afford the title compound as a colorless solid.
[0799] LC-MS (Method E): Rt 1.24 min (97% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.43(s,1H),7.28(s,1H),7.04(s,1H),3.79(s,3H),3.65(s,2H),1.31(s,9H).
[0800] intermediate G 2-(4-tert-butyl-2-fluoro-5-methoxy-phenyl)acetic acid TIFF0007583022000232.tif38170
[0801] 2-(2-Fluoro-5-methoxy-phenyl)acetic acid (585 mg, 3.17 mmol) was treated with concentrated sulfuric acid (677 μL, 12.7 mmol) and tert-butanol (1.21 mL, 12.7 mmol) and stirred for 3 h. The reaction mixture was concentrated in vacuo. MeOH was used during material transfer, resulting in the formation of the methyl ester. The residue was purified by C18 reverse-phase chromatography eluting with 10–100% aqueous MeCN. The resulting material was dissolved in 2 M LiOH (7 mL) and THF (7 mL) and stirred for 2 h. The volatile solvents were removed in vacuo, and the aqueous solution was acidified with 1 M HCl. The suspension was extracted with DCM (3 × 20 mL), and the combined organic extracts were dried over NaSO and concentrated in vacuo to give the title compound as a pale yellow solid.
[0802] LC-MS (Method E): Rt 1.17 min; MS m / z 239.0 = [MH] (96% at 215 nm) 1 H NMR(500MHz,DMSO-d6)δ 12.42(s,1H),6.94(d,J=7.0Hz,1H),6.92(d,J=1.9Hz,1H),3.77(s,3H),3.57-3.53(m,2H),1.31(s,9H).
[0803] Intermediate H 4-[2-(4-bromo-2-fluoro-5-methoxyphenyl)acetamido]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide TIFF0007583022000233.tif38170
[0804] To a solution of 2-(4-bromo-2-fluoro-5-methoxy-phenyl)acetic acid (Intermediate U, Step 1) (99%, 15.5 g, 58.33 mmol) in DMF (150 mL) was added DIPEA (15.28 mL, 87.5 mmol) and 4-amino-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Intermediate A) (15.02 g, 61.25 mmol), and the mixture was cooled to 0 °C. A 50% solution of T3P® in EtOAc (41.67 mL, 70 mmol) was added dropwise over 5 minutes, and the reaction mixture was gradually warmed to room temperature and stirred for 4 hours. The resulting mixture was diluted with EtOAc (200 mL) and washed with brine (500 mL). The aqueous washes were back-extracted with EtOAc (200 mL), and the combined organic portions were washed with saturated NaHCO (200 mL) and 1 M HCl (200 mL). A precipitate formed which was filtered, washed with EtOAc (100 mL), and dried to give a white solid. The solid was suspended in EtOAc (200 mL), and saturated NaHCO (500 mL) was added. After vigorously stirring for 30 minutes, the organic layer was separated, dried over NaSO, and concentrated in vacuo to give the title compound as a white solid.
[0805] LC-MS (Method G): Rt 1.01 min; MS m / z 490.0,492.0=[M+H]+(100% at 215 nm) 1H NMR(500MHz,DMSO-d6)δ 10.83(s,1H),9.39(s,1H),8.50(d,J=5.6Hz,1H),8.19(d,J=1.8Hz,1H),7.84(dd,J=5.5,2.2Hz,1H),7.5 3(d,J=8.8Hz,1H),7.18(d,J=6.6Hz,1H),3.83(s,3H),3.81(s,2H),1.36-1.23(m,2H),1.22-1.12(m,2H).
[0806] Intermediate I 4-[[2-(4-bromo-2-fluoro-5-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide TIFF0007583022000234.tif39170
[0807] Step 1: Methyl 4-[[2-(4-bromo-2-fluoro-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate TIFF0007583022000235.tif40170
[0808] To a s...
Claims
1. General formula (I), including all tautomers, all enantiomeric and isotopic variants: (In the formula, R 1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; R 2 is methyl and CH 2 OH, R 3 is selected from H and methyl; or R 1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; R 2 and R 3 together with the carbon atom to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, any of which may be selected from R 1 In addition to the groups, OH, halo, C 1-4 Alkyl, C substituted with one or more OH substituents 1-4 Alkyl, and C 1-4 haloalkyl; or R 1 is H or selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; R 2 and R 3 together with the carbon atom to which they are attached, R 1 In addition to the group, OH, halo, methyl or CH 2 forming a 4-6 membered carbocyclic ring substituted with OH; or R 1 is CH 2 OH or is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; R 2 and R 3together with the carbon atom to which they are attached, R 1 forming a 4- to 6-membered carbocyclic ring which is unsubstituted except for the group; or R 1 , R 2 and R 3 together with the carbon atom to which they are attached, OH, halo, C 1-4 Alkyl and C 1-4 forming a 5-8 membered bridged carbocyclic or heterocyclic ring system optionally substituted with one or more substituents selected from haloalkyl, R 4 is H or halo, R 5 and R 7 each independently represents H, halo, C 1-3 Alkyl and C 1-3 haloalkyl; R 6 is optionally substituted with one or more substituents selected from halo, CN, and halo and OH; 1-4 alkyl, R 8 is methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; R 9 OH, CH 2 OH or methyl or ethyl, any of which may be substituted with one or more halogen substituents; or R 8 and R 9 together with the carbon atom to which they are attached, R 10 In addition to the groups OH, F and CH 2 OH, or forming an ethenyl group optionally substituted by one or two halogen substituents; R 10 is H, CN, OH, cycloalkyl optionally substituted with OH, and C optionally substituted with one or more substituents selected from halo, OH, and 3- to 6-membered cycloalkyl or heterocyclic groups; 1-4 alkyl, any of which may be substituted with OH; or R 8 , R 9 and R 10 together with the carbon atom to which they are attached, OH, F, and CH 2 forming a 5-8 membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from: however, i.R 5 and R 7 is H, and R 6 If F, then R 1 , R 2 , R 3 , R 8 , R 9 and R 10 is not all methyl, and ii. R 2 , R 3 , R 8 , R 9 and R 10 are all methyl, R5 and R 7 are not both H, and iii. R 1 is CN, and R 2 and R 3 together with the carbon atom to which they are attached form a 3- to 10-membered oxygen-containing heterocyclic ring, R 8 , R 9 and R 10 is not all methyl, and iv. R 9 and R 10 does not mean that both are OH. or a salt or solvate thereof.
2. R 8 and R 9 together with the carbon atom to which they are attached, R 10 In addition to the group, one or more CH 2forming a 3-6 membered cycloalkyl or oxygen-containing heterocyclic ring substituted with an OH substituent and optionally substituted with one or more further substituents selected from OH and F; or R 8 and R 9 together with the carbon atom to which they are attached, R 10 In addition to the group, a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring may be substituted with one or more substituents selected from OH and F, and R 10 is CN or C substituted with one or more substituents selected from OH, a 3- to 6-membered cycloalkyl group optionally substituted with OH, and a 3- to 6-membered heterocyclic group optionally substituted with OH; 1-4 is alkyl, or R 8 and R 9 together with the carbon atom to which they are attached form an ethenyl group which may be substituted by one or two halogen substituents, or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form one or more CH 2 forming a 5-8 membered fused or bridged carbocyclic ring system substituted with an OH substituent and optionally substituted with one or more further substituents selected from OH and F; The compound according to claim 1, wherein
3. R 8 and R 9 together with the carbon atom to which they are attached, R 10 forms a 3-6 membered cycloalkyl or oxygen-containing heterocyclic ring system which is unsubstituted except for the group, and R 10 CN and CH 2 OH, or R 8 , R 9 and R 10 together with the carbon atom to which they are attached, CH 2 forming a 5-8 membered fused or bridged carbocyclic ring system substituted with OH; The compound according to claim 2, wherein
4. R 8 is methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; and R 9 But OH, CH 2 OH or methyl or ethyl, any of which may be substituted with one or more halogen substituents; or R 8 and R 9 together with the carbon atom to which they are attached, R 10 In addition to the group, a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring may be substituted with one or more substituents selected from OH and F, and R 10 C, optionally substituted with H, OH or one or more halo substituents 1-4 is alkyl, or R 8 , R 9 and R 10 together with the carbon atoms to which they are attached form a 5-8 membered fused or bridged carbocyclic ring system which may be substituted with one or more substituents selected from OH and F; The compound of claim 1.
5. R 8 is methyl or ethyl, R 9 is OH or CH 2 OH and R 10 is methyl or ethyl, R 8 is methyl or ethyl, R 9 is methyl or ethyl, R 10 is OH or C substituted with OH 1-4 is alkyl, or R 8 , R 9 and R 10 are all methyl, The compound according to claim 4.
6. R 1 The compound according to any one of claims 1 to 5, wherein is methyl, difluoromethyl, trifluoromethyl, ethynyl or CN.
7. R 1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; R 2 is methyl, R 3 is H or methyl, or R 1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; R 2 and R 3 together with the carbon atom to which they are attached, R 1 In addition to OH, halo, C 1-4 Alkyl and C 1-4 forming a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring system, optionally substituted with one or more substituents selected from haloalkyl; R 1 is H, and R 2 and R 3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring substituted with OH; The compound according to any one of claims 1 to 6, 8. The compound of claim 7, wherein R 1 is trifluoromethyl and R 2 and R 3 together with the carbon atom to which they are attached form a cyclopropyl ring which is unsubstituted except for R 1 .
9. R 4 is H, and / or R 5 and R 7 is H; and / or R 6 But, Haro, CN, CH 3 , C.F. 3, C.H.F. 2 , C.H. 2 F or CH 2 The compound according to any one of claims 1 to 8, wherein said compound is OH.
10. R 8 is methyl or ethyl, and R 9 Methyl, CH 2 OH or OH, or R 8 and R 9 are each independently methyl or ethyl; or R 8 and R 9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring, said ring being 10 is unsubstituted except for the moiety and is selected from cycloalkyl rings and heterocyclic rings having a single ring oxygen atom; A compound according to any one of claims 1 to 9.
11. The compound of claim 10, wherein R 8 is methyl.
12. R 10 is selected from CN, cyclopropyl, cyclobutyl, unsubstituted methyl, or methyl substituted with one or more substituents selected from fluoro, OH, and 3-6 membered cycloalkyl or heterocyclyl groups.
13. R 8 and R 9 together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl or oxetanyl ring, which is represented by R 10 is unsubstituted except for the group R 10 In addition to the group, a single CH 2 has an OH substituent and R 10 Methyl, CH 2 The compound according to any one of claims 1 to 12, which is OH, trifluoromethyl or cyano.
14. R 8 , R 9 and R 10 together with the carbon atom to which they are attached form a bridged ring system, said bridged ring system being unsubstituted or consisting of a single CH 2 The compound of any one of claims 1 to 13, which is substituted with an OH substituent.
15. The compound of claim 14, wherein the bridged ring system is bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane or bicyclo[2.2.1]heptane, said bridged ring system being unsubstituted or substituted with a single CH2OH substituent.
16. 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (compound 1), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (compound 1.1), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclopentyl)pyridine-2-carboxamide (compound 1.2), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanoethyl)pyridine-2-carboxamide (compound 1.3), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyanoethyl]pyridine-2-carboxamide (compounds 1.3a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyanoethyl]pyridine-2-carboxamide (compounds 1.3a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (compound 1.4), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (compound 1.5), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide (compound 1.6), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (compounds 1.6a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (compounds 1.6a / b), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 1.7), 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.1), N-tert-butyl-4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.2), 4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.3), N-tert-butyl-4-[[2-[4-(1-cyanocyclopropyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.4), N-(1-cyano-1-methyl-ethyl)-4-[[2-[4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.5), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.6), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.7), 4-[[2-[4-(1-cyclopropyl-1-hydroxy-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.8), 4-[[2-[4-(4-cyanotetrahydropyran-4-yl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.9), 4-[[2-[2-fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.10), 4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.11), 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compounds 2.11a / b), 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compounds 2.11a / b), 4-[[2-[5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.12), 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclobutyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.13), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]pyridine-2-carboxamide (compound 2.14), 4-[[2-[2-fluoro-5-hydroxy-4-[4-(hydroxymethyl)tetrahydropyran-4-yl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.15), 4-[[2-[2-fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclopropyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 2.16), 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)-5-fluoro-pyridine-2-carboxamide (compound 3), N-(1-cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (compound 4), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclobutyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 5), N-tert-butyl-4-[[2-(4-tert-butyl-5-hydroxy-2-isopropyl-phenyl)acetyl]amino]pyridine-2-carboxamide (compound 6), N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 7), 4-[[2-(2-fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 7.1), N-tert-butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclopropyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 8), N-(1-cyanocyclopropyl)-4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxamide (compound 9), 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (compound 10), 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 10.1), 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (compound 10.2), 4-[[2-[2-fluoro-5-hydroxy-4-(3-hydroxy-1,1-dimethyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 11), N-(4-cyanotetrahydropyran-4-yl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 12), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[3-(trifluoromethyl)oxetan-3-yl]pyridine-2-carboxamide (compound 12.1), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (compound 12.2), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide (compound 12.3), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (compound 12.4), 4-[[2-[2-fluoro-5-hydroxy-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 13), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 14), 4-[[2-[5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 14.1), N-(3,3-difluoro-1-methyl-cyclobutyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 15), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (compound 15.1), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide (compound 15.2), 4-[[2-[2-chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(difluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 15.3), N-[1-(difluoromethyl)cyclopropyl]-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 15.4), N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 16), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (compound 16.1), N-(1-cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (compound 16.2), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (compound 16.3), 4-[[2-[2,6-difluoro-3-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 16.4), 4-[[2-[2-fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 17), 4-[[2-[2-chloro-6-fluoro-3-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 18), 4-[[2-[2-chloro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 19), 4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 20), 4-[[2-[2-fluoro-5-hydroxy-4-[(1S)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 20a / b), 4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 20a / b), 2. The compound according to claim 1, selected from:
17. 17. The compound of claim 16, which is 4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (compound 1.5), or a salt or solvate thereof.
18. The compound according to claim 16, which is N-(1-cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (compound 4), or a salt or solvate thereof.
19. The compound according to claim 16, which is 4-[[2-[2-fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 17), or a salt or solvate thereof.
20. 17. The compound of claim 16, which is 4-[[2-(4-tert-butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (compound 10.1), or a salt or solvate thereof.
21. 21. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment or prevention of diseases and conditions affected by modulation of TMEM16A.
22. A pharmaceutical for the treatment or prevention of diseases and conditions affected by modulation of TMEM16A, comprising an effective amount of a compound according to any one of claims 1 to 20.
23. 22. The use of claim 21, wherein the diseases and conditions affected by modulation of TMEM16A are selected from respiratory diseases and conditions, dry mouth (xerostomia), intestinal hypermotility, cholestasis and ophthalmic conditions.
24. The pharmaceutical composition of claim 22, wherein the diseases and conditions affected by modulation of TMEM16A are selected from respiratory diseases and conditions, dry mouth (xerostomia), intestinal hypermotility, cholestasis and eye conditions.
25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 and a pharma- ceutically acceptable excipient.
Citation Information
Patent Citations
Pyridine carboxamide and methods for inhibiting HIV integrase
WO2005042524A1
Substituted 2-acylamino-cycloakylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16a
WO2018195127A1
compounds
WO2019145726A1
